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The Human Genome Project, initiated in 1990, creates an enormous amount of 
excitement in human genetics—a field of study that seeks answers to the understanding 
of human evolution, diseases and development, gene therapy, and preventive medicine. 
The first completion of a human genome in 2003 and the breakthroughs of sequencing 
technologies in the past few years deliver the promised benefits of genome studies, 
especially in the roles of genomic variability and human health. However, intensive 
resource requirements and the associated costs make it infeasible to experimentally verify 
the effect of every genetic variation. At this stage of genome studies, in silico predictions 
play an important role in identifying putative functional variants.  
The most common practice for genome variant evaluation, the sequence conservation-
based approach, assumes important positions in a DNA or a protein sequence have been 
conserved throughout the evolution. Therefore, the predicted variant effect (deleterious or 
benign) is based on the evolutionary conservation at the mutation site. Nonetheless, 
phylogenetic diversity of aligned sequences used to construct the prediction algorithm 
has substantial effects on the analysis since sequence conservation is not the absolute 
predictor for deleteriousness. 
This dissertation aims at overcoming the weaknesses of the conservation-based 
assumption for predicting the variant effects. The dissertation describes three different 
integrative computational approaches to identify a subset of high-priority amino acid 





For genetic variants found in genomes of healthy individuals, an eight-level Association-
Adjusted Consensus Deleterious Scheme (AACDS) is implemented. It ranks amino acid 
mutations based on suggestive evidence from association studies and conservation-based 
predictors. The ranking scheme has particular utility for the development of 
individualized health profiles. A database-driven web application promotes the utility of 
AACDS by granting access to AACDS data for 68 million amino acid mutations in over 
18,000 human genes.  
For candidate genetic variants of epilepsy disorders, a novel 3-dimensional structure-
based assessment protocol for amino acid mutations is established. It models protein 
structure and contrasts structural characteristics that distinguish between residues altered 
by disease-causing mutations vs. neutral mutations. A structural disruption score (SDS) is 
introduced as a measure to depict the likelihood that a candidate variant is functional. 
SDS is correlated with standard conservation-based deleteriousness, but shows promise 
for improving discrimination between neutral and causal variants at less conserved sites. 
The implementation facilitates variant prioritization for experimental validations. 
For genomic variants that may affect inter-individual variability in drug responses, a 
systematic 3-dimensional screening is performed on key proteins of drug metabolism. 
“SDS Pharmacogenes” is an explicit structure-based predictor that comprises five 
predictive features for structural disturbances. Unlike conservation-based predictors, SDS 
Pharmacogenes is able to annotate VIP variants as functional rather than neutral 
mutations based on the distinguishable characteristic profiles of structural disturbances. 
The systematic variant evaluation pipeline allows efficient structural examination of 





implementation of SDS Pharmacogenes and the future development of a database-driven 
web application will offer comprehensive understanding of genetic variants and 





CHAPTER 1: INTRODUCTION 
Genomic variations of human genomes 
Genetic variation refers to differences in DNA of a person when compared to the DNA of 
a human reference genome. Genome studies indicate that each healthy individual carries 
a large number of genetic variants (Figure 1.1) [1-4]. Single nucleotide variants (SNVs) 
are the most common form. Single nucleotide polymorphisms (SNPs), a subset of SNVs, 
are single base genetic variations observed in at least 1% of the population.  Both SNVs 
and SNPs can be associated with diseases. SNVs may alter gene expression levels via 
regulatory controls. Nonsynonymous SNPs (nsSNPs), also known as missense variants, 
are SNPs that introduce amino acid changes to proteins. The change may affect protein 
function. Both types of genetic variation contribute significantly to disease states: about 
60% and 25% of known disease-causing mutations are nsSNPs and regulatory SNVs, 
respectively [5]. 
 
Figure 1.1: Types and number of genetic variations found per a human genome and 






Current challenges in genome studies 
Genome studies have several goals, one of which is to identify genes and genetic variants 
that give rise to diseases. Scientists are now facing several challenges in genome studies 
[6, 7], particularly in the area of identifying candidate genes and/or causal mutations. To 
infer candidate genes, the study requires complete re-sequencing of candidate genomic 
intervals in large population samples [6]. To test the hypothesis that a given SNP is a 
causative factor, the process requires: (1) linkage-disequilibrium studies on a very dense 
SNP map, and (2) comparisons of allele frequencies between affected and unaffected 
individuals [8]. Nevertheless, genetic associations between case and control groups may 
also be due to several discrepancies, most of which are functionally irrelevant. In 
addition, the direct method requires follow-up studies to further examine the genetic 
differences: typically by surveying larger panels of control individuals for the presence or 
absence of exclusive case SNPs [9]. 
The confirmation of true positives for disease-causing mutations entails laboratory testing 
[10]. The process is difficult and expensive. When a genetic variant is found in a well-
known disease-causing gene, causality is difficult to conclude.  For genes without known 
functions, functional assays are not easy to design [6]. Taking into account that some 
researchers do not publish results of failed attempts, a rough estimate on the number of 
truly causative variants from exome sequencing projects is 10-50% of cases [6]. Despite 
the difficulties in establishing causality, the scientific community still shows great 
interest in pursuing genome studies to understand the core of human health and the 





Roles of bioinformatics for evaluating genome variants 
Major efforts have been made in recent years to identify nsSNPs (missense variants) with 
strong effects because of their prevalence in number and high penetrance of association 
with diseases. Intensive resource requirements and the associated cost make it unfeasible 
to verify the effect of every genetic variation. At this stage of human genome study, in 
silico predictions play an important role in identifying putative functional variants in a 
systematic and efficient manner. Computational tools substitute the current elaborate 
process of in vitro and in vivo experiments. Several approaches have been developed to 
narrow down the list of candidate variants or genes from genome data [11-13]. 
Irrespective of differences in underlying algorithms and scoring functions, most tools 
evaluate nsSNPs as either deleterious (having a strong functional effect) or neutral 
(having a weak functional effect) from the level of DNA or protein sequence 
conservation [14]. The results often indicate a probability that the amino acid substitution 
is damaging. 
Recently, a database named dbNSFP [15] has compiled prediction scores of commonly 
used deleterious predictors into a stand-alone database for easy retrieval of scores. This 
contribution greatly facilitates the evaluation of variant deleteriousness in large genome 
datasets. Scores from six prediction algorithms, with various complimentary 
methodologies were included. They are: conservation-based (SIFT [16], LRT [17], and 
MutationAssessor [18]), conservation- and structure-based (PolyPhen2_HumDiv and 






Limitations of sequence conservation-based approaches for predicting 
variant deleteriousness 
While a conservation-based approach is the common practice for assessing the effects of 
nsSNPs, there are still some concerns when it comes to interpreting the results: (1) 
Sequence conservation is not an absolute predictor for deleteriousness— phylogenetic 
diversity of sequences used to infer evolutionary conservation has substantial effects on 
the analysis [14]. (2) The score cut-offs for different levels of variant deleteriousness are 
sometimes not well determined [21]. (3) Predictions from several programs occasionally 
differ; it is quite problematic to represent a consensus result [22]. (4) Some documented 
disease-causing variants may be false positives—prediction programs trained on this data 
set may suffer from the classification error [6]. (5) Some novel variants may be 
misclassified since there is not enough phenotypic information to infer the significant 
effects of nsSNPs [23]. (6) A predicted deleterious variant may result in reduced or 
damaged protein functions; however, the chance that the altered phenotype is observable 
may be small. (7) Variant classification programs which are mature enough for general 
use may have low accuracy for certain genes [24, 25]. 
Integrative analysis of variant effects: a novel approach for personal 
genome interpretations 
Because of advances in sequencing technologies [26], personal genome analysis is now 
being marketed for evaluating disease risk and/or adverse drug responses in healthy 
individuals, or for identifying disease-causing variants in people with diseases. Genome 
interpretation is a complex and time-consuming process. This requires a good knowledge 





deleterious prediction algorithms show a reasonable range of accuracy (~70-80%) [22, 
27] for evaluating nsSNPs, the lack of comprehensive knowledge of protein biology and 
its role in human disease restricts the usage of prediction results in the practical way.                                     
Information from three sources (clinical annotations, protein sequences, and protein 
structures) can be used simultaneously to estimate the functional significance of a variant 
[28]. The integrative approach utilizes prior knowledge of genome biology to define a set 
of genetic variants that are important for an individual’s health. Researchers have begun 
to apply this integrative procedure in variant deleteriousness algorithms [29-32], but the 
implementations have not yet realized their full potential. The reasons include: the 
massive amount of genomic-related data yet to be explored, the insufficient expertise to 
perform certain analyses, and sub-optimal procedures for combining prediction results 
from various predictors. Once the integrative protocol is mature, it will have great impact 
on personal genome interpretation and variant prioritization; that is, promoting the 
comprehensive understanding of genomic variants from interrelated SNP data. 
1) Adding clinical annotations to conservation-based approaches 
Owing to the rapid improvement of sequencing technologies, data on the clinical 
associations with a SNP, a protein residue, or a gene are accessible in many SNP 
databases [11, 13, 30, 33]. However, these functional annotations are quite scattered; the 
search for the clinical effects of a variant may be time-consuming and as a result, obstruct 
the practical analysis of genomic variations. The meaningful combination of interrelated 
data and the extension of existing predictive features to include any prior knowledge will 





addressed in the implementation of the Association-Adjusted Consensus Deleterious 
Scheme (AACDS) for categorizing personal genome variations (Chapter 2). 
2) Incorporating protein structures into conservation-based approaches 
An amino acid mutation is caused by a single point mutation of the coding nucleotide. 
Many amino acid pairs have different physicochemical properties, so the mutant residues 
may prompt observable effects on protein functions. The consequence of amino acid 
mutations can be readily predicted by many algorithms, based on protein sequences or 
structures [12, 34]. Some genomic tools have begun to incorporate protein analysis 
algorithms into the traditional conservation-based predictors [13, 35-39]. 
Visual inspections of wild type vs. mutant protein structures can help pinpoint the protein 
residues that are responsible for aberrant protein functions. Success in homology 
modeling alleviates the fundamental limitation of structure-based approach; i.e., the 
limited availability of 3-dimensional (3D) protein structures. Using various sources for 
protein structures, my Structural Disruption Score (SDS) is established. It represents 
predictive features for amino acid mutations that induced by the candidate case missense 
variant for epilepsy disorders (Chapter 4) and by missense variants in pharmacogenes 
(Chapter 5). 
Description of this dissertation 
My dissertation aims to overcome the weaknesses of traditional conservation-based 
predictions for variant deleteriousness. The integration of conservation- and structural-





understanding of protein function, enables the identification of functional protein 
residues, and promotes a more accurate classification of genetic variants with respect to 
overall protein function or disease development. The implementation is applied to three 
disciplines of genome analysis, and restricted to the evaluations of amino acid mutations 
induced by missense variants (nsSNPs) since they are the most prevalent type of genetic 
variations that are closely associated with diseases [5]. 
The first objective is to categorize personal genome variations of healthy individuals into 
distinct classes; each class of nsSNPs reflects the strength of evidence which collectively 
suggest the variants may contribute to adverse gene functions. The implementation of this 
novel variant prioritization scheme, an Association-Adjusted Consensus Deleterious 
Scheme (AACDS), is described in Chapter 2. To promote the utility of this schema, a 
database-driven web application is developed (Chapter 3). 
The second objective is to develop a disease-specific predictor to evaluate missense 
variants found in a set of epilepsy-related genes (Chapter 4). This implementation 
integrates results of conservation-based predictors with the outputs of many protein 
structural analyses. Distinguishable characteristics between documented disease-causing 
and neutral mutations within these genes are used to establish a “Structural Disruption 
Score” (SDS) for epilepsy variants. Using SDS, the candidate variants are ranked based 
on the likelihood that each mutation may disrupt protein structure. The list of high 
priority variants can be used to assist further experimental validations. 
The last objective is to extend the implementation of SDS into an exclusive structure-





Pharmacogenes” consists of 13 predictive features; it can be used to evaluate almost 





CHAPTER 2: AN ASSOCIATION-ADJUSTED CONSENSUS 
DELETERIOUS SCHEME TO CLASSIFY HOMOZYGOUS 
MISSENSE MUTATIONS FOR PERSONAL GENOME 
INTERPRETATION [40] 
Abstract 
Background: Personal genome analysis is now being considered for evaluation of 
disease risk in healthy individuals, utilizing both rare and common variants. Multiple 
scores have been developed to predict the deleteriousness of amino acid substitutions, 
using information on the allele frequencies, level of evolutionary conservation, and 
averaged structural evidence. However, agreement among these scores is limited and they 
likely over-estimate the fraction of the genome that is deleterious. 
Method: This study proposes an integrative approach to identify a subset of homozygous 
non-synonymous single nucleotide polymorphisms (nsSNPs). An 8-level classification 
scheme is constructed from the presence/absence of deleterious predictions combined 
with evidence of association with disease or complex traits. Detailed literature searches 
and structural validations are then performed for a subset of homozygous 826 missense 
mutations in 575 proteins found in the genomes of 12 healthy adults. 
Results: Implementation of the Association-Adjusted Consensus Deleterious Scheme 
(AACDS) classifies 11% of all predicted highly deleterious homozygous variants as most 





8 with no significant difference between African and Caucasian Americans. Detailed 
analysis of mutations affecting the APOE, MTMR2, THSB1, CHIA, αMyHC, and 
AMY2A proteins shows how the protein structure is likely to be disrupted, even though 
the associated phenotypes have not been documented in the corresponding individuals. 
Conclusions: The classification system for homozygous nsSNPs provides an opportunity 
to systematically rank nsSNPs based on suggestive evidence from annotations and 
sequence-based predictions. The ranking scheme, in-depth literature searches, and 
structural validations of highly prioritized missense mutations compliment traditional 
sequence-based approaches and should have particular utility for the development of 
individualized health profiles. An online tool reporting the AACDS score for any variant 
is provided at the authors’ website. 
Background 
Personal genome interpretation is a process of determining the personal genome 
sequences and assessing the likely consequences of an individual’s genetic variation. 
Personalized genome data interpretation can be used, for example, to predict diseases and 
traits, identify mutations for family planning purposes, and guide medical treatments 
based on likely drug responses. Developments in next-generation sequencing 
technologies over the past five years have enabled personal genome interpretation to 
become feasible and affordable [26]. Despite these advances, understanding of the impact 
of specific genetic variants remains limited. Major efforts have been made to identify 
nsSNPs with strong effects because of their collective high prevalence and likelihood that 





Sequence-based prediction algorithms are commonly used to categorize nsSNPs into 
damaging and non-damaging, and to predict the effects (small or large) of nsSNPs with 
respect to undesirable phenotypes. The algorithms score the amino acid changes from the 
level of sequence conservation observed in homologous sequences or from the degree of 
physicochemical changes. Structure-based predictions evaluate 3-dimensional (3D) 
structural features, e.g., solvent accessibility, stability, number of residue contacts, which 
are altered in the mutant proteins. Approaches that include annotation of biological 
function also support functional assessments of amino acid substitutions. Ng and 
Henikoff (2006) proposed that the combination of all three types of data may provide the 
most accurate assessment of likely deleteriousness [28], which motivates the 
development of the schema proposed in this study. 
A pioneer study in personal genome interpretation stated that the human reference 
genome carries 1104 nsSNPs predicted to have impact on protein functions [41]. A 
similar study indicated that there are 796–837 predicted deleterious nsSNPs per 
individual [17]. This number of predicted damaging nsSNPs is much greater than both 
the theoretically estimated 15–60 damaging nsSNPs per genome [5] and the classified 
disease-causing nsSNP number of 40–100 per genome [42]. These observations highlight 
the complexity of personal genome interpretation and the need for a variant classification 
schema that builds on algorithmic prediction by integrating sound knowledge of the 
biological and structural impact of genetic variants. 
There are many databases that provide useful information about genetic variants. Because 





improvement of available resources is required to more accurately define the set of 
variants that are likely to be most important for an individual’s health. In this study, we 
constructed a classification schema (Figure 2.1, Supplementary Figure A.1) to rank 
nsSNPs identified in healthy individuals by their functional significance. Each ranking 
category reflects the strength of evidence that a variant may adversely affect gene 
function from several standpoints, incorporating both database searches and sequence-
based predictions. The newly developed variant classification scheme is designed to 
generate a best estimate of clinical significance for each variant of interest, with the 
intention of focusing attention on the most likely deleterious SNPs. 
 
Figure 2.1: Flow diagram for AACDS classification algorithm. Upon receiving a list 
of homozygous rare missense variants, the nsSNPs were mapped to the corresponding 
amino acid residue within a reference protein (identified with UniProt accession number). 
We use an SQL server to hold SNP-related information from several resources: 
deleterious predictions (from dbSNFP database [15]), known diseases associations of 
each variant and known disease/trait associations of each gene (from MSV3d [43], 
SwissVar [44], and GWAS databases [45]). The AACDS classification algorithm extracts 
relevant fields from the AACDS database to populate the report on the variant category 
(categories 1–6). The output (Supplementary Figure A.1) is converted from an SQL 
data table to the user-defined formats (HTML, text), and is available for download, or 





Given the very large number of candidate disease-promoting variants per genome, we 
here focus just on the homozygous variants reasoning that highly penetrant effects are 
most likely to be recessive. The methods developed could be applied to all heterozygous 
nsSNPs as well, but this would be a daunting task for manual inspection, which would 
only be warranted given extensive phenotype data and a desire of an individual to receive 
the information. Here we describe homozygous nsSNPs in the genomes of 12 healthy 
participants in a predictive health study, the Emory-Georgia Tech Center for Health 
Discovery and Well Being (CHDWB). Since the IRB consent does not allow 
communication of genetic data, given potential negative consequences of knowledge of 
variants that cannot be acted upon, the identities of the individuals are anonymous and no 
concerted attempt has been made here to link genotypes to phenotypes directly. 
Expanded and appropriately consented studies will be required to evaluate the actual 
utility of the proposed schema as a means of focusing attention on those variants that are 
most likely to influence personalized health behaviors. 
Methods 
Whole genome sequence dataset 
Whole genome sequence (WGS) data was obtained for 12 healthy adult participants in 
the Center for Health Discovery and Well Being (CHDWB) study, including 4 African 
American women, 4 Caucasian women, and 4 Caucasian men. None of the individuals 
has any known complex or Mendelian diseases, but they cover a variety of profiles with 
respect to overall physical and mental health. Prediction of disease risk based on common 





have provided written consent to publication of their whole genome sequence data for 
research purposes only. They do discuss their clinical profile with a health professional 
following annual visits to the Center, but are not currently permitted to receive the 
genetic data generated during the study. In order to protect participant identities, their 
identifying numbers have been randomized for this study. 
WGS was performed on Illumina HiSeq2000 automated sequencers at the University of 
Washington facility under contract to the Illumina Genome Network. Approximately 125 
billion bases passing the Illumina analysis filter were obtained for each genome. Mean 
non-N reference coverage (after excluding gaps) is ~36X with 95.5% of the positions 
having an average coverage of at least 10X. The genome sequences were aligned against 
the human reference genome assembly (hg19 sequence) using CASAVA (Consensus 
Assessment of Sequence And VAriation, Illumina, Inc, San Diego, CA). On average, 
87% of each individual’s quality filtered reads were aligned. High-confidence variants 
with a quality score above 20 were retained. Accuracy of the generated genome 
sequences was confirmed by comparison with previously determined genotypes from 
Illumina OmniQuad arrays, which showed >99% concordance for all individuals. 
The coding variants were functionally annotated using Variant Annotation Tool (VAT) 
[47] which uses the GENCODE v7 gene annotation set [48]. We identified “homozygous 
rare variants” with allele frequency <10% in the Caucasian or African 1000 Genomes 
dataset, using the data provided by dbNSFP [15]. All homozygous rare nsSNPs relative 
to hg19 were identified for each person, and assigned to two categories: known nsSNPs 





but found exclusively in each individual. Information on the number of variants of each 
type is provided in Table 1. Minor allele frequencies (MAFs) for all nsSNPs were 
obtained from NHLBI GO Exome Sequencing Project (ESP6500) (June 2012 release) 
[50], Genomic data for known homozygous nsSNPs (n = 826, including 29 private 
variants) were analyzed as a whole and per individual. 
Amino acid indices for the alternate residues were mapped to the corresponding proteins 
using transcript IDs for the major isoform. All protein sequences and related information 






Table 2.1: Summary of genetic variations in genome sequences of 12 individuals. 
Subject ID Eth, sex 
Total Variants Coding variants Homozygous nsSNPs 
(>q20) (based on Gencode v7) (based on dbSNP build 137) 
SNPs Indels SVs 









genes S MS NS 
Splice Indels Indels Indels 
Overlap 
SVs 
Overlap FS NFS Overlap 
1 Afr, F 4513763 733596 4251 14793 14039 72 98 381 342 137 37 88 77 2 2 
2 Afr, F 4472988 754399 4545 14500 13712 66 106 393 335 147 55 71 63 3 3 
3 Afr, F 4287739 722922 4447 13755 13166 84 79 374 301 120 43 77 71 3 2 
4 Afr, F 4443799 746111 4368 14488 13874 73 104 366 338 142 40 58 56 1 1 
5 Cau, F 3734820 645032 3977 11929 11745 62 90 343 307 123 43 57 40 2 2 
6 Cau, F 3691337 633475 4114 11757 11457 56 90 317 280 106 49 52 45 none none 
7 Cau, F 3691270 632544 4033 11912 11488 65 71 279 304 116 37 50 44 4 4 
8 Cau, F 3722234 641792 4197 11887 11434 64 76 303 299 125 41 55 42 none none 
9 Cau, M 3647944 590064 3828 11619 11255 54 76 311 281 95 38 60 50 2 2 
10 Cau, M 3643046 597363 4011 11814 11480 61 85 289 287 109 31 82 65 2 2 
11 Cau, M 3650690 602744 3916 11560 11285 60 80 342 280 112 32 72 65 5 5 
12 Cau, M 3701558 639005 4739 11842 11708 60 81 334 290 118 37 75 64 5 5 








Abbreviations: Eth ethnicity, SNPs single nucleotide polymorphisms, SV structural variants, S synonymous, MS mis-sense, NS 





Sequence annotation using published algorithms 
Evidence for association of each SNP or gene with diseases or traits was obtained from 
public repositories of amino acid polymorphisms (MSV3d, July 2012 release [43] and 
SwissVar, accessed December 2012) [44], from Online Mendelian Inheritance in Man 
(OMIM) [52], and from the NHGRI genome wide association studies (GWAS) [45] 
catalog. Initially, each nsSNP was assigned as disease-causing, probably disease causing, 
unclassified, or neutral. Functional predictions, and information on disease- and trait-
associations to the gene were collected from dbNSFP [15]. In addition, we used UniProt 
sequence feature records [51] to annotate whether the mutated amino acid is localized to 
any structurally/functionally important sites (molecule processing sites, binding sites, 
modification sites, etc.). 
To annotate deleterious nsSNPs, consensus predictions from several algorithms were 
compared. Pre-computed deleterious scores for each nsSNP were retrieved from dbNSFP 
[15]. To our knowledge, dbNSFP is the first database that provides pre-computed 
functional predictions from multiple algorithms, facilitating interpretation of the 
deleteriousness of variants in large datasets. The database provides the output of six 
different prediction algorithms that have complimentary methodologies. Three are 
sequence-based (SIFT [16], LRT [17], and MutationAssessor [18]), while two are both 
sequence and structure-based (PolyPhen2_HumDiv and PolyPhen2_HumVar [19]), and 
the sixth is the MutationTaster Bayesian classifier [20]). Each of these tools relies 
primarily on the basic assumption that residue functionality dictates sequence 
conservation, which can consequently be used to infer deleteriousness. Raw scores for the 





stronger (deleterious) effect of a nsSNP [15]. A MutationAssessor score of > 3.5 
designates high functional impact [18], hence, “deleterious”. The six prediction programs 
were used to construct the classification scheme of nsSNPs presented in Table 2.2. 
Putative deleterious nsSNPs were identified as nsSNPs reported as “deleterious” by at 





Table 2.2: AACDS classification of homozygous nsSNPs in 12 genomes. 






count ≥ 3 




1 2 3 4 5 6 7 8 9 10 11 12 
Afr, F Afr, F Afr, F Afr, F Cau, F Cau, F Cau, F Cau, F Cau, M Cau, M Cau, M Cau, M 
1 X    1 none none none 1 none none 1 1 none 1 none 5 
2A   X  8 7 6 5 6 5 11 7 12 7 10 9 93 
2B  X X  1 none none none 2 2 4 1 2 none 2 none 14 
3A    X 9 24 17 7 6 10 9 10 5 13 16 10 136 
3B  X  X 1 5 none none 1 1 3 4 2 2 none 2 21 
4  X   5 5 8 6 none 5 3 7 4 6 5 4 58 
5   X X 14 21 20 10 8 12 9 11 13 18 20 14 170 
6     68 40 49 42 46 32 33 33 40 56 45 55 539 
Total #unique nsSNPs 88 71 77 58 57 52 50 55 60 82 72 75 797 





In addition to the deleterious predictions, protein regions under evolutionary constraint 
were detected using three evolutionary conservation-based indicators: GERP++ [53], 
phyloP [54], and SiPhy [55]. We also used Grantham scores [56] to reflect the degree of 
physicochemical differences between pairs of amino acids. These four indicators were 
included in the analysis for comparison purposes but were not utilized for nsSNP 
categorization. 
Other popular variant annotation tools might also be useful but were considered to be 
redundant with respect to our purposes. For example, ANNOVAR [57] has the ability to 
perform variant annotation (intronic, intergenic, untranslated region, exonic: non-
synonymous, synonymous, etc.), but this information was already available from the 
VAT output. At the time of our analysis, ANNOVAR provided dbSNP build 135 
mapping, not the dbSNP build 137 [49] used in our analysis pipeline. Note that gene 
definitions from ANNOVAR refer to the nucleotide reference sequence where a SNP is 
located; the format is not directly applicable for working with records from the two 
selected SNP databases (MSV3d [43] and SwissVar [44]), in which UniProt accessions 
were used to identify gene products. Similar to ANNOVAR, SnpEff [58] is another 
popular program that can assign structural annotations of variants. This function would 
be valuable when one wants to analyze different types of genetic variations within a 
genome. Because we only focused on analysis of missense mutations, the annotation 





Supervised and automated structure-based predictions of variant function 
High quality protein 3D structures are essential to identify functional impacts of nsSNPs. 
Due to the limited availability of experimentally-determined human protein structures 
[59], an assortment of 3D structure sources was used to manually evaluate the effects of 
single point mutations found in specific proteins (Supplementary Table A.1). Crystal 
structures were retrieved from the RCSB Protein Data Bank (PDB) [60]. Homology 
models were retrieved from Protein Model Portal (PMP) [61] repository, or were built 
manually by joining multiple structures into a single model of a protein. Steric conflicts 
found within homology models were resolved by energy minimization with explicit 
solvent using YASARA force field [62]. Structural validation of homology models was 
evaluated by using two independent scores: QMEAN6 [63] and ModFOLD4 [64]. All 3D 
structures were visualized and rendered using Chimera [65]. 
The analysis began with a visualization of wild type proteins in the context of bound 
ligands. Additional variants that are known to be associated with diseases, or affect 
protein functionality and/or stability were also identified for each protein structure. Next, 
we used SDM [66] to compare the protein stability changes upon amino acid mutations 
with the default modeling of a mutant structure using Andante [67]. A mutation is 
classified as affecting protein function (stabilizing or destabilizing) using the stability 
cut-off of ±2 kcal mol-1 [66]. For evaluating the impact of amino acid changes on protein 
stability in a high throughput fashion, we obtained the tertiary classification of protein 
stability changes (increase, decrease, neutral) caused by a SNP from I-Mutant 2.0 [68], 
available from MSV3d [43]. The predictions are based on the protein (or homolog) 





In order to expand the structure-based predictions to a larger dataset without the 
requirements of manual inspection or in-depth literature searches, we applied a 
combination of database searches and computational predictions to a larger set of 
proteins. In addition to the 6 protein structures described in the main text, we identified 
an additional 25 protein coordinates from PDB [60] (Supplementary Table A.2). We 
assessed these 25 wild type proteins in 4 areas of structural analysis: protein stability, 
ligand binding capability, protein dynamics, and protein-protein interactions. For protein 
stability, we used the aforementioned approach along with predictions of amino acids 
with specialized roles regarding protein stability, namely long-range stabilization center 
(SC) residues and stabilizing residues (SRs). These residues were inferred from the SCide 
[69, 70] and SRide webservers [71], respectively. Ligand binding residues for each 
protein were retrieved from PDBe (www.ebi.ac.uk/pdbe/) or were predicted using 
3DLigandSite [72]. Amino acid residues that are located in or near predicted binding 
pockets are likely to alter the binding capability for ligand(s). As disease-causing 
mutations that do not occur in binding sites or buried sites are predominantly found on 
protein interfaces [36], we used the PatchFinder program [73, 74] to computationally 
predict the most significant cluster of conserved residues on a protein’s surface that may 
indicate possible functional sites of the protein; i.e., sites of protein-protein interactions. 
Changes in protein dynamics were evaluated by the crystallographic B-factor of Cα 
atoms. In addition, we also used PredyFlexy [75] and FlexPred [76, 77] to predict the 
dynamic class of an amino acid residue (rigid, intermediate, flexible), and to estimate 





Assessment of functional enrichment 
The g:Profiler web server [78] was used to detect enrichment of gene functions for genes 
whose nsSNP are homozygous. Functional profiling and statistical enrichment analysis 
were performed with two distinct methods. First, we compared the annotations of 
multiple gene lists, where each list represents the genes with known homozygous variants 
found in an individual, using G:Cocoa (n = 40–77 genes per genome). Then, we analyzed 
a gene list for each individual using G:GOSt. The second analysis was performed in two-
steps: with and without genes harboring private variants. Enriched functions, such as 
common gene ontology, biological pathways, shared transcription factor or miRNA 
binding sites, were reported using the default g:SCS method for significance threshold 
determination. It is worth mentioning that significant enrichment of protein-protein 
interactions, derived from the BioGRID database [79], does not imply that all genes with 
significant enrichment p-value are interacting with each other, but simply indicates which 
query genes are present in the entire BioGRID dataset. The actual number of interactions 
and associated genes can be visualized from the network output. The enriched 
annotations and their gene members were confirmed by literature searches. Furthermore, 
the SNPshot text-mining tool for PubMed abstracts was used to explore if any of the 
private homozygous nsSNP-containing genes have clinical or experimental evidence for 






Results and discussion 
Sequence-based variant description in 12 genomes 
A total of 797 known homozygous non-synonymous substitutions was observed in 575 
different genes (Table 2.1). The genomes of the four African individuals harbor on 
average 73 homozygous nsSNPs (range 58–88), while the eight Caucasian genomes have 
an average of 63 homozygous nsSNPs (range 50–82). The slight excess in African 
Americans is not statistically significant (p = 0.18, 2-tailed t-test). 456 of the genes (79%) 
have a single homozygous variant in the 12 genomes, but two genes (HLA-DRB5 and 
ANKRD20A4) have more than 10, detected in at least 6 individuals. 
The vast majority of all of the variants have been observed previously in the 
1000Genomes project, with just 29 private homozygous nsSNPs observed in 25 different 
genes, with a range of 0 to 5 per genome. Private variants were found in 10 out of 12 
genomes of CHDWB dataset and are listed in Supplementary Table A.3. Most are 
predicted to be neutral, though they affect nucleotides with a range of conservation 
levels. Almost one-third of the 25 genes have no defined functions, and only a minor 
proportion of the genes have been previously associated with a disease or trait. 
Among the 575 genes whose nsSNPs are homozygous and present in dbSNP build 137, 
the fractions with known functions, putative functions, and unknown functions are ~47, 
20, and 33%, respectively (Table 2.3). Almost 10% of the homozygous nsSNPs are 
found in four highly represented protein groups: transcriptional regulators, keratin-





Table 2.3: Functional annotation of all homozygous nsSNP. 
Gene groups 
Genes nsSNPs Most common proteins 
# % # % (#proteins, #nsSNPs) 
Genes with known 
functions 
268 47% 340 43% Transcriptional regulator proteins (15 proteins, 
17 nsSNPs), Keratin-associated proteins (6 
proteins, 9 nsSNPs) 
Genes with putative 
functions 
118 20% 167 21% Potential odorant receptors (21 proteins, 27 
nsSNPs), Zinc finger-containing proteins, 
potentially for transcriptional regulations (16 
proteins, 22 nsSNPs) 
Genes with unknown 
functions 
189 33% 290 36% - 
Total 575 100% 797 100%  
Six programs were used to predict deleterious variants, and three to indicate the level of 
sequence conservation at the polymorphic site. The results are summarized in Figure 2.2, 
which shows the cumulative number of predicted deleterious (blue) or highly conserved 
(red) scores for each of the 797 variants. Although 58% of all homozygous missense 
variants in the 12 genomes alter conserved sites in all three assessments, almost 40% of 
these (183/463) are predicted to be functionally neutral by all six programs. 45% of the 
homozygous rare variants are predicted deleterious by at least one program, and 11% (88 







Figure 2.2: Number of deleterious and conserved site predictions. Data labels indicate 
the numbers of homozygous nsSNPs predicted to be damaging or conserved by n 
programs (n = 0-6 for deleterious predictions, and n = 0-3 for conservation predictions.)  
Differences among the deleteriousness prediction algorithms are underscored by the 
cumulative score distribution plots in Figure 2.3. The solid lines in the top half of each 
plot are for the 294 homozygous rare variants in the African Americans (black) and 503 
homozygous rare variants in the Caucasians (blue). The two curves are not significantly 
different, and predict that as many as 28% of variants are deleterious (MutationTaster) or 
as few as 2% (MutationAssessor), with the two most commonly used algorithms, SIFT 
and PolyPhen2, giving intermediate estimates of 80% neutral. The lower curves show 
cumulative distributions for a set of 24,703 disease-promoting non-synonymous variants 
in 1,789 proteins compiled from the MSV3d [43] and SwissVar [44] databases (red 
dashed curve), as well as from subsets of these disease variants found only in the 23 
genes (348 SNPs) harboring homozygous nsSNPs in the four African Americans, or 44 
genes (547 SNPs) in the eight Caucasians in our sample (black and blue-dashed curves 
respectively). All six programs show an elevated tendency to predict known disease-





as neutral. This is particularly obvious for the MutationTaster score and least pronounced 
for SIFT. A similar observation of differences among Asians, Caucasians and Africans in 
the fraction of damaging SNPs predicted deleterious was made by [81]. 
 
Figure 2.3: Cumulative distribution plots for the six deleterious prediction scores. 
The X-axis represents the prediction scores, ordered by the deleteriousness. The lowest 
and the highest scores for each prediction algorithm indicate the neutral and damaging 
nsSNP, respectively. For each prediction program, the score threshold for defining 
damaging SNPs is indicated by a vertical dashed green line (threshold for LRT is at 
0.999). Five sets of SNP data are shown in each plot. Black solid lines: data from 
homozygous nsSNPs of four African individuals; blue solid lines: data from homozygous 
nsSNPs of eight Caucasian individuals; red dashed lines: data from all disease-causing 
nsSNPs (n = 24,703 nsSNPs in 1,789 proteins); black dashed lines: data from disease-
causing nsSNPs found in homozygous nsSNP-containing genes of the four African 
individuals (n = 348 nsSNPs in 23 genes); blue dashed lines: data from disease-causing 
nsSNPs found in homozygous nsSNP-containing genes of the eight Caucasian individuals 
(n = 547 nsSNPs in 44 genes). All disease-causing nsSNPs were retrieved from MSV3d 
[43] and SwissVar [44].  
The notable differences in deleterious predictions given a set of disease-promoting 





suggest these prediction algorithms may have population-specific effects. To further 
investigate that this observation is not an artifact of the small samples, we plotted similar 
curves for a set of 1,789 genes harboring disease SNPs (total 24,703 SNPs). The genes 
were classified into four groups depending upon population bias of their SNPs, using 
%MAF difference cutoff of ± 5% between European American (EA) and African 
American (AA) populations. The four gene groups are: EA bias, AA bias, EA&AA bias, 
and no bias. Unlike Figure 3 where homozygous variants in the African Americans were 
consistently predicted to be more neutral, the larger-sample plots (Supplementary 
Figure A.2) illustrate a small difference in the cumulative scores of population specific-
disease SNPs, with the exception of a noticeable prediction bias of MutationTaster. The 
results highlight the need for development of mutation assessment pipelines that go 
beyond these algorithms, particularly when evaluating homozygous nsSNPs of non-
Caucasian genomes. 
Association-adjusted consensus deleterious scheme (AACDS) for variant 
classification 
Consequently, we developed a ranking system that classifies homozygous nsSNPs into 
eight categories according to the overlap of (i) consensus deleterious prediction, (ii) 
documentation that the SNP causes a disease, and evidence that the SNP is in a gene that 
has been associated with (iii) a disease or (iv) a quantitative trait (Figure 2.1). Category 1 
contains documented disease-causing nsSNPs. Categories 2A and 3A represent nsSNPs 
in genes that have known associations with diseases (2A) or traits (3A), and these are 
sub-divided into categories 2B and 3B if they are also predicted to be deleterious by three 





lie in genes that have no clinical associations. Conversely, Category 5 nsSNPs are located 
in genes that have disease or trait associations, but variants are predicted to be neutral. 
Category 6 represents neutral nsSNPs, whose genes have no clinical relations. Table 2.2 
lists the number of variants in each category from each individual’s genome. 
The list of disease-promoting nsSNPs was retrieved from MSV3d [43] and SwissVar [44] 
and is based on manual curation of evidence that the variant is causal, or probably causal, 
in disease. Most are relatively rare (MAF < 5%) presumed highly penetrant mutations, 
but an unknown fraction may be false positives. Among the 575 genes in our dataset, 93 
harbor disease causal variants (n = 787 nsSNPs). The 797 homozygous nsSNPs in our 
dataset include 4 category 1 “disease-causing” mutations (1 SNP is present in two 
individuals) and another 6 listed as probably pathogenic (Table 2.4). Another 143 are 
classified as having unknown effects, leaving 644 polymorphisms presumed not to cause 
disease in a highly penetrant manner. The 10 probably or known pathogenic missense 





Table 2.4: List of all four known disease-causal variants and six probable pathogenic variants. 
SNP type Gene 














ATP6V0A4 7:138417791 rs3807153* 
(4.8/18.5/9.4) 
Distal renal tubular acidosis (dRTA) with preserved hearing 81 Neutral TRANSMEM 
A-->G (M580T) [Del count: 2; Con count: 3] 
MTMR2 11:95569448 rs558018 
(0.02/3.9/1.3) 
Charcot-Marie-Tooth disease type 4B1 (CMT4B1) 46 Decrease DOMAIN 
T-->C (N545S) [Del count: 2; Con count: 3] 
APOE 19:45412079 rs7412 
(5.6/8.7/6.6) 
Lipoprotein glomerulopathy (LPG) 180 Decrease REPEAT 
C-->T (R176C) [Del count: 5; Con count: 3] 
BMP15 X:50658966 rs104894767 
(1.4/0.3/1.0) 
Premature ovarian failure type 4 (POF4) 58 Neutral PROPEP 
G-->A (A180T) [Del count: 0; Con count: 1] 
Probable 
pathogenic 
FRZB 2:183699584 rs7775 
(8.8/28.4/15.4) 
Osteoarthritis type 1 (OS1) 125 Neutral - 
G-->C (R324G) [Del count: 1; Con count: 3] 
HABP2 10:115348046 rs7080536 
(3.9/0.7/2.8) 
[Del count: 5; Con count: 3] 98 Decrease DOMAIN 
G-->A (G534E) 
HNF1A 12:121416650 rs1169288 
(33.5/12.1/26.2) 
Insulin-dependent diabetes mellitus type 20 (IDDM20) 5 Neutral REGION 
(Dimerization) A-->C (I27L) [Del count: 1; Con count: 3] 
XYLT1 16:17564311 rs61758388 
(-/-/1.7) 
[Del count: 0; Con count: 3] 99 Neutral TOPO_DOM 
C-->A (A115S) 
CYP2A6 19:41354533 rs1801272 
(2.5/0.5/1.8) 
[Del count: 1; Con count: 3] 99 Decrease - 
A-->T (L160H) 
ADA 20:43255220 rs11555566 
(6.3/6.8/6.5) 
Severe combined immunodeficiency autosomal recessive 
T-cell-negative/B-cell- negative/NK-cell-negative due to 
adenosine deaminase deficiency (ADASCID)  
[Del count: 1; Con count: 3] 
26 Decrease - 
T-->C (K80R) 






Table 2.4 (continued) 
The minor allele frequency (MAF) in percent listed in the order of European American (EA), African American (AA), and all 
populations (All), delimited by “/”. Prediction counts indicate the number of deleterious predictions (Del count) and conservation 
predictions (Con count) by six and three programs, respectively. Grantham score determines the similarity in amino acid changes: 
small (score < 60), intermediate (score 60–99), and large (score ≥ 100). Tertiary classification (increase, decrease, neutral) for protein 
stability change caused by a SNP was obtained from I-Mutant 2.0 [68], available from MSV3d [43]. Site annotations list any 
structurally/functionally important sites (molecule processing sites, binding sites, modification sites, etc.) where the altered amino acid 





Among the 93 disease-associated genes with homozygous nsSNPs in our CHDWB 
genomes, 18 have homozygous variants present in more than one individual, and these 
account for 40 nsSNPs, observed at 33 different sites. Only one of these sites, G56R in 
the MYH6 myosin heavy chain, is predicted to be deleterious. Since it is also associated 
with resting heart rate, it is classified in both categories 2B and 3B. Data for the variant 
categorization in these 18 disease-associated genes is summarized in Supplementary 
Table A.4. Similarly, we also observed 101 genes with trait associations, including 126 
SNPs. Since there are a total of 14 and 21 variants in categories 2B and 3B respectively, 
most of these cases are restricted to a single individual in the sample of 12. Details for 
these predicted deleterious variants are listed in Supplementary Tables A.5 and A.6, 
respectively. On average, each individual carries 3.33 category 1, 2B or 3B homozygous 
variants (range 0 to 7), and although the two individuals with no variants of this type are 
both African Americans, there is no significant difference in prevalence relative to the 
Caucasians (p = 0.21, 2-tailed t-test). All of the remaining predicted deleterious variant 
that do not have disease or trait associations (namely, category 4) are listed in 
Supplementary Table A.7. 
The set of 35 disease- or trait-associated SNPs that are also predicted to be deleterious is 
seven times larger than the set of 5 category 1 “known to be deleterious” mutations. They 
represent 15% of the 93 disease-associated and 136 trait-associated category 2A and 3A 
SNPs. Supplementary Figure A.3 compares the allele frequency distributions of the 
2B/3B SNPs relative to all 2A/3A SNPs and shows a tendency to reduced allele 
frequency, also consistent with them having deleterious effects on fitness. Another 170 





not predicted to be deleterious (category 5). Their frequency distribution is approximately 
equivalent to those of the category 2A and 3A SNPs. The vast majority (539) of the 797 
SNPs we have considered are in category 6 and represent the subsets that are least likely 
to be damaging. 
A limitation of our analysis is the uncertainty in the accuracy of phenotypic annotations 
of SNPs, as well as the variable confidence level in annotations of causal SNPs. We 
obtained the list of disease-promoting nsSNPs from MSV3d [43] and SwissVar [44]. 
Most of the variants were classified as either causal variants (to a specific disease), or as 
polymorphisms. In MSV3d, many variants have ambiguous annotations, e.g., probable-
pathogenic, or unknown. In SwissVar, some proteins are noted to have associations with 
diseases, but the list of variants is not provided. 
Supervised structure-based variant evaluation 
Personal genome studies indicate that each healthy individual carries a large number of 
rare homozygous genetic variants [1-4]. While these variants can be found in any 
structural regions along the genome and can have diverse effects on biological function, 
Cooper (2010) estimated that as many as 60% of known disease-causing mutations are 
nsSNPs [5]. This viewpoint simply reflects the more obvious impact of nsSNPs on 
coding regions than regulatory regions: the substitutions tend to alter the amino acid 
sequences of the proteins. Amino acid changes are thought to have profound effects on 
the protein, impacting their structure or function. Furthermore, it is believed that there 
exist some structure-function relationships for each individual amino acid residue within 





information [82]. Therefore, many algorithms have been developed to assess the effects 
of amino acid changes within the context of protein 3D structures. Numerous structural 
features have been used to explain/quantify the changes [83]. A few successful 
implementations have demonstrated that protein 3D structures add to prediction accuracy 
[35, 39]. In addition, in silico analysis of 3D structures can facilitate variant prioritization 
because it provides systematic screening of nsSNP effects in the context of the protein 
structure and suggests which mutations may critically alter the function of the protein. 
Implementation of the AACDS classification scheme reduces the number of potentially 
deleterious variants to a number per genome that can feasibly be evaluated manually on a 
case-by-case basis. For this purpose, we have devised a further pipeline that involves 
sequence annotations, extracting either X-ray crystal/NMR structures or homology 
models from structure databases, and computing a series of predictions that capture 
protein features. In this way, each of the up to 5 variants in categories 1, 2B or 3B can be 
assessed in the context of the actual protein. While this approach requires that an 
individual with experience in protein structures be engaged in the personal genome 
evaluation, the potential gain in accuracy is likely to be meaningful. 
Our preliminary analysis utilized sequence features for all amino acid residues in each 
protein, obtained from UniProt features records [51]. The entries had been curated and 
are predicted (and compatible with the protein function), experimentally proven, or 
determined by resolution of the protein structure. The analysis was restricted to 62% of 
the nsSNPs, since the remaining fractions do not currently have feature information. 
Figure 2.4 illustrates that although the annotated 494 nsSNPs are found in various 





These proportions are approximately equivalent to the proportions of each of the 9 types 
of annotated protein region for all residues in the included proteins (Supplementary 
Figure A.4). Locations of homozygous variants relative to the length of each sequence 
feature indicate the variants are located throughout the entire sequence length 
(Supplementary Figure A.5). 
 
Figure 2.4: Distribution of homozygous nsSNPs by sequence type. Data labels 
indicate the number (and percentage) of SNPs altering protein residues with each 
specified sequence features. All sequence features were obtained from the UniProt 
database [51]. 
Subsequent detailed analyses involved manual inspection and evaluation of individual 
proteins. The remainder of this section discusses detailed structural evaluations of two 
known causative variants, two predicted deleterious variants in proteins that have been 
associated with a disease or trait, and two predicted deleterious variants for which the 
clinical associations are inconclusive. The first disease causing nsSNP is the well-known 
Arginine to Cysteine substitution at residue 176 (residue 158 if omitting the signal 
peptide) that defines the APOE2 allele of Apolipoprotein 2 (SNP category 1/2B/3B). This 





Alzheimer’s disease and coronary artery disease [84-86]. Homozygosity for R176C is 
also associated with Type III hyperlipoproteinemia (HLPP3) in approximately 2% of 
cases (though 94% of HLPP3 cases have the genotype) [87]. Onset of the disorder is 
usually only after menopause in women and rarely manifests before the third decade in 
men. Several other rare variants in the gene have been annotated to disease, most of 
which affect intra- and inter-helical salt bridges (Figure 2.5A). With the neutral cysteine 
at position 176 in APOE2 protein, this pattern of salt bridge is eliminated. Although 
Arg176 does not interact with the LDL receptor, the R176C substitution has been shown 
to indirectly reduce the receptor-binding activity of APOE [88]. Stability prediction 







Figure 2.5: Location of variants in six protein structures. A-B describe two causative 
variants, C-D demonstrate two predicted deleterious variants, E-F illustrate two predicted 
deleterious variants whose clinical associations are inconclusive. For all figures, the 
representations are as follows: ribbon for proteins, ball and stick for ligands, mesh for 
ligand binding sites, and sphere for amino acid variants. Amino acid variants caused by 
homozygous or heterozygous nsSNPs are indicated as (***) or (*), respectively. 
Additional variants that are known to be associated with diseases (D), or affect protein 
functionality (F), and/or stability (S) are also identified. A: Apolipoprotein E 
(PDB:2L7B). B: Myotubularin-related protein 2 (PDB:1LW3). C: Thrombospondin-1 
(PDB:1UX6 and homology model). Residues 1–548 are missing from the structure, 
residues 549–829 (brown ribbons) are modeled from human THBS2 (PDB:1YO8), 
residues 848–1169 (white ribbons) are from a crystal structure of THBS1 (PDB:1UX6). 
Coordination complexes of amino acid side chains and Ca2+ ions (green spheres) as seen 
in the crystal structures are indicated with purple lines. The Ca2+ ions with unidentified 
coordination complexes are derived from the superposition of Ca2+ ions in 1YO8 onto 





nsSNPs were also identified from the same genome, but only two are present in the 
crystal structure. E: Myosin heavy chain 6 (αMyHC) modeled from Myosin heavy chain 
7 (βMyHC) (PDB:4DB1). The C-terminal (residues 778–1939) is missing from the 
template crystal structure. F: Pancreatic alpha-amylase (AMY2A) (PDB:3OLE). The 
Pro145 is located at the end of the extended β-loop and is part of a binding site for α-D-
glucose. For clarity, only one α-D-glucose binding site is shown. Other variants known to 
affect the enzymatic activities are located around the chloride ion (green sphere) in the 
central vicinity of the protein.  
The second example of causative mutation is in Myotubularin-related protein 2 
(MTMR2), a putative tyrosine kinase that is associated with Charcot-Marie-Tooth disease 
type 4B (CMT4B) [89]. One African individual has an Asparagine to a Serine 
substitution at the position 545 of the protein that has previously been reported as a rare 
variant in patients with CMT disease [90]. This SNP is classified as category 1. The 
minor allele frequency of this nsSNP is reported as 3.88% and 0.02% in African 
Americans, and European Americans, respectively, so the penetrance is much reduced in 
African Americans since disease prevalence of all forms of CMT is just one in 2,500 
[91]. The variant is situated in a conserved site, but only two algorithms predict it to be 
deleterious. The crystal structure places Asn545 in a protein domain, but it is not in close 
proximity with two other causative variants or part of a binding site. This mutation is also 
predicted to be neutral (∆∆G = 0.36 kcal mol-1) (Figure 2.5B). 
One predicted damaging nsSNP was found in Thrombospondin 1 (THBS1), a 
glycoprotein that stabilizes fibrinogen platelet cross-bridges [92]. The homology model 
indicates the substitution of a Serine for Asparagine at residue 700 of THBS1 occurs at a 
critical position in one of the calcium-binding domains (green spheres project 
coordination of CA2+ ions) (Figure 2.5C). This Asn700Ser substitution in THBS1 (SNP 





occurrence of premature (age < 45) coronary heart disease in both homozygous and 
heterozygous individuals [92]. However, a study of Asn702Ser in THBS2 (homologous 
to 700 in THBS1) demonstrated that this variant does not alter calcium-binding 
capability. Instead, it induces a local conformational change leading to destabilization of 
surrounding structures [93], consistent with the computational prediction that the variant 
has a destabilizing ∆∆G of 0.58 kcal mol-1. 
The second example of a predicted deleterious nsSNP is a missense substitution in Acidic 
mammalian chitinase (CHIA), an enzyme that stimulates chemokine production by 
pulmonary epithelial cells. Arg35Trp (SNP category 4) is located in a buried site, where it 
causes changes in residue side chain volume, charge, polarity, and hydrophobicity 
(Figure 2.5D). The substitution was predicted to disrupt the hydrophobicity of the protein 
and increase solvent accessibility of the residue [43]. The individual who is homozygous 
for this variant also carries three heterozygous nsSNPs (N278D, I339V, and V432G). The 
first two of these replacements are parts of disulfide bonds, while the third substitution 
resides in the chitin-binding domain. Interestingly, the Arg35Trp mutation is predicted to 
stabilize the protein (∆∆G = −1.19 kcal mol-1), a finding that may appear counter-
intuitive. However, it is suggested that protein flexibility is crucial for enzyme catalysis 
[66]. The increase in protein stability and the dramatic change in physicochemical 
properties caused by this homozygous nsSNP, along with the disulfide bond reduction 
from heterozygous variants, strongly suggest the possibility for protein malfunction in 
this individual. As far as we are aware, he does not have asthma or an aberrant T-helper 





The last two examples highlight cases where the variant is predicted deleterious but its 
clinical associations are inconclusive. The first example is a Glycine to Arginine 
substitution at residue 56 of Myosin heavy chain alpha (MYH6) (SNP category 2B/3B). 
As mentioned earlier, this is the only predicted deleterious variant among a set of 18 
disease-associated genes with variants present in more than one individual 
(Supplementary Table A.4). SNP databases indicate six well known causative variants 
in this gene that lead to familial hypertrophic cardiomyopathy and atrial septal defect. 
Although G56R is not one of them, this variant had been previously identified in affected 
individuals but it does not segregate perfectly with the disease in families of probands 
[94, 95]. With regard to the homology model (Figure 2.5E), many of the known variants 
associating with heart disease are located in the coiled-coil regions of this protein 
(missing from the crystal structure) and are not part of the ATPase catalytic site or actin 
binding site. Nonetheless, the G56R found in one of the CHDWB participants is 
particularly interesting, since the mutation occurs in a myosin head-like domain, a key 
component for muscle contraction, and with a large degree of amino acid change 
(Grantham score = 125). Stability prediction also suggests this variant destabilizes the 
protein (∆∆G = 1.10 kcal mol-1). 
The second example of a variant with uncertain functional effect is taken from a set of 
143 SNPs (18% of CHDWB dataset) that do not currently have phenotypic annotations. 
Among these, 117 SNPs have neither disease nor trait association at the gene level. Form 
143 SNPs, we identified 15 variants predicted to be damaging, of which 8 are located in 
genes with no clinical associations. Our example is a Proline to Serine substitution at 





calcium ion and one chloride ion per subunit, the protein is able to bind to several ligands 
throughout the structure. Mutagenesis studies identified several amino acid residues that 
are essential for the protein’s catalytic activity and affinity to calcium and chloride ions, 
but the impact of Pro145Ser has not been established [96, 97]. Despite the limited 
information of the variant, crystal structure indicates Pro145 is part of one, among many, 
binding sites for alpha-D-glucose (Figure 2.5F). In general, amino acids with similar 
physicochemical properties may substitute each other while maintaining the protein’s 
functionality. One study demonstrates some uncommonly predominant inter-species 
amino acid variations, such as serine-proline pairs or glutamic acid-alanine pairs [98]. 
The notable feature corresponds with the proline to serine substitution caused by this 
SNP. It is well known that the proline residue is sterically restricted and that it tends to 
disrupt regular secondary structural elements. Most proline residues are found in very 
tight turns or on protein surface [99]. The unusual occurrence of Pro145, especially in the 
extended β-loop indicates that this residue is essential for proper protein folding. Further 
investigation revealed that this residue is in the cis isomer, a very rare phenomenon since 
proline residues are exclusively synthesized as the trans isomer. In fact, AMY2A 
contains two cis-proline residues (Pro69 and Pro145); both are located in the loop 
regions. It had been suggested that the two residues help accommodate a sharp turn of the 
β-loop [100]. Substitution of proline to serine is predicted to be highly stabilizing for 
residue 145 (∆∆G = −2.77 kcal mol-1), but highly destabilizing for residue 69 (∆∆G = 
5.23 kcal mol-1). In any case, strong stability changes are suggested to cause protein 





Automated structure-based variant evaluation 
To facilitate high throughput evaluation of protein structures, we devised a structural 
analysis pipeline that assesses the functionality of protein residues using data directly 
obtained from the atomic coordinates or from computational predictions. Using this 
approach, a list of potentially deleterious variants from a structural perspective can be 
generated rapidly, providing a way to integrate structural analysis into the variant 
categorization scheme. 
The four areas of automated structure-based variant analysis include stability, flexibility, 
and potential to disrupt protein-protein or protein-small molecule interactions. Many 
mutations disrupt these structural features and as a result, lead to altered protein functions 
or diseases. Our assumption is that the analysis may be able to identify some variants 
with strong effects. The results are summarized in Supplementary Table A.8, which 
indicates that predicted deleterious variants show a wide variety of residue features. In 
general, SNPs that do not cause stability change (∆∆G < ± 0.5 kcal mol-1) tend to be non-
deleterious, but not vice versa. Four amino acid residues have B-factors of Cα atoms 
larger than 60 Å2, a characteristic which may indicate that the atom is disordered due to 
dynamic motion, or may be an artifact of crystal imperfection. However, three out of 
these four amino acids are predicted to be at rigid sites and do not induce conformational 
switches. Another three residues are predicted to lie within a cluster of conserved 
residues on a protein surface, but none is categorized as damaging variants. Lastly, we 
found only one amino acid mutation that is located within the binding site, but the variant 





Imposing the constraint that the 3D structures must be of high quality, our initial analysis 
was restricted to only 24 experimentally-determined structures and 1 high quality 
theoretical model. Their sequence coverage ranges from 23–100% (average 69%) 
(Supplementary Table A.2). However, the implementation can be further applied to any 
available structures. For example, using the automated Phyre2 homology modeling server 
with single/multiple template methodology [101], we were able to model an additional 77 
full length proteins with high confidence. Each full length protein model has a percentage 
of residues modeled at >90% confidence in the range of 59-99% (average 86%). For 
larger proteins (>1,300 amino acids), we truncated them into smaller domain(s) and our 
modeling attempt returned 10 models with confidence between 96-100%. 
Enrichment for mutations disrupting protein interactions 
As a parallel approach to evaluating the deleterious potential in homozygous protein 
substitutions, we used g:Cocoa [78] to evaluate whether there is an enrichment for 
proteins that have similar functions. The analysis revealed four significant gene 
annotations that include a significant number of the queried genes from more than one 
individual. These four terms are: X-linked recessive inheritance, epithelial cell signaling 
in H.pylori infection, microRNA miR-708 binding sites, and Rho GTPase signaling 
pathway (Supplementary Figure A.6). 
Although 96 homozygous nsSNPs were identified on the X chromosome, only 1 nsSNP 
has been documented as a causal variant (X:50658966 G → A) (Table 2.4). Genes 
involved in X-linked recessive inheritance from the 12 genome data were identified in 





identified only two predicted damaging SNPs. One was found in TBX22 that is associated 
with X-linked cleft palate. The other is located in SYTL5, a trait gene associated with 
erectile dysfunction and prostate cancer treatment. The remaining X chromosome 
variants are predicted as neutral. Two male individuals have the same mutation in the F9 
gene, for which reduced function can result in hemophilia B (HEMB). Unlike hemophilia 
A, symptoms of HEMB are usually milder or can be asymptomatic. Three male 
individuals also carry an identical SNP in FRMD7 gene. Malfunctions of this gene can 
cause nystagmus congenital X- linked type 1 (NYS1), a condition that appears at birth 
and up to three months old. The indications are spontaneous and involuntary ocular 
oscillations. Given that most X-chromosome variants are predicted neutral and there is no 
indication that either of these individuals have these conditions, it is unlikely that the 
associated disease or trait will develop. 
Finally, we used BioGRID [79] to evaluate enrichment for proteins that form physical 
interaction networks, and found that one of the 12 individual’s genomes has 7 mutations 
potentially involved in an unusually high number of contacts (Supplementary Figure 
A.7). Three of these proteins (FHL2, STK17A, and DSP) are linked together by other 
interacting partners. The FHL2 gene encodes a four and a half LIM domain protein that 
acts as a molecular transmitter between signaling pathways and transcriptional regulation. 
The wild type amino acid affected by the homozygous missense variant of the FHL2 gene 
is evolutionarily conserved, but the Arg177Gln substitution is only predicted to be 
deleterious by one program. This variant is not predicted to affect protein stability and the 
protein is not associated with a disease or trait. However, we mention it as an example of 





multiple partners may result in cumulative disruption that would lead to disease under a 
multiplicative burden of rare variants model. 
Conclusions 
Intensive resource requirements and the associated costs make it infeasible to 
experimentally verify the effect of every genetic variation. At this stage of human 
genome study, in silico predictions play an important role in identifying putative 
functional variants. While a sequence-based approach is the current standard practice for 
assessing SNP effects, there are still some concerns that sequence conservation alone is 
not a reliable predictor of deleteriousness. In this study, we propose the AACDS 
classification scheme using variant annotation and sequence-based predictions. We used 
AACDS to classify homozygous nsSNPs found in the genomes of twelve healthy 
individuals into eight categories according to the consensus sequence-based deleterious 
prediction, types of mutation (disease-associated vs. neutral), and information on disease- 
or trait-associations with the gene. The classification scheme provides a comprehensive 
framework for prioritizing a list of SNPs suitable for detailed evaluation, in this study 
reducing the evaluation space from 826 to 98 variants (in categories 1, 2B, 3B, and 4). An 
online tool for computing the AACDS scores for any variant is provided at 
http://www.cig.gatech.edu/tools. 
Several previous studies have shown that structural information plays an important role in 
understanding the relationship between genetic variation and the structure and function of 
the protein. The addition of 3D structural analysis following AACDS classification 





highlights how functional interpretation can in some cases be inferred exclusively from 
3D structures. By using a combination of solved structures or high quality homology 
models for all human proteins, we demonstrate that up to 117 of the 575 proteins bearing 
homozygous mutations in our CHDWB dataset are available for detailed SNP evaluation, 
providing detailed analysis of the 150 prioritized variants. 
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CHAPTER 3: AACDS—A DATABASE FOR PERSONAL GENOME 
INTERPRETATION [102] 
Abstract  
Background: Incorporation of diverse data sources add value to genomic studies, 
especially for annotation and categorization of personal genome variation, based on the 
putative functionality of variants. The database for Association-Adjusted Consensus 
Deleterious Scheme (AACDS) and its web application deliver a novel approach to assess 
genetic variation; the schema combines commonly used conservation-based measures of 
deleteriousness with phenotypic and/or disease association statistics to prioritize 
functional assessments.  
Description: The AACDS database covers over 68 million nsSNPs in approximately 
18,000 human genes. The simple but interrelated queries classify each variant into an 8-
level category, according to its consensus deleterious prediction and the presence/absence 
of clinical or phenotypic association data. Retrieval of AACDS classes can be performed 
through a simple search platform. Given a list of single nucleotide variants located at 
chromosomal locations, or within gene or protein sequences, the AACDS web 
application returns the AACDS category for each variant, along with known data. The 
categories can be ranked, enabling straight-forward interpretation of relative likelihood of 
functionality. The ranking thus facilitates improved efficiency in prioritizing further 





Conclusions: The AACDS database is built upon integrated knowledge of variant data, 
with the aim of relating clinical phenotypes to predictions of variant deleteriousness. The 
schema highlights a list of variants in individual genomes that are worth examining. The 
AACDS web application is available at http://cig.gatech.edu/tools. 
Background  
Non-synonymous single nucleotide polymorphism (nsSNP) is one of the most common 
forms of genomic variability. About 60% of known disease-causing mutations are 
nsSNPs [5]. One of the major goals for personal genomics is to identify a subset of 
variants that have the potential to influence an individual’s health. Each individual 
genome is estimated to contain roughly ten thousand nsSNPs [41, 46, 103]. The 
assessment of deleteriousness for SNPs is commonly performed on a per variant basis, by 
using many available computational tools that typically classify each SNP into two 
groups: benign and damaging. Although many prediction programs have been proven to 
have acceptable accuracy, mostly in the range of 70-80% [22], it is deemed an advantage 
to incorporate more data into the assessment [28]. 
In our recent study on interpretation of personal genome data [40], we developed “An 
association-adjusted consensus deleterious scheme” (AACDS) to facilitate variant 
prioritization of personal genome studies. AACDS is constructed from the combination 
of existing databases that implicate the variant in disease or a phenotype, and traditional 
sequence-based predictions. It assigns a variant into an 8-level category. Not only does 





individual, it also narrows down the variants to a subset that is appropriate for further 
follow-up experiments and validation with respect to individualized health profiles. 
To promote the utility of our variant classification schema AACDS, we have 
implemented the assessments in a database-driven web application that allows users to 
search the AACDS categories and relevant information for a list of user-defined variants. 
The AACDS website aims to provide a user-friendly platform for anyone who is 
interested in personal genome interpretation. The database schema was designed to cover 
the annotated list of functional variants (31,092 disease-associated amino acid variants in 
3,363 genes), 4,225 pairs of gene-disease associations, 5,113 pairs of gene-trait 
associations, and all possible coding genomic variants in 18,349 human genes (n= 
68,165,196 nsSNPs). Therefore, our newly developed database-driven web application 
for AACDS can serve as a tool to generate the best estimate of clinical significance of 
each variant from the large and growing accumulation of personal genome data. In 
addition to identifying causal variants or variants in disease- or trait- associated genes 
from a list of genomic variability, the application also allows further functional analyses 
of all SNPs in any gene of interest.  
Although many tools and databases exist for the purpose of variant prioritization and/or 
personal genome interpretation, we are not aware of any tool with similar features as 
ours, especially in the categorization of genomic variants. Our AACDS tool allows SNP 
evaluations to be performed simultaneously on the ground of deleterious predictions, 
direct connections between variants to diseases, and associated traits and diseases to the 
genes. The tool assigns an AACDS class to each individual SNP; it also reports the 





are particularly significant and original since it assists effortless interpretations of whole 
genome SNP searches. The results facilitate the identification of high impact variants 
within a genome in an effective and efficient manner. 
Compared to aggregative variant association methods such as in VAAST 2.0 [104], our 
tool does not require that users have prior knowledge of various additional genomic 
attributes to perform the search and interpret the results. VAAST requires not only target 
and background genome datasets, but also the user’s defined set of genes and prior 
knowledge of genetic parameters (e.g. inheritance, penetrance, locus heterogeneity, allele 
frequency, etc.) in order to search for causal SNPs or genes [104]. The search pipeline is 
not designed for evaluation of all genomic variants nor to be used as a simple look-up 
utility. 
Two recent genome analysis tools, eXtasy [105] and Phen-Gen (www.phen-gen.com/) 
[106], introduce a new phase of genome interpretation in which the tools link genome 
variants to a specific phenotype. Although both tools have great potential for guiding 
diagnostics of rare disorders through the identification of phenotype-specific causal 
variants, the evaluations are performed on a per disease basis. Most personal genome 
variants are likely to be neutral and contain a minimal number of annotated disease SNPs 
[40, 42]; the individuals are considerably healthy or are unlikely to have noticeable 
clinical phenotypes [46]. These limitations represent a significant challenge for personal 
genome variant annotation for sub-clinical phenotypes, which AACDS is designed to 






Construction and content 
The AACDS site (http://cig.gatech.edu/tools) serves as an interface for queries of the 
AACDS databases, which is built to categorize nsSNPs into an 8-level class, based on the 
consensus predicted deleteriousness and the evidences of disease or complex trait 
associations with a SNP of its gene. The AACDS database includes a set of 68,165,196 
nsSNPs that can be found in a human genome. The AACDS website allows users to 
retrieve the AACDS classification and relevant information of variants in genes of 
interest.  
Data sources 
To facilitate the variant mapping of various data formats (chromosome coordinates, gene 
names, protein names), we chose UniProt [51] as the main database to interrelate with the 
others. UniProt accession numbers represent the unique identifiers for gene products. The 
unique accessions allow a direct lookup of the disease-association data from the selected 
SNP databases: MSV3d [43] and SwissVar [44]. A list of 20,277 reviewed human 
proteins was compiled from UniProt [51] (accessed 11/01/2013). This protein set 
represents the gene products of 19,700 genes. (Some genes have multiple UniProt 
accession numbers due to the presence of multiple protein isoforms, thus explaining the 
differences in the absolute numbers of UniProt accessions and genes.) 
Next, we used dbNSFP v2.1 [15]  (released 10/03/2013) to extract all possible locations 
of SNPs within each gene. The database provides the translation of nucleotide variants 
into alternate amino acids. Amino acid variations were indexed with respects to the 





retrieved from the pre-computed scores for six sequence-based deleterious predictors 
available from dbNSFP v2.1 [15]. To resolve discrepancies among prediction algorithms, 
we assigned the level of deleteriousness using the consensus prediction. A variant is 
regarded as “deleterious” if ≥ 3/6 predictors reported the variant as “deleterious” and as 
“non-deleterious” if the predictions suggest otherwise. Later, the initial set of SNPs had 
been filtered such that our AACDS database excludes all variants that do not currently 
have all of the six pre-computed deleteriousness scores available and variants in 
chromosome locations where only transcript IDs are available but cannot be mapped to a 
single gene. The high confidence dataset includes a total of 68,165,196 nsSNP locations 
in 18,349 genes (18,390 gene products). 
Gene-trait associations were retrieved from the NHGRI genome wide association studies 
(GWAS) catalog [107], available from dbNSFP v2.1 [15]. Additional information 
provided at the AACDS website includes essential information of each variant; i.e., 
dbSNP reference SNP ID number (db138 release, downloaded from the NCBI’s FTP site 
at ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606/BED/, accessed 1/16/2014), gene 
name and protein name from UniProt database (accessed 11/01/2013) [51]), and 
population-specific minor allele frequencies (retrieved from dbNSFP v2.1 [15]).  
Database construction 
AACDS was designed as a relational database on a MySQL server. The data relationships 
are presented in Figure 3.1. In-house Perl scripts were used to extract variant information 






Figure 3.1: AACDS database schema. AACDS database constructs its data 
relationships from several sources. Each SNP receives the deleterious predictions of six 
predictors, available from dbNSFP v2.1 [15]. The consensus deleteriousness of the 
variant is assigned; variants with high deleterious count refer to those which are predicted 
to be damaging by at least 3 predictors. Documentation on gene-trait associations from 
GWAS were also obtained from dbNSFP v2.1 [15]. A list of associated diseases to the 
variant or to its gene is populated from publicly available SNP databases (MSV3d [43] 
and SwissVar [44]). The AACDS category for each variant is assigned from whether: the 
variant has a high deleterious count, its gene is associated with a trait, its gene is 
associated with a disease, or the variant is documented as a disease causal variant.  
Our original paper describes the AACDS as an 8-level category (variant categories 1, 2A, 
2B, 3A, 3B, 4, 5, and 6) [40]. However, many SNPs cannot be exclusively defined into 
one class, therefore, a maximum of 12 classes are reported in this implementation to 
represent all distinct conditions possible when joining multiple assigned AACDS 
categories together; e.g. a variant can be in class 1/2B, 1/3B, or 1/2B/3B, etc. (Table 3.1). 





Table 3.1: Descriptions of the 12 combined AACDSS classes. The original paper 
describes the AACDS as an 8-level category (variant categories 1, 2A, 2B, 3A, 3B, 4, 5, 
and 6), but many variants can belong to multiple classes. Twelve combined AACDSS 




Features of SNPs 








1 yes no no no 
Disease-causing (but not located in gene with 
disease- or trait-associations nor predicted as 
deleterious by most programs) 
1, 2B yes yes yes no 
Disease-causing, predicted as deleterious by 
most programs, located in gene with disease-
associations (but no gene-trait associations) 
1, 2B, 3B yes yes yes yes 
Disease-causing, predicted as deleterious by 
most programs, located in gene with disease 
and trait-associations 
1, 5 yes no yes yes 
Disease-causing, located in gene with disease- 
and trait-associations (but most programs 
predicted it to be benign) 
2A no no yes no 
Located in gene with disease-associations (but 
no other implications) 
2B no yes yes no 
Predicted deleterious by most programs, 
located in gene with disease-associations (but 
not a causal variant) 
2B, 3B no yes yes yes 
Predicted deleterious by most programs, 
located in gene with disease and trait-
associations (but not a causal variant) 
3A no no no yes 
Located in gene with trait-associations (but no 
other implications) 
3B no yes no yes 
Predicted as deleterious by most programs, 
located in gene with trait-associations (but not 
a causal variant) 
4 no yes no no 
Predicted as deleterious by most programs 
(but no other implications) 
5 no no yes yes 
Located in gene with disease and trait-
associations (but not a causal variant nor 
predicted as deleterious) 
6 no no no no No implications 
Column descriptions: (1) disease-causing: if MSV3d [43] and/or SwissVar [44] indicate 
the variant is a disease-causal; (2) predicted deleterious: ≥ 3/6 programs predict the 
variant to be deleterious; (3) in disease gene: if MSV3d [43] and/or SwissVar [44] 
indicate the gene has disease associations; (4) in trait gene: if GWAS [45] indicates the 






Figure 3.2: Number of nsSNPs within each AACDS category. Each variant is 
exclusively defined into one of the 12 combined AACDSS classes.  
The SNP-disease or gene-disease associations were collected from all associations that 
have been documented in either of the SNP databases (SwissVar (accessed 11/01/2013) 
[44] and MSV3d (released 07/29/2012) [43]). It is worth mentioning that the two 
databases employ different formats for clinical annotations, such as the minor differences 
in disease names and the sub-categorization of certain diseases. We did not attempt to 
standardize these terms. Similar association records for a particular SNP or a gene from 
the two data sources were dealt with by reporting only the record which has the most 
detailed descriptions. Some SNPs have ambiguous clinical annotations; for example, 
when one of the two databases documents a SNP as a disease-associated variant, but the 
other suggests it is a polymorphism or has missing data, the intuition we followed was to 
regard the variant to have clinical associations. Such example includes 2,797 and 6,738 
pairs of associations which have only MSV3d [43] or SwissVar [44] annotations 





In total 31,092 instances of variant-disease associations and 4,225 pairs of gene-disease 
associations were included in our database. The number of genes whose gene-trait 
associations were identified from GWAS is 5,113. 
To ensure that the search results are returned quickly, we performed the computation of 
AACDS for all variants and utilized the assigned categories as the pre-computed variant 
classification during web searching.  
The online service of the AACDS database was implemented in PHP, MySQL, 
JavaScript and Apache. The AACDS website can be accessed at 
http://cig.gatech.edu/tools. All standard browsers are supported. 
Utility and Discussion  
Our AACDS web application allows users to retrieve AACDS classifications and the 
relevant information of variants or variants in genes of interest. Figure 3.3A illustrates 
the three major components of the website: (1) Variant query, (2) Gene query, and (3) 
AACDS-based genome analysis. Users can search the AACDS database via a single 
entry query or a batch query. The batch query permits the practical analysis of personal 
genome data, since users can upload a list of variants of unlimited size and retrieve the 






Figure 3.3: Overview of the AACDS web interface. (A) The three query options: 
Variant query, Gene query, and AACDS-based genome analysis. (B-E) Example outputs 
in form and tabular formats. Included in the tabular outputs are the direct links to dbSNP 





Performing the search via a single entry query 
1) Variant query 
Users can search for the AACDS classification of their variant of interest, by providing 
some search parameters. For query by DNA: chromosome number, hg19 coordinate and 
alternative nucleotide. For query by protein: gene name or Uniprot accession number, 
amino acid position, and alternative amino acid. 
The website outputs a variant summary page, which reports the AACDS category of the 
variant and its relevant information, along with any additional variant data (Figure 3.3B). 
Note that all the deleterious and conservation scores reported here are the original scores 
used in their corresponding papers; i.e., we did not perform any re-scaling of the scores. 
2) Gene query 
Users can retrieve a list of variants within a gene whose variants’ characteristics match 
the user’s interest. If a particular AACDS class is specified, the website returns all SNPs 
that belong to the searching AACDS category. If any of the four features (high 
deleterious count, has gene-trait association, has gene-disease-association, and has 
variant-disease association) are specified, a list of variants whose characteristics are 
compatible with the searching feature is returned. The SQL “AND” statement is used to 
extract the list of variants which match multiple search terms; for example, searching for 
variants that are documented as causal variants whereas most of the deleterious prediction 
algorithms suggest it is benign, or searching for variants in disease-associated genes that 





When more than one variant meets the search criteria, a summary table (Figure 3.3C) is 
returned in addition to the results in form formats, which display up to the first 25 entries. 
The displayed table provides a short description (11 attributes) of the variants; users can 
also download the complete table (37 attributes) through the “download” button. 
Exported file types include .csv and .txt.  
3) AACDS-based genome analysis  
For this search feature, we aim to provide the overall statistics for a set of SNPs found in 
an individual’s genome. Users can perform the AACDS-based genome analysis on two 
levels: (1) Whole genome statistics and (2) Gene-by-gene statistics. Figures 3.3D and 
3.3E demonstrate the output examples from the two analyses, respectively. In either case, 
the schema classifies SNPs into several groups, based on the assigned AACDS classes. 
The results can be ranked by gene names or by AACDS groups. 
In addition to the number of variants within each AACDS class, the tabular output also 
presents the average (and the standard deviation) for all six deleterious scores, three 
conservation scores, and two population-specific minor allele frequencies. Note that the 
raw scores for the first five deleterious predictors were re-scaled to [0, 1] for comparison 
purposes; a score closer to 1 represents a stronger (deleterious) effect of a variant. A 
MutationAssessor score of > 3.5 designates high functional impact, hence “deleterious” 
[18]. The averages of original scores can be obtained via the download link. 
Performing the search using batch query  
For each of the above analyses, a batch search is possible if users provide a .txt file (tab 





help page. An example format for a batch search is shown below; other search types will 
have slight differences in the required fields. For the example below, column legends are 
chromosome, coordinate (hg19), reference nucleotide, and alternate nucleotide, 
respectively. 
Chr:10 26781257 T A 
Chr:10 26781257 T C 
Chr:10 26781257 T G 
Conclusions  
The integration of both sequence-based deleterious prediction and clinical association 
data in our AACDS algorithm provides a novel approach to integrative variant 
classification for personal genomes. Manual inspection of a variant for both predicted 
deleteriousness and phenotypic association is possible, but certainly not practical for 
analyzing large genome data. For this reason, the implementation of a database-driven 
web application is considered to be an important tool for promoting the utility of the 
AACDS. We believe that with the scope of our database coverage, both in terms of 
genomic variations and phenotypic data, this web application will help to bring a 
comprehensive framework of personal genome interpretation to a more practical level.  
We will keep on refining the database so that it offers AACDS classes for the most 
complete set of SNPs in a human genome. The improvement may include quality control 
and subsequent addition of variants in the remaining genes once their curated protein 
sequences are available, the inclusion of clinical and trait associations from other data 





used by the International Classification of Diseases (ICD) [108], and the implementation 
of an automatic online update with the selected data sources. 
Availability and requirements  
AACDS is publicly available at http://cig.gatech.edu/tools. It supports any standard 
browsers. The current implementation does not have an automatic online update feature, 
but we will regularly check for new releases of our selected external databases. The 
update for AACDS will be performed quarterly and upon major releases of MSV3D [43], 
SwissVar [44], and dbSNP [109]. 
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CHAPTER 4: SDS, A STRUCTURAL DISRUPTION SCORE FOR 
ASSESSMENT OF MISSENSE VARIANT DELETERIOUSNESS 
[110] 
Abstract 
We have developed a novel structure-based evaluation for missense variants that 
explicitly models protein structure and amino acid properties to predict the likelihood that 
a variant disrupts protein function. A structural disruption score (SDS) is introduced as a 
measure to depict the likelihood that a case variant is functional. The score is constructed 
using characteristics that distinguish between causal and neutral variants within a group 
of proteins. The SDS score is correlated with standard sequence-based deleteriousness, 
but shows promise for improving discrimination between neutral and causal variants at 
less conserved sites. 
The prediction was performed on 3-dimentional structures of 57 gene products whose 
homozygous SNPs were identified as case-exclusive variants in an exome sequencing 
study of epilepsy disorders. We contrasted the candidate epilepsy variants with scores for 
likely benign variants found in the EVS database, and for positive control variants in the 
same genes that are suspected to promote a range of diseases. To derive a characteristic 
profile of damaging SNPs, we transformed continuous scores into categorical variables 
based on the score distribution of each measurement, collected from all possible SNPs in 
this protein set, where extreme measures were assumed to be deleterious.  A second 





Causal variants tend to receive higher sequence-based deleterious scores, induce larger 
physico-chemical changes between amino acid pairs, locate in protein domains, buried 
sites or on conserved protein surface clusters, and cause protein destabilization, relative 
to negative controls. These measures were agglomerated for each variant. A list of nine 
high-priority putative functional variants for epilepsy was generated. Our newly 
developed SDS protocol facilitates SNP prioritization for experimental validation. 
Introduction 
Several prediction programs are available to evaluate missense variants as either 
deleterious (having a strong functional effect) or neutral (having no or only a weak 
functional effect) from the level of DNA or protein sequence conservation [14]. While 
existing sequence-based damaging scores agree for the most deleterious variants, 
predictions for candidate moderate effect variants identified from sequencing studies are 
not much better than chance. Since there is no clear way to truly evaluate the predictive 
accuracy of the scores prior to experimental assessment of function, there is scope for 
development of orthogonal methods for variant prioritization.  Our study explores the 
utility of solely using protein structure-based assessments as a complement to existing 
sequence-based scores. 
Of the commonly used automatic tools for prediction of variant deleteriousness, 
PolyPhen2 [19] already incorporates protein structure information.  It uses an iterative 
greedy algorithm to select certain features from a restricted training set, and then takes a 
Bayesian approach to assign each variant into one of four effect categories: probably 





evaluations on the actual protein structure that each variant is found in. Rather, 
PolyPhen2 includes experimentally derived-structures that are available for ~10% of the 
training set. Although the implementation has high accuracy (73-92%) for the 
identification of true positives in cross-validation data, structural data does not directly 
contribute to evaluations of novel genes and it is not clear how efficiently the generalized 
structural characteristic rules used by the algorithm can contrast clinically-associated 
variants from neutral variants in a diverse gene set. 
In this study, we therefore introduce a new approach for assessing the deleteriousness of 
nonsynonymous single nucleotide polymorphisms (nsSNPs). Our newly developed 
protocol uses additional information, that is, protein structure-based assessments applied 
only where the structural solution is available, to complement existing sequence-based 
scores. More specifically, our evaluation pipeline focuses on functionality of protein 
residues derived from 3-dimensional (3D) protein structures.  We also incorporate 
multiple classes of structural assessment, namely measures of protein stability, flexibility, 
protein-protein interaction potential, and small-molecular binding.  As several studies 
[35, 39] have proven that structural information increases classification accuracy of 
SNPs, we hypothesized that by incorporating results from several structure-based 
assessments, it may be possible to generate characteristic profiles that enhance prediction 
of the degree to which a candidate rare variant may disrupt protein function, and lead to 
disease development. 
We applied this newly developed variant assessment protocol to a set of 57 gene products 
harboring homozygous missense variants, discovered in a recent large-scale exome 





genetically heterogeneous disease, for which each likely causal variant is observed in a 
small fraction of individuals, likely with variable expressivity and penetrance [112].  As a 
result, it is difficult to ascertain which variants are truly responsible for the etiology of 
disease in individual patients.  None of the case-exclusive variants documented by 
Heinzen et al. (2012) had a high enough prevalence to support statistical association with 
the disease, so experimental tests will be needed to filter putative causal variants.  By 
contrasting the spectrum of structural features of the case variants with positive control 
known causal variants and negative control neutral variants observed in healthy 
individuals for the same proteins, we illustrate the potential for structural assessment to 
prioritize new variants for functionalization.     
Materials and Methods 
Our analysis pipeline applied sequence- and structure-based assessments to missense 
mutations and their 3D protein structures to depict the likelihood that a mutation disrupts 
protein function. Numerous databases and prediction programs were used. The flow 






Figure 4.1: Flow diagram of the analysis pipeline. The analysis employed sequence-
based deleterious prediction scores, parameters which reflect the nature of amino acid 
changes, and 3D structure-based evaluations. Structural analyses were performed by 
characterizing functionality of mutated protein residues caused by negative and positive 
SNPs (indicated by green and red stick representations, respectively). All analysis results 
were collectively used to evaluate enriched features found predominantly in causal SNPs. 
We then examined these predictors with regard to the case variants. The number of 
deleterious structure predictions per substitution represents a “structural disruption score” 





Genomic dataset and candidate protein sequences 
The epilepsy-specific amino acid substitutions identified from a recent exome sequencing 
study of epilepsy disorders [111] served as our case variants for which we aimed to 
assess whether or not they are likely to impact protein function. In that study, exome 
sequencing was performed on 118 cases and 242 controls. Follow-up genotyping for 
candidate causal variants included approximately 90% and 65% of individuals with 
European ancestry in the case (n=878) and control (n=1,830) groups, respectively [111]. 
The study identified 72 homozygous variants (68 are nsSNPs) found in 71 genes (“gene 
set 1”) that were exclusive to cases. Among these, 52 nsSNPs were present in more than 
one affected individual.  All genes in this first dataset had been previously characterized 
but not known to cause epilepsy; therefore, we added a second gene set (“gene set 2”) to 
represent genes known to associate with the disorders. We attained the second gene list 
(n=41 genes) from two public repositories of genetic variations: MSV3d  [43] and 
SwissVar [44]; none of the genes overlap with entries from the primary dataset. There are 
373 missense variants in the 41 genes that have been documented to cause epilepsy; 
therefore, we treated them as case variants for gene set 2. 
For both sets of genes, we compiled corresponding negative neutral and positive causal 
variants from the EVS database (retrieved March 201) [50], and MSV3d (July 2012 
release) [43] and SwissVar (accessed February 2013) [44], respectively. Positive controls 
are documented non-epileptic disease-causing nsSNPs found in the same genes (n=134 
nsSNPs from 14 genes of set 1, and n=205 nsSNPs from 41 genes of set 2). Likewise, 
negative controls are variants observed in these genes, but with no clinical associations 





were excluded from the list of neutral SNPs, resulting in 5,281 and 1,490 putatively 
neutral (i.e. negative control) SNPs for sets 1 and 2, respectively. 
Gene and variant annotations  
In order to infer amino acid indices for the altered amino acid residues, nsSNPs were 
mapped to their corresponding protein sequences and structures using transcript IDs. All 
protein sequences (major isoforms) were downloaded from the UniProt database 
(accessed February 2013) [51].  Prior to applying our new variant analysis protocol, we 
performed literature searches on the genes and SNPs in our datasets in order to manually 
annotate their influence on the disease.  In particular, we compared the features of gene 
sets 1 and 2, and recorded relevant findings.  
First we grouped genes by their related biological pathways or biological functions using 
a gene group profiling method [78]. Second, we performed literature searches using 
SNPshot—a text mining tool for PubMed abstracts (accessed December 2012) [80]. 
Third, we assumed that amino acid mutations caused by the rare case SNPs or the causal 
SNPs would locate in the vicinity of functional sites of protein chains. Therefore, we 
utilized UniProt’s sequence feature records (accessed February 2013) [51] to check if the 
mutating amino acids locate in any of the important sites; e.g., molecule processing sites, 
binding sites, modification sites, etc. 
Population-specific minor allele frequencies (MAFs) for all variants were compiled from 
NHLBI GO Exome Sequencing Project (ESP6500) (June 2012 release) [50], available 





Protein structure dataset 
We used protein 3D structures to determine the structural nature of altered protein 
residues and to evaluate the effects of single point mutations introduced by nsSNPs on a 
specific protein. To ensure that we represent most of the proteins with high quality 3D 
structures, we employed several structural sources. Experimentally derived structures 
were retrieved from RCSB (retrieved April 2013) [60].  Homology models were 
compiled from SAHG (retrieved July 2013) [113] or automatically built using Phyre2 
(accessed April 2013) [101]. Multiple structural candidates representing an overlapping 
protein chain were compared and only one best structure was chosen to represent the best 
non-overlapping protein segment. 
Details of the two approaches for acquiring protein homology models are as follows. 
First, we searched for 3D models from the SAHG database [113], which contains a 
collection of encoded human protein structures, constructed by Modeller software [114]. 
We downloaded only structures having >15% sequence identity to the template. The 
retrieved proteins exhibit either ligand bound (holo) and/or unbound (apo) forms. Second, 
we built protein models by multiple template methodology using the automated Phyre2 
homology modeling server [101]. Structure templates were selected by default and 
models were built from variable numbers of high confidence templates. This multi-
template approach ensures that the model covers most of the protein chain.  Large 
proteins (>1,300 amino acids) were truncated into smaller domain(s) using domain 
boundary information from InterPro [115]. A model representing each shortened 
sequence was built independently using either the single- or multi-template method; there 





created with the Phyre2 server, we retained the best homology model based on the 
empirical criteria that >50% of the residues were modeled at >90% confidence.  
After the initial homology model selection, the models were further subjected to energy 
minimization with explicit solvent using the YASARA force field [62] to resolve any 
steric conflicts found within the structures. Next, we validated the homology models 
using two independent scores: QMEAN6 [63] and ModFOLD4 [64]. Both scores show 
good ability to distinguish between good and bad models in the recent Critical 
Assessment of protein Structure Prediction (CASP) experiments [116]. To facilitate the 
structural validation step, we selected structures that pass the QMEAN6 threshold for 
subsequent ModFOLD4 evaluations. 
In many cases, we initially selected more than one validated structure to represent an 
identical protein domain. To retain only one best representative structure for a protein 
segment, we used Chimera [65] to visualize all structure candidates and determined the 
structural similarity among them using two parameters: root-mean-square deviation 
(RMSD) of Cα atoms, and quality score (Q-score) that normalizes an RMSD by the 
alignment length. All measurements were performed with Chimera’s MatchMaker tool 
[65]. When several overlapping structures agreed with each other, we selected the one 
with the best ModFOLD4 score. When the structures were in disagreement, we discarded 
them all together. Our retrieval and validation pipeline for protein 3D structures yielded 
114 non-overlapping structures representing 57 gene products from gene set 1, and 51 





Table 4.1 summarizes the number of missense variants from our genomic dataset in three 
categories (case, negative, and positive controls), with respect to the presence/absence of 
their corresponding 3D structures. 
Table 4.1: Number of variants within each gene set, classified into three classes 
(cases, negative controls, and positive controls), and numbers of 3D structures used 





Number of variants by 
categories* 






























20 (24) 8 (35) 35 (59) 
20 
(86) 
31 (80) 114 57 









2 (2) 3 (19) 5 (17) 
21 
(46) 
20 (38) 51 36 
* Number of variants by categories is indicated by the number of SNPs locate within the 
set of selected 3D structures (114 structures for gene set 1, and 51 structures for gene set 
2), followed by the total number of SNPs with and without 3D structures (number shown 
in parentheses). 
** Number of structures represents the number of selected 3D structures that passed 
quality validation scores. The initial number of structures obtained from each data source 
is much larger, indicated by numbers in parentheses. 
Inferring variant deleteriousness from sequence-based predictors 
We obtained sequence-based predictions for each amino acid variant from dbNSFP 2.0 
(accessed March 2013) [15]. The program provides pre-computed deleteriousness scores 
for six established deleterious prediction algorithms: SIFT [16], PolyPhen2_HumDiv and 
PolyPhen2_HumVar [19] , LRT [17], MutationTaster [20], and MutationAssessor [18]. 
Three evolutionary conservation-based scores were also included: GERP++ [53], phyloP 





conservation to each mutation based on how many predictors reported the mutation to be 
either “deleterious” (maximum score of 6) or “conserved” (maximum score of 3). 
Additional parameters for sequence-based analysis 
In addition to the SNP-based prediction parameters that are derived from multiple 
sequence alignments, some useful information can be analyzed from a single protein 
sequence alone. For example, amino acids with similar physicochemical properties may 
substitute for one another while maintaining the functionality of the protein. Three 
indicators may be used to highlight the most severe changes of amino acid pairs. First, 
Grantham scores [56] reflect the degree of physicochemical difference between pairs of 
amino acids. Second, changes involving any glycine or proline residues are likely to 
affect protein function since these two residues have special roles with regard to protein 
structure: proline has an exceptional conformational rigidity compared to other amino 
acids while glycine is much more conformationally flexible [117]. Third, gain or loss of 
disulfide bonds occurs when variants induce changes in cysteine residues. Disulfide bond 
formation between non-adjacent cysteines can facilitate protein folding; hence, they are 
important for maintaining the structural integrity of the protein [118]. In this context, we 
used DiANNA webserver [119] to predict the disulfide connectivity patterns in the wild 
type protein, and then determined if the amino acid mutation affects the bonding of 
cysteine pairs. 
Inferring variant deleteriousness from structure-based predictors 
A number of currently available protein structural analysis tools have the potential to be 





of mutated protein residues, we concentrated on four features of structural analysis: 
protein stability, protein flexibility, protein-ligand binding potential, and protein-protein 
interaction potential. Many mutations disrupt these elements, and as a result, contribute to 
disease etiology. 
1) Protein stability.  For assessment of protein stability, we aimed to first identify amino 
acids with specialized roles in promoting protein stability, and second to determine which 
mutations cause a significant change in protein stability. For the first objective, we used 
SCide webserver [69, 70] and SRide program [71] to identify amino acids with essential 
stability functions. Long-range stabilization center (SC) residues are pairs of amino acids 
having close atomic contact (sum of van der Waals radii <1 Å), but locate at least ten 
amino acids apart on the primary sequence [69, 70]. A subset of SC residues may make 
distinct contributions to protein stability because they are also evolutionary conserved 
and located in the core region of the protein, and/or have many interacting partners. SC 
residues with these two extra properties are referred as stabilizing residues (SRs); they 
are also expected to make key contributions to protein stability [71]. For the second 
objective, we aimed to determine if a particular mutation affects protein stability by 
means of inducing a large magnitude of free energy change (∆∆G). For this purpose, we 
selected PoPMusic 2.1 [120] as our ∆∆G predictor.  
Amino acid changes that increase protein stability (∆∆G < 0) and those associated with 
the destabilizing mutation (∆∆G > 0) are noted. Due to large differences in performance 
of stability change calculations [121], the proper margin for severe stability change can 





mutations is much less than for destabilizing ones [66], and the correlation between 
predicted stability change (∆∆GP) and measured values (∆∆GM) of our selected program 
is ~1 kcal mol-1 [120]. Therefore, in our study, we followed the suggestions made by 
Dehouck et al. (2011). The stability changes are categorized into four levels: no change if 
∆∆G is between ±0.5 kcal mol -1, mildly stabilizing if ∆∆G is between -0.5 and -2 kcal 
mol -1, mildly destabilizing if ∆∆G is between 0.5 and 4 kcal mol -1, and strongly 
destabilizing if ∆∆G is ≥4 kcal mol -1. 
2)  Protein flexibility.  Protein flexibility is an important protein feature because highly 
dynamic sites are often involved in special functions, such as binding residues that can 
undergo subtle motion rearrangements when a small molecule is bound. Flexible amino 
acid residues permit large protein movements during protein folding and conformational 
switches [122]. For evaluating the levels of residue dynamics within a protein, we 
employed the predicted B-factors (relative vibrational motion) and root-mean-square 
fluctuations (RMSFs) obtained from a prediction program PredyFlexy [75] to classify 
amino acid residues into rigid, intermediate or flexible sites. For predicting protein 
movements of higher amplitudes, such as in conformational switches, we used the 
program FlexPred [76, 77] to determine which amino acid residues are located at 
conformationally flexible sites, indicated by a probability value P(Flexible). 
3) Protein-ligand binding potential.  For a SNP that causes an amino acid change in the 
vicinity of a catalytic site or a ligand binding site, it is possible to determine whether the 
mutation is indeed affecting the catalytic activity or the ligand binding affinity of the 





resources. We utilized two alternative approaches to predict the ligand binding sites or 
catalytic sites from protein 3D structures, and assessed whether or not the altered protein 
residues locate in or near the predictions. The first approach began with the use of 
3DLigandSite [72] to search for ligands present in homologous structures. Then, a cluster 
of amino acids located within a default distance setting of 0.8 Å of the selected ligand 
was predicted as a pocket site, and amino acid residues that make up that pocket site were 
specified as ligand binding residues. In the second method, catalytic sites were predicted 
by scanning for protein residues that are not well optimized. This assumption is based on 
the finding that catalytic sites are generally designed for function rather than stability 
[120]. Low optimality residues are those whose several possible mutations would 
improve protein stability. The program PoPMusic [120] is fast enough that it can 
calculate stability changes (∆∆Gs) of all possible mutations at a given position in the 
protein sequence, and was used to identify non-optimized amino acid residues based on 
the summation of all stabilizing ∆∆Gs. This parameter designates the degree of non-
optimality (Γ) for each amino acid residue along the protein chain. 
4)  Protein-protein interaction potential.  Disease-causing mutations that do not occur in 
binding sites or buried sites are predominantly found on protein interfaces [36];  
therefore, we assessed which of the mutating protein residues may be involved in this 
type of inter-molecular interaction. We used PatchFinder program [73, 74], which 
evaluates evolutionary conservation scores in conjunction with solvent accessibility of 
protein residues to determine the most significant cluster of conserved residues on the 






Additional parameters for structure-based analysis 
Other information retrieved from the structure-based data includes the type of protein 
secondary structure that each variant interrupts, and the relative solvent accessibility of 
the altered protein residue. We obtained these predictions from PoPMusic [120]. Due to 
the small sample size, we modified the eight reported types of protein secondary structure 
[123] into five groups: (G/H/I), E, (T/B), S, and C. The 3-, 4- and 5-turn helices (groups 
G, H and I, respectively) were grouped jointly as helices. Extended strand in parallel 
and/or anti-parallel β-sheet remains as an individual group (group E). Groups T or B 
correspond to helices or sheets whose hydrogen bonding patterns are too short to form 
proper secondary structures. Lastly, groups S and C denote bend and coil annotations, 
respectively. 
The relative solvent accessibility (RSA) for residue X is expressed as a percentage of that 
observed for an Alanine-X-Alanine tripeptide. This conformation would expose the 
central X residue in the tripeptide as much as would normally be possible in a protein 
[120]. We considered protein residues whose RSA ≤20% as buried sites. Otherwise, they 
are expected to be on the protein surface. 
Statistical comparison of positive and negative SNPs 
We tested which predictions and measures can statistically distinguish between negative 
and positive control SNPs from each gene group. Particularly, we assessed which 
characteristics are most likely to be enriched in positive controls, and therefore imply 
disruption of functionality. After defining thresholds of likely deleterious function, we 





category. The categories for structural indicators, the numerical cutoff values, and the 
numbers of mutations with extreme values from the two datasets are summarized in 
Table 4.2. 
Table 4.2:  Categories for structural indicators, cutoff values for continuous 
numerical parameters, and number of SNPs with extreme measures. All cutoff 
values were defined exclusively for gene set 1. The counts and percentages of variants 
with extreme values in each of the three variant classes are included.  









Stabilizing: ∆∆G between -2 to -0.5 kcal mol -1 0 19 (1%) 0 
Strong stabilizing: ∆∆G ≤ -2 kcal mol -1 0 0 0 
Destabilizing: ∆∆G between 0.5 to 4 kcal mol -1 20 (65%) 830 (50%) 66 (66%) 
Strong destabilizing: ∆∆G ≥ 4 kcal mol -1 0 1 (0%) 0 
Dynamic sites 
Highly rigid: B-factornorm ≤ -0.537 (@2.5 percentile)          0 38 (2%) 3 (3%) 
Highly dynamics: B-factornorm ≥ 1.17 (@97.5 percentile) 1 (3%) 44 (3%) 1 (1%) 
Highly rigid: RMSFnorm ≤ -0.607 (@0.5 percentile) 0 48 (3%) 2 (2%) 
Highly dynamics: RMSFnorm ≥ 1.195 (@99.5 percentile) 1 (3%) 48 (3%) 3 (3%) 
Flexible sites 
Conformationally rigid: P(Flexible) ≤ 0.158 (@2.5 
percentile) 
1 (3%) 34 (2%) 2 (2%) 
Conformationally flexible: P(Flexible) ≥ 0.860 (@97.5 
percentile) 
1 (3%) 52 (3%) 0 
Sequence 
optimality Highly non-optimal: Γ ≤ -5 kcal mol
 -1 1 (3%) 49 (3%) 5 (5%) 
For continuous parameters, we compared the difference between the means of the 
positive and negative controls using two-tailed unpaired t-tests (Table 4.3). The 
distributions of scores within each SNP group were also illustrated by density plots 
(Figures 4.2-4.3). For non-numerical characteristics, we used Fisher’s exact test to 
determine whether the proportions of negative and positive control SNPs for each of the 
features are significantly different (Table 4.4). For continuous measures, similar analyses 
were performed after first transforming the scores into discrete categories based on pre-





Once a series of predictions and measures was generated for all possible variants in a 
gene set, we converted continuous parameters into categorical classes, utilizing both 
literature-based and empirical cutoff values to represent the extremes (Table 2).  
Table 4.3: T-test statistics for gene sets 1 and 2. All tests were performed on a subset 
of SNPs whose protein structures pass quality validations. Significant statistics indicate 
different means between negative and positive SNPs. 
 Parameters 
Prob > |t|, (t ratio), df† 





SIFT <.0001* (6.60) df 1704 <.0001* (4.61) df 598 
PolyPhen2_HDIV <.0001* (8.15) df 1772 <.0001* (7.38) df 657 
PolyPhen2_HVAR <.0001* (10.22) df 1772 <.0001* (8.70) df 657 
LRT <.0001* (4.19) df 1734 .0066* (2.73) df 654 
MutationTaster <.0001* (9.39) df 1674 <.0001* (5.57) df 631 




GERP <.0001* (5.30) df 1772 <.0001* (3.92) df 657 
phyloP <.0001* (4.81) df 1772 0.0010* (3.29) df 657 
SiPhy <.0001* (5.89) df 1771 <.0001* (4.95) df 657 
Structure-
based scores 
∆∆G <.0001* (4.81) df 1772 <.0001* (3.83) df 657 
B-factor .0190* (-2.35) df 1756 .2450 (1.16) df 657 
RMSF .2304 (-1.20)  df 1756   .2264 (1.21)  df 657 
P(Flexible) .1185 (-1.56)  df 1772 .7594 (-0.31)  df 657 
Γ .9090 (-0.11)  df 1772 .2308 (-1.20)  df 657 
RSA .0035* (-2.93)  df 1772 .0658 (-1.84)  df 657 
† Statistic parameters include the two-tailed p-value, value of the t-statistics (t ratio), and 
the degree of freedom (df). Significant p-values (α =.05) are designated with ‘*’. The 






Figure 4.2: Density plots of six deleterious scores for Case, Neutral and Causal 
SNPs. By most of the standard deleteriousness scores, the distributions of cases in gene 
set 1 (Panel A) are closer to the neutral than the causal variants, and the neutral and 
causal variants are significantly different. The “known epilepsy” dataset (gene set 2, 
Panel B) demonstrated similar results. In this gene set, variants documented to cause 
epilepsy were regarded as “cases”, while variants associated with other disease types 
were considered as “causal SNPs (positive control)”. Although three prediction programs 
(SIFT, Polyphen2_HDIV, and Polyphen2_HVAR) suggested case and causal SNPs share 
similar distributions of deleterious scores, the remaining three programs illustrate their 
prediction algorithms do not favor the two types of causal variants equally. More 
importantly, case SNPs (epilepsy-causing SNPs) resemble neutral SNPs more than the 






Figure 4.3: Density plots for relative solvent accessibility and free energy change for 
Case, Neutral and Causal SNPs. The two structure-based scores demonstrate that Case 
and Causal SNPs share similar characteristics. Results were obtained from two 
independent sets of genes (Panels A-B).  Note the shift of the blue curves (cases) toward 






Table 4.4: Fisher’s exact test statistics for gene sets 1 and 2. High sequence 
conservation (conservation count = 3) is a feature that enriched in causal SNPs of gene 




Fisher's exact test (one-tailed)† 
Set 1 (57 genes) Set 2 (36 genes) 
Enriched in 
causal SNPs 
Deleterious count ≥ 4 < .0001* < .0001* 
Conservation count = 3 
Enriched in  
neutral SNPs 
< .0001* 
Induce large amino acid change (Grantham score ≥ 100) < .0001* < .0001* 
Induce disulfide change NS (p = .6081) < .0001* 
Induce gly/pro change .0003* < .0001* 
Locates in buried site (RSA ≤ 20%) .0109* < .0001* 
Locate in conformationally rigid site (P(Flexible) ≤ 0.74) NS (p = .0558) .0060* 
Locate on protein patch < .0001* < .0001* 
Locate in protein domain .0204* < .0001* 
Strongly reduce protein stability (∆∆G ≥ 4 kcal mol -1) NS (p = 1) .0400* 
Reduce protein stability (∆∆G ≥ 0.5 kcal mol -1) .0009* < .0001* 
Enriched in 
neutral SNPs 
Conservation count = 3 < .0001* 
Enriched in  
causal SNPs 
Locate in highly dynamics site (B-factornorm ≥ 97.5 
percentile) 
NS (p = .2671) .0224* 
Locate in highly flexible site (P(Flexible) ≥ 97.5 
percentiles) 
.0468* NS (p = .1432) 
† Data for gene set 1 includes 100 causal SNPs and 1674 neutral SNPs. Data for gene set 
2 includes 289 causal SNPs (184 epilepsy case variants plus 105 non-epilepsy positive 
control variants), and 554 neutral SNPs. Significant p-values (α =.05) are designated with 
‘*’. Non-significant test statistics are labeled with NS, followed by the correspondent p-
value. 
For protein stability and sequence optimality measures, we followed the suggested 
thresholds from the PoPMusic program [120]. Stability changes were classified into four 
groups (mildly stabilizing, strongly stabilizing, mildly destabilizing, and strongly 
destabilizing) using the aforementioned cutoffs for ∆∆G. Regarding sequence optimality, 
it has been shown that as the threshold for Γ becomes more stringent, the proportion of 





which residues having Γ ≤ -5 kcal mol -1 are more likely to locate in ligand-binding 
domains.  
For the remaining continuous measures, i.e., B-factor, RMSF, and P(Flexibility),  we 
used empirical criteria to define the extremes. Extreme values for data set 1 and 2 were 
derived independently, but with an identical approach. First, we compared the score 
distributions of each measurement, collected from all possible SNPs in the protein set. 
Then, we selected the thresholds for each parameter so that we captured a handful of 
extreme variants. When applicable, we made sure that our thresholds do not induce large 
numbers of misclassifications. In summary, our empirically-defined thresholds are 
generally set at the top and bottom 2.5 percentiles. B-factor and RMSF predictions were 
classified into either highly rigid (extreme small negative values) or highly dynamic 
(extreme large positive values). Similarly, we denoted residues as conformationally rigid 
if the P(Flexibility) is exceptionally low, or conformationally flexible if the probability is 
notably high. 
Assigning a structural disruption score to candidate epilepsy variants 
After testing for statistically significant differences between negative and positive SNPs, 
we summarized the list of deleterious structure predictions and examined these predictors 
with regard to the case variants. We counted the number of deleterious structure 
predictions per substitution and represented this number as a “structural disruption score” 
(SDS). The scores were ranked and candidate epilepsy variants with a score of ≥ 4 out of 
7 are suggested to be “putative structural disrupted variants”. Further partitioning of this 





variants of high tolerance genes (genes that have more variants than expected), and 
variants of low tolerance genes (genes that have less variants than expected). These two 
groups of variants are also discussed in detail with respect to their disease implications. 
To examine the contribution of each selected parameter, especially the sequence-based 
deleterious score, towards our SDS, we compared the values of SDS with the Condel 
composite score [22], derived from three of the deleteriousness measures (SIFT, 
PolyPhen, and MutationAssessor). The evaluation was performed with a step-wise 
procedure. First, we tested for a correlation between the Condel score and SDS—
including all parameters from the sequence-based and structure-based predictions (total n 
parameters). Then, we re-evaluated the correlation using n-1 parameters, by excluding 
one of the SDS components at a time. 
Results 
Candidate gene and variant annotations  
Despite the fact that Heinzen et al. (2012) performed pathway analysis on 1183 genes 
harboring either homo- and/or heterozygous nsSNPs, with a genotype exclusive to the 
case group, no significantly over-represented biological pathways were found [111]. 
Using an alternative gene group profiling method [78], we also did not observe a 
statistical abundance for any biological terms derived from gene set 1.  However, this 
method did reveal that ~40% of genes in set 2 have roles in transmission of nerve 
impulses, ion channel complexes, or ion gated channel activity. A text mining method 
[80] discovered only 1 gene from set 1 that may be linked to epilepsy. This gene codes 





that plays roles in GABAergic and cholinergic neuronal development [125]. Specifically, 
mutations in ubiquitin protein ligase along with disruptions in the important neuronal 
GABA receptor genes are suggested to induce seizure [126]. By contrast, all genes in set 
2 are suspected to be involved in a wide range of epilepsy disorders [43, 44]. Also note 
that the proportion of variants in cases relative to controls is much lower for genes in set 
1 than in set 2 (Table 4.1). 
Annotation of altered amino acid residues indicated some consistent patterns between 
case and causal variants. When we performed sequence feature searches [51] to compute 
the number of variants localizing in structurally or functionally important sites of a 
protein chain, we observed that more than half of the positive SNPs in both gene sets 1 
and 2 were predicted to locate in transmembrane, topological domain, or repeat regions. 
Similar patterns were found for the case-exclusive epilepsy variants. 
Statistically significant differences between positive and negative SNPs 
Table 4.3 documents that all deleteriousness scores, all conservation scores, and some of 
structure-based scores have significantly different means between negative and positive 
SNPs. The single parameters that best differentiate the groups are the MutationAssesssor 
prediction for gene set 1 and the PolyPhen2_HVAR prediction for gene set 2, but more 
notable is the highly significant differentiation for all of the sequence-based scores. 
Although the t-ratios are consistently lower in set 2 than set 1, the smaller sample of 
genes precludes inference that there is a difference between the two sets.  Notably, three 
of the structure-based measures are also at least nominally significantly different between 





∆∆G protein stability, B-factor protein flexibility, and relative solvent accessibility 
(RSA).  
We converted several of the continuous structural measures to categorical ‘normal’ 
versus ‘extreme’ values and compared profiles of disease causal variants with those of 
neutral variations in gene sets 1 and 2. Table 4.4 reports the list of significantly distinct 
sequence/structural features for each variant category based on Fisher’s exact test. Seven 
significant characteristics of causal variants found in the 57 genes in set 1 are: having a 
high deleterious count (≥ 4 out of 6 scores), introducing an amino acid change with large 
physicochemical dissimilarity, inducing glycine or proline change, being situated in a 
protein domain, buried site or on a conserved protein surface, and causing at least mild 
protein destabilization. By contrast, negative control SNPs of this gene set were found to 
be enriched in conserved variants (conservation count = 3 out of 3) and generally locate 
in conformationally flexible sites. 
These findings were validated with a parallel analysis of gene set 2, although in this case 
we gained statistical power by combining the set of epilepsy case variants with the non-
epilepsy positive control SNPs (combined disease-SNPs n=289). Each of the significant 
features detected in gene set 1 replicates in set 2, and additional evidence that disruption 
of disulfide bonds and location in conformationally rigid sites differentiate neutral and 
disease variants were obtained. These findings emphasize that causal variants are likely 
to affect protein functional sites, a conclusion that can only be obtained from structure-





Structural features predict deleteriousness of case SNPs 
Next, we asked how the distribution of scores for the putative epilepsy-case variants 
compares with the negative and positive controls.  By most of the standard 
deleteriousness scores, the distributions of cases are closer to the negative than the 
positive controls in both datasets (Figure 4.2). We conclude that there is little evidence 
from standard measures for enriched deleteriousness in the case variants from the 
epilepsy study. Similar observations were found for Grantham score, protein flexibility 
parameters, and a few other structural measures (data not shown).  
However, we determined that the solvent accessibility measure (RSA) and a protein 
stability measure (∆∆G) assign case variants to be more comparable to positive than 
negative controls (Figure 4.3A).  Likewise, the same two structural parameters place 
“known epilepsy” variants in gene set 2 (Figure 4.3B) closer to the distribution observed 
in other disease-causing mutations. This analysis emphasizes the potential for structure-
based deleteriousness measures to generate predictions that are more discriminating than 
those derived from measures of sequence conservation.    
To obtain a list of high-priority functional nsSNPs for epilepsy, we applied the 
deleterious structure predictions enriched in positive SNPs (Table 4.4) to all candidate 
epilepsy variants and identified the ones with high SDSs (score ≥ 4 out of 7). A list of 14 
high-likelihood structure-disrupted variants from 30 missense mutations was generated. 
To account for differences in the burden of mutations among genes, we used the Residual 
Variation Intolerance Score (RVIS) [124] to identify and compare the levels of 





deviation of observed vs. expected numbers of common variants in a gene. Petrovski et 
al. (2013) found that genes which carry many common mutations (large positive RVISs) 
are less likely to influence disease development. Comparison of average RVIS between 
genes in sets 1 and 2 indicated that the two groups do not have the same tolerance to 
variations (p-value .0011, two-tailed t-test). The average RVIS for gene set 1 is 0.39 
(range 0.11 to 0.67, 95% CI) whereas the value for gene set 2 is -0.40 (range -0.77 to -
0.03, 95% CI). As expected, lower RVISs were observed for the documented disease 
causal genes (gene set 2). The finding is consistent with low RVISs in many OMIM 
genes [124]. Nonetheless, the positive average RVIS for gene set 1 is not surprising; 
among the 57 genes in set 1, 38 genes (67%) are classified as being high tolerance.  
Sub-classification of our 14 high SDS structure-disrupted variants yields 9 and 5 genes 
that are highly acceptable or tolerant of mutations, respectively (Table 4.5).  Although 
variants in genes with low tolerance (negative RVISs) are more likely to be deleterious, 
our structural disruption score focuses at the variant level, and the structural analysis 
potentially provides novel intuition that is not apparent from any sequence- or gene-based 
analysis. Therefore, the indication of many “high tolerance genes” in our dataset does not 
preclude potential functional effects of specific variants. For this reason, we performed 
in-depth literature searches on all 9 and 5 variants of the 2 subgroups, and provide our 
inference of the likelihood that a particular SNP may contribute to the epilepsy disorders 
(Table 4.6). Interestingly, we found that half (4 out of 9) of the SNPs in high tolerance 
genes have potential to promote epilepsy. The proportion is comparable (2 out of 5) for 
variants located in the low tolerance genes. Of the 9 variants in high tolerance genes, one 





alters a highly flexible protein site; therefore, we disregarded it as a putative functional 
variant. Similar consideration of the low tolerance genes suggests that just one, 
PPP1R27, is likely to harbor a mutation that promotes epilepsy. This leads to 
prioritization of 9 “high-priority putative functional variants for epilepsy”.  The locations 
of each of these variants with respect to their protein 3D structures are shown in Figure 





Table 4.5: Case SNPs with high structural disruption scores. Each candidate epilepsy variant is suggested to disrupt protein 
structure/function if its structural disruptions score (SDS) is high (≥ 4 out of 7). A list of 14 putative structural disrupted variants from 
30 missense mutations is reported, along with the corresponding 7 scores that make up the SDS. The variants are classified into two 


































































































yes [10.55] yes 
yes [up-down 
bundle] 
































































































































































































yes [4]  yes [E>G]   
yes [up-down 
bundle] 




* Only the values corresponding to enriched characteristics of causal SNPs are included in the table; the empty cells do have values 






Table 4.6: Summary of structural disrupted case SNPs. The table summarizes the structural and clinical findings for each of the 
top 14 case variants. The 9 putative functional variants for epilepsy (variants A-H, M) are identified from of a subset of the 14 
variants.  Eight variants (variants A-H) are located in “high tolerance genes” and do not possess a compatible feature with those of 































ABC transporter A family 
member 6  
[lipid homeostasis] 
large change in amino acid 
properties, mutation causes 
protein destabilization but 
does not alter disulfide bonds 






near active site (low Γ), loss 
of side chain (R>G) 
linked to Chanarin-Dorfman 
syndrome (fat depositions in 
internal organs) 






near active site, on best 
protein patch 
shares substrate with COX 
(COX-2 expression increases 
upon electrical stimuli) 





[mRNA degradation control] 
stabilization center 
gain of function in 
Drosophila's homolog 
suppresses seizure; mRNA 
loss accounts for 1/3 of 
human diseases 






stabilization center, mutation 
yields preferred hydrophobic 
core 




DNA helicase  
[DNA damage repair] 
3 indications as a binding 
residue, confirmed by 
mutagenesis 
effective cellular protection 
mechanism helps animals 
survive brain injuries after 
induced seizures 






mutation locates at a turn 
region (not favorable in 
highly structured proteins) 
antiepileptic drugs interfere 








neuromedin-U receptor 1 
[uterus contraction, 
vasoconstriction] 
diminishes stabilizing salt 
bridge and causes protein 
destabilization 




partner and localizer of 
BRCA2 [homologous 
recombination repair] 
mutation may interfere with 
conformational flexibility of 
protein, largely decreases 
protein stability 
several mutations identified 
in breast cancer but disease 
associations are not definitive 





































[programmed cell death] 
rigid residue at turn region, 
controls positioning of C-
terminal and active site, 
confirmed by mutagenesis 
n/a but reduces substrate 
binding 




fatty-acid amide hydrolase2 
[lipid metabolism] 
mildly decreases protein 
stability 
gene’s regulation of 
endocannabinoid system is 
linked to Alzheimer’s and 
other CNS disorders 




monoamine oxidase type A  
[neurotransmitter 
metabolism] 
far from functional sites, 
mildly reduces protein 
stability  
gene catalyzes several 
neurotransmitters and 
associated with behavioral 
phenotypes, confirmed by 
animal studies 





[cellular process regulation] 
longer amino acid side chain 
causes steric clash 
member of KEGG epilepsy 
pathway;  protein in the same 
family linked to Lafora 
disease (teenager-onset of 
epilepsy) 






non-receptor type 14  
[cellular process regulation] 
mutation does not alter inter-
residue bonding but slightly 
decreases protein stability 
several mutations identified 
in colorectal cancers 
no 4 0.93, 3.22 
*Variant’s features include all structural changes/implications that were collected during the analysis, regardless of their significant in 
feature enrichment towards causal SNPs. 
†Disease implications denote any clinically-relevant associations in found in literatures. Epilepsy implications indicate our opinions on 
whether or not the variant contributes to epilepsy development. The opinion is based upon several data sources. However, the 
considerations exclude the SDS of a variant and its minor allele frequencies (MAFs). (The SDS had already been utilized as a filter 








Figure 4.4: 3D structures for the nine high-priority variants for epilepsy. Mutated 
protein residues caused by the SNPs are indicated with blue surface representations along 
with the amino acid name (wild type) and residue index. Yellow surface representations 
refer to predicted binding sites or catalytic sites, except in (M) in which it represents a 
protein residue with close proximity to the altered amino acid. Orange representations in 
(C) indicate the predicted best conserved residue cluster on the protein surface. The 
substitution of Ser150Cys in (E) adds one favorable hydrophobic residue (green surface 
representation) to the core of the α/β horseshoe. The magenta sticks in (H) represent the 
partner residue, Glu117, which forms a salt bridge with wild type Arg137. This salt 





Individual assessment of putative structurally deleterious variants 
A) Cys1359Arg in ABCA6 Cys1359 mutation is located in a buried site of ABCA6, a 
protein that plays roles in macrophage lipid homeostasis (Figure 4.4A). Despite the high 
SDS of this variant (score 5/7), it has not been associated with diseases. The functionality 
of cysteine residue depends largely on the protein structure and its cellular location. For 
this instance of Cys to Arg change, it does not alter the pattern of disulfide bonds, partly 
due to the rarity of this bonding type within membrane proteins [99]. However, the 
C1359R mutation is still considered as a crucial change (Grantham score 180, ∆∆G 1.64 
kcal mol-1), especially when the mutation occurs in the middle of protein domain.  
B) Arg277Gly in ABHD14A.    Arg277 is located on an exposed site of ABHD14A 
(Figure 4.4B). Another member of this protein family, ABHD5, is thought to be 
responsible for a rare genetic disorder called Chanarin-Dorfman syndrome. This is the 
only variant among the 14 structural disrupted case SNPs that was not detected as 
“deleterious” by any sequence-based algorithms (deleterious count 0/6), but our SDS 
suggests it has potential impact on the protein (SDS 4/7). The wild type Arg227 residue 
has low sequence optimality (Γ -0.58 kcal mol-1), a likely indicator that it has close 
proximity to a catalytic site. Moreover, the Arg to Gly change is considered as an 
unfavorable substitution, especially when it occurs in a structured protein, as the lack of a 
side chain in Gly may diminish proper protein folding or intermolecular interactions.  
C) Arg404Gln in ALOX12  Arg404 is found in a buried site of ALOX12 (Figure 4.4C). 
Arg404 is in close proximity with the catalytic site of this protein and is also predicted to 
be part of the protein patch for intermolecular interactions. The Arg404Gln substitution 





kcal mol-1), despite the acceptable Grantham substitution score (< 100). We suspect the 
variant may play roles in epilepsy implication, since a link between its substrate 
(arachidonic acid) and seizure susceptibility had been proposed [127].  
D) Ile463Thr in DDX52   Ile463 is located in a buried site of DDX52 (Figure 4.4D). A 
study of seizure susceptibility in Drosophila discovered that a gain-of-function mutation 
in the maleless helicase gene can suppress seizure susceptibility in bang-sensitive 
Drosophila mutants [128]. The Ile463Thr mutation in this protein affects the structural 
integrity of the protein since it is detected as a stabilization center (SC), consistent with 
its destabilization effect (∆∆G 1.37 kcal mol-1). 
E) Ser150Cys in EYPC    The Ser150Cys variant is located in the core of the leucine-
rich repeat (LRR) structural motifs of EYPC (Figure 4.4E). Several disulfide bonds are 
formed between cysteine clusters that flank the LRRs, providing additional structural 
support, but no changes of disulfide bonds or hydrogen bonds appear in the mutated 
protein. Ser150Cys has minimal impact on protein stability (∆∆G = -0.41 kcal mol-1), and 
while the substitution induces a large physicochemical change (Grantham score ≥ 100), 
the substitution is considered neutral if located in α/β protein [129]. Indeed, we observed 
Ser150Cys added one favorable hydrophobic residue to the core of the α/β horseshoe.  
Despite its high SDS (4/7), we consider it unlikely that this variant contributes to any 
disorders.  
F) Asp506Gly in HELB  Asp506 is situated in a buried site of HELB (Figure 4.4F) and 
several of its features are predicted to interfere with ligand binding. First, wild type 
Asp506 has an exceptionally low sequence optimality value (Γ -4.14 kcal mol-1). Second, 





the values are not extreme. Third, the Asp506Gly substitution is predicted to destabilize 
the protein (∆∆G 1.40 kcal mol-1). These characteristics coincide with a recent 
mutagenesis experiment that proves Asp506 is part of a binding motif, and the mutation 
of D506A induces loss of substrate binding when associated with E499A and D510A 
[130]. Study of another human DNA helicase, Twinkle, demonstrated that two missense 
mutations were detected in patients with a wide range of psychiatric symptoms, including 
severe epileptic encephalopathy, possibly due to inefficient recovery from molecular 
stress [131].  HELB Asp506 is thus particularly interesting for further assessment of a 
role in epilepsy.  
G) Leu43Val in IAH1  Leu43 is located at a buried site in IAH1, although it lies far from 
the substrate binding site (Figure 4.4G). The protein is of interest given that many 
antiepileptic drugs are potent enzyme inducers and inhibitors of the cytochrome P450 
system, which affects lipid and glucose metabolisms, as well as evidence that increased 
lipase level is one of the side effects of anti-psychotic and anti-epileptic drugs [132, 133]. 
Substitution of Leu to Val is quite favorable in all protein folding types [129], but 
Leu43Val in this protein is suspected to reduce protein stability (∆∆G 2.06 kcal mol-1). A 
plausible explanation may be that this protein is highly structured, comprising only a few 
loop residues. The turn regions may play an essential role in bringing together and 
enabling or allowing interactions between regular secondary structure elements.  
H) Arg137Cys in NMUR1 Arg137 is situated in the central cavity of NMUR1 (Figure 
4.4H). The presence of the a mutant Cys at position 137 diminishes the stabilizing salt 
bridge between wild type Arg137 and Glu117, and results in a decrease in protein 





M) Ile112Met in PPP1R27 Ile112 is found at a buried site of PPP1R27 (Figure 4.4M). 
A study of a similar protein, PPP1R3C, identified one missense mutation that may lead 
to a mild phenotype in Lafora disease—a teenage onset epilepsy disorder [134]. In 
addition, protein phosphatase 1 (PP1) was identified as a member of long term 
potentiation (PTP) pathway in epileptogenesis and epilepsy (KEGG: map04720) [135, 
136]. Other genes in this pathway mostly regulate neurotransmission and ion channel 
receptors.  The Ile to Met substitution is quite favorable both in general (Grantham score 
< 100) and in distinct types of protein folding [129]. However, the longer aliphatic side 
chain of Met creates steric clashes with Ala104 of an adjacent helical region. This single 
point mutation is predicted to destabilize the protein (∆∆G 1.41 kcal mol-1). 
Structural disruption score correlates with sequence-based deleterious score 
Finally, we tested whether the SDS correlates with measures not used to construct the 
score itself. We performed an additional sequence-based deleterious prediction of case 
SNPs using Condel: a weighted score that integrates the output of five tools [22], three of 
which were used in our analysis. There is a significant positive correlation between our 
SDS and the Condel score (p-value .0342, n= 30). The trend persists after removing the 
sequence-based deleterious scores from SDSs of 16 variants (the variants have 
deleterious count ≥ 4 out of 6), although the significance in correlation is reduced to a 
marginal level (p-value .0717). In addition, we performed a similar analysis by 
sequentially removing one SDS component from the total score, and found the 
significantly positive correlation between SDS and Condel is maintained (Table 4.7). 
The weakest structure-based parameter among all of the SDS components is the 





variants, we did not detect any correlation between the two measures (p-value .13). Note 
that this analysis is complicated by the small sample sizes. Nonetheless, the finding 
supports our expectation that although the deleterious count is one of the major 
components for constructing our SDS, the remaining non-conventional deleteriousness 
parameters also have substantial impact on the overall missense variant evaluation. 
Table 4.7: Step-wise analysis for correlation of SDS and Condel score. Initial SDS 
includes 7 parameters, described in Table 4; the maximum SDS for each variant is 7. The 
revised SDS calculates the score by exclude one SDS component at a time; the maximum 
revised score for a variant equals 6.  
SDS parameters R2 of linear fit 
P-value of 
correlation 
#of variants affected by the revised SDS
†
 
All SDS .1504   .0342** none 
SDS-high deleterious count .1112 .0717* 16 
SDS-large amino acid change .1508   .0340** 5 
SDS-induce gly/pro change .1308   .0496** 7 
SDS-locate in buried site .0782 NS (p = .1344) 15 
SDS-locate on  protein patch .1629   .0270** 3 
SDS-locate in protein domain .2093   .0110** 25 
SDS-reduce protein stability .1243 .0560* 20 
† The full dataset has 30 missense variants. All data points were used to test for a 
correlation between SDS and Condel score. When an SDS component was removed 
during the step-wise analysis, the SDSs for some numbers of variants were affected, i.e. 
the excluded parameter was applicable to the variant. For such cases, the correlation 
analysis was performed with all of the 30 data points, minus the number of exclusions 
indicated in the last column. 
Significant p-values are designated with ‘**’ and ‘*’ for α =.05 and α =.10, respectively. 







Current perspectives in prioritization of epilepsy variants 
The evaluation and prioritization of candidate case variants is particularly difficult when 
the disorder involves a dissimilar set of genes, as is the case for epilepsy disorders, which 
are now known to involve diverse molecular pathways [112, 137]. The classic epilepsy 
genes (ion channel genes/regulatory genes, neurotransmitter genes/receptor 
gene/regulatory genes, genes that disrupt cortical circuits, and genes that lower the 
convulsion stimuli) rarely present in genomic data from sequencing studies.  This may be 
because the classical epilepsy mutations are Mendelian, whereas exome sequencing 
likely targets more polygenic cases, noting that only 1% of epilepsy disorders are 
inherited in a Mendelian  manner [138].  
Ferraro and coworkers (2012) highlighted how daunting the task is for epilepsy when 
they exemplified some factors in the design of cohort studies that influences the 
discovery of true positive epileptic variants: the selection of cases (presence/absence of 
the cause of symptoms), the seizure types (determine the amount of genetic influences), 
the patient profiles (age at onset, gender, characters of seizure incidences, etc.), and the 
assumption of genetic patterns (common variant effects, rare variant effects, or a 
combination of both) [139]. Some authors are starting to incorporate disease information 
as prior knowledge in the probabilistic evaluation of candidate causal SNPs [105, 140, 
141], but the scarcity of knowledge related to epilepsy genes limits this approach.  
Indeed, we found that the genes in our dataset are somewhat poorly understood and their 





In addition to SNPs, structural variations have been shown to associate with epilepsy 
genetics. Jia et al (2011) used stepwise enrichment analysis of protein-protein interactions 
to derive a molecular network of 20 high priority candidate genes linked to copy number 
variation [142]. Interestingly, the genes do not overlay with the 68 homozygous nsSNP-
containing genes in our dataset (but they do overlap with 4/1,604 genes that harbor 
heterozygous variants: [111]). An independent comparison with nine genes that harbor de 
novo mutations (identified from trios—unaffected parents and their affected child) also 
found no overlap [143].  
Consequently, we cannot be sure that any of the variants discussed in this article are truly 
causal for epilepsy.  However, the variant prioritization scheme does suggest a reduced 
number of candidates which, on the basis of careful curation of protein structure, might 
be taken forward for targeted experimental manipulation and assessment of biological 
function in cell lines or model organisms. 
Key findings 
We have developed a structure-based variant analysis protocol that evaluates the effects 
of missense mutations with respect to their predicted effects on protein features, such as 
solvent accessibility, stability, and flexibility. Replicated trends for putative case SNPs to 
have aberrant structural features that more closely match those of established disease 
mutations in the same proteins, than to those of neutral polymorphisms, establish the 






Starting with 71 genes harboring putative case SNPs from an exome sequencing study of 
epilepsy disorders [111], we were able to perform the assessments on 57 gene products.  
Presumably only a fraction of these are actually causal, so our expectation was simply 
that the distribution of risk scores may be shifted from neutral toward disease-associated.  
Several features were observed to classify SNPs into two groups: putative functional 
variants, or presumably neutral variants, and a composite risk score based on summation 
of these features highlighted nine putative functional variants, from thirty exclusive 
missense mutations whose protein 3D structures are available.  Although none of these 
has been previously linked to epilepsy disorders, detailed case-by-case analysis strongly 
suggests that several should be prioritized for further functional evaluation. 
Although our structure-based analysis only captured a fraction of variant residues due to 
the limited availability of 3D structures (Table 5.1), we show that 44%, 32%, and 75%, of 
case, negative, and positive variants from the first gene set are amenable to structure-
based predictions. The equivalent percentages for set 2 genes are 49%, 37%, and 51%, 
respectively. More importantly, we were able to represent 84% of the proteins in our first 
set, and 86% in the second set, despite the difficulty in generating high quality structures. 
Our preliminary analyses suggest that it is not necessary to have structural data for all 
variants in order to construct the SDS. Since the sequence-based predictions of variants 
with structure data are similar to those obtained for all SNPs in the dataset (data not 
shown), we are confident that the conclusions from our structure-based variant 






With our combined sequence- and structure-based analysis pipeline, we discovered that 
some features are predominantly found among negative or positive SNPs. Structure-
based parameters contribute as much as 50% of the features that differentiate the two 
types of variants. There are several key observations from our feature enrichment 
analysis. First, we noticed seven common characteristics that are predominantly found in 
the positive control SNPs, regardless of the set of genes. SNPs with strong effects are 
those that: have deleterious count  ≥ 4, have Grantham score ≥ 100, induce glycine or 
proline changes, locate in protein domains, in buried sites, or on conserved protein 
patches, and destabilize the protein. Second, variants with neutral effects (negative SNPs) 
have a few strong enriched features. In gene set 1, we found negative SNPs are more 
likely to be in conformationally flexible sites. A similar feature was detected in gene set 
2, in which non-damaging SNPs are mostly highly dynamic sites.  An additional 
distinctive characteristic of the negative SNPs in gene set 1 is that they tend to affect 
highly conserved residues. This finding appears to be counter intuitive; we suspected that 
this unique observation seems to be an exception for this particular gene group. 
Study limitations  
A primary limitation of our approach is the requirement for homology models that 
support computational prediction of structural characteristics. Specifically, only 18/68 
proteins had at least partial experimental structures, so homologous templates were used 
in most cases. These were not available for just 9% of the proteins (n = 6), but the 
retained models did not cover the disrupted site for another 56% (36/68 variant sites), and 
24 of the potentially disrupted proteins are larger than 1000 amino acids, which also 





Nevertheless, by restricting the modeling to domains, we were able to model 84% of the 
68 candidate genes (covering 44%, 32%, and 75%, of case, negative, and positive 
variants). This is a clear improvement on the automated pipelines used in training 
algorithms such as PolyPhen2. We also ensured that the quality of the models was 
validated wherever possible, which also introduces an intensive manual curation 
requirement into the analytical pipeline, requiring some knowledge with methods that 
most genomicists are not familiar with. 
An analytical limitation is that the size of the dataset is relatively small, since only one 
variant per gene was studied, and just 68 proteins were available to begin with. Since 
these are structurally diverse, it is likely that different aspects of protein structure are 
affected and the probability of enrichment for any one structural feature is 
correspondingly reduced.  While approximately three quarters of amino acid changes 
leading to Mendelian diseases consistently induce protein destabilization [37], the 
structural consequences of missense variants in complex diseases such as the epilepsy 
disorders are likely to be of a more diverse nature.  
Study innovations 
The Structural Disruption Score (SDS) offers a novel strategy for genomic profiling of 
variants that have uncertain but likely weakly deleterious function.  It combines similar 
instances of variants with respect to their predicted impact on aspects of protein structure, 
allowing joint assessment of the impact of the variants as a class on biological function.  
Instead of evaluating each variant one by one, SDS provides a ranking that might be used 





Other studies using structural biology approaches to examine the variant effects have 
considered a large number of variants per gene, facilitating direct contrasts of variant 
characteristics and predictions for individual genes [144] or genes with similar 
structures/functions [39, 145]. The genomic data that we started with is relatively small 
by comparison.  However, we provide an alternative structure-based approach that can 
accommodate the small number of variants expected from exome sequencing samples as 
well as the large diversity of gene functions they will typically generate. 
Most importantly, our SDS score implementation assures that case variants share similar 
characteristics as those observed in causal variants, but not neutral variants known to 
reside in the same proteins. We have validated the findings in a replication dataset, and 
show how the approach can be used as a unique solution to prioritizing case variants in 
unrelated genes.  Though not providing a guarantee of disrupted function, the score 
should be considered as a complementary approach to existing sequence-based 
deleteriousness prediction.  
Conclusion 
Using the list of enriched features, we concluded that this novel structure-based 
assessment protocol for missense variant deleteriousness has a potential to determine 
high-priority candidate variants suitable for experimental validations. The analysis may 
prove to be useful, particularly when traditional sequence-based predictions are 
inconclusive.  An important question is whether the same structural attributes 





Because our study employed large numbers of external resources (variant predictions, 
gene information, 3D structure modeling and quality controls, sequence- and structure-
based predictions), the analysis pipeline presented here is not readily automated.  Aspects 
of it are in theory readily generalizable to all classes of proteins, and once all the above 
steps have been accomplished, the variant deleteriousness structure-based predictions 
could be effectively populated into a database. After that labor-intensive step is 
completed, the SDS for any variants in a dataset may be computed and retrieved virtually 
by combining the predictions for the genes specific for the study. 
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CHAPTER 5: SYSTEMATIC 3D SCREENING OF AMINO ACID 
MUTATIONS IN PHARMACOGENES 
Abstract 
Next-generation sequencing technologies have promoted steady progress in the 
identification of genetic factors that influence drug responses. Priority is being given to 
genes whose variants are predicted to alter pharmacokinetic and/or pharmacodynamic 
parameters, which may result in an increased risk of drug toxicity or therapeutic failure. 
Therefore, rational analysis of an individual’s genomic variants can guide personalized 
medical treatments. In this study, we selected 48 genes identified as “Very Important 
Pharmacogenes (VIPs)” by the PharmGKB database. Despite their high potential impact 
for prescription of specific drugs, only ten gene-drug pairs currently have dosing 
guidelines suggested by the Clinical Pharmacogenetics Implementation Consortium 
(CPIC).  
To promote more practical usage of genetic test results, we have developed a systematic 
screening for structural disturbance of amino acid mutations within the 48 VIPs in the 
context of their 3-dimensional (3D) protein structures. Our pipeline focuses on the 
changes in inter-residue bonding, protein stability, protein flexibility, drug binding 
capability, protein-protein interactions, and amino acid dissimilarity, in addition to the 
localization of the variants and the amino acid secondary structure preference. These 
results are incorporated into the construction of a five-feature “SDS Pharmacogenes” 





functional rather than neutral mutations. Unlike most existing conservation-based 
measures, SDS Pharmacogenes can be used to evaluate unknown variants of these 48 
VIPs and predict the degree to which each one will have strong impacts towards 
pharmacogenomics, potentially aiding optimization of drug therapy. 
While expertise in 3D-protein analysis is beneficial, our implementation does not require 
that an individual with experience in protein structures be engaged in the personalized 
genome evaluation. In addition, the analysis pipeline is systematic and scalable, thus 
expected to keep pace with the rapid accumulation of pharmacogenomic data. 
Introduction 
Pharmacogenomics aims to predict the effect of genetic polymorphisms and mutations on 
therapeutic efficacy and/or toxicity. To this end, one of many challenges for 
bioinformaticians is the development of variant evaluation methods that may be used to 
guide the interpretation of genomic variation.  
In this study, we surveyed genomic variability of 48 Very Important Pharmacogenes 
(VIPs) identified in the PharmGKB database [146] (Table 5.1), and implemented a novel 
3-dimensional (3D)-protein structure based method to systematically screen the 
characteristics of their amino acid mutations. The implementation incorporates results 
from many protein structural analysis tools. It generates an integrative score that offers a 
comprehensive understanding of potential mutational effects. The analysis also reveals 
some key structural features that are generally present in functional variants (mutations 
that lead to functional differences between wild type and mutant proteins) as well as 





are highly interactive. Our findings may assist the refinement of existing deleterious 
prediction algorithms by adding protein structural data to sequence conservation based-
parameters, particularly to predict the functional significance of variants in 
pharmacogenes. The objective is to provide a comprehensive understanding of potential 
mutational effects towards inter-patient drug responses and lead to the practical usage of 






Table 5.1: List of 48 VIPs and number of their pharmacogenomics associated 
variants. The data were obtained from PharmGKB’s curated list of clinical annotations. 
There are no variants in level 2B or level 4.  
 Gene Protein name  CPIC 
























































































Breast cancer type 1 
susceptibility protein 
no 











































































































































Table 5.1 (continued) 
Gene Protein name  CPIC 











































subfamily H member 
2 
















no 2 (2/0/0)    2 (2/0/0) 
NR1I2 
Nuclear receptor 
subfamily 1 group I 
member 2 
no 1 (0/0/1)    1 (0/0/1) 
P2RY1 P2Y purinoceptor 1 no 1 (0/1/0)    1 (0/1/0) 
P2RY12 P2Y purinoceptor 12 no 6 (1/1/4)    6 (1/1/4) 




no 3 (0/0/3)    3 (0/0/3) 
SCN5A 
Sodium channel 
protein type 5 subunit 
alpha 
no      
SLC19A1 Folate transporter 1 no 6 (5/1/0)    6 (5/1/0) 
SLCO1B1 
Solute carrier organic 
anion transporter 




1 (1/0/0)  8 (4/0/4) 
26 
(16/0/10) 













yes 13 (5/0/8)   4 (2/0/2) 9 (3/0/6) 






Table 5.1 (continued) 
Gene Protein name  CPIC 























no 9 (9/0/0)   3 (3/0/0) 6 (6/0/0) 
























The 48 VIPs have important roles in drug metabolism. Some mutations are expected to 
influence drug efficacy and/or toxicity through perturbation of the drug-binding ability of 
the protein (directly or indirectly), or via altered drug metabolism and excretion [147]. 
The PharmGKB database [146] (accessed January 19, 2014) lists 546 drug molecules that 
interact with one or many of the VIPs (Supplementary Table B.1). However, little is 
known about the function of most of the genetic variants. Despite their high potential 
impact for prescription of specific drugs, only ten gene-drug pairs currently have 
genotype-specific dosing guidelines developed by the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) [148] (Table 5.1). These shortcomings highlight the 
need for a novel strategy to examine and predict the outcomes of genetic variations 
towards a diverse range of drug toxicity or therapeutic failure.  
Several research groups have focused on expanding variant assessment methodologies for 
proteins, generally by including more predictive features [13, 35-39]. One of the notable 
improvements arises from adding predictive parameters which are derived from protein 
structural context. Even so, the space of protein study is large and many unexplored fields 
are worthy of attention [34]. Our study explores a broad range of protein analyses and 
employs statistical tests to derive key structural features of functional variants. The 
implementation utilizes numerous computational tools in the following eight areas of 
protein analysis: inter-residue bonding, protein stability, protein flexibility, drug binding 
capability, protein-protein interactions, residue localization, amino acid dissimilarity, and 
amino acid secondary structure preference. A subset of 11 tests which represent disrupted 
protein characters that are preferably targeted or induced by functional variants was 





enriched features is subsequently reduced to the 5 strongest indicators that can 
discriminate pharmacogenomics variants from neutral mutations. 
The implementation of our fully structure-based variant assessment algorithm enhances 
our knowledge of residue features that are susceptible to or induced by functional 
mutations. Structure-based information provides both the understanding of local changes, 
as well as those that occur non-locally and cannot be deduced from sequence 
conservation analysis alone.  
Methods 
This research aims to provide a rational analysis of genetic variants in 48 Very Important 
Pharmacogenes (VIPs). The implementation of our 3D screening approach was designed 
such that it is systematic and scalable so that it offers a broad understanding of various 
protein characteristics while being flexible enough to accommodate emerging genomic 
data for future refinement. 
Dataset of 48 Very Important Pharmacogenes (VIPs) 
A list of VIPs was populated from the PharmGKB’s external data source on October 7, 
2013. In addition, we retrieved a list of curated gene-drug and gene-chemical pairs for 
each VIP from the gene’s record, available at the PharmGKB website (accessed January 
19, 2014) [146]. Supplementary Table B.1 provides the descriptions of the 48 VIPs, 






Genomic variation dataset  
A) Genomic variants for construction of the algorithm (training set) 
Genomic variants were obtained from publicly available databases and were categorized 
into two groups: functional mutations and neutral mutations. The data sources for 
attaining functional mutations include MSV3d [43] (accessed October 25, 2013), 
SwissVar [44] (accessed October 25, 2013), ClinVar [149] (accessed January 9, 2014), 
and UniProt’s functional mutagenesis records [150] (accessed March 4, 2014). For 
neutral variants, we obtained the data from EVS [151] (accessed January 4, 2014) and 
Uniprot [150] (accessed January 28, 2014). Quality control of the genomic data was 
carried out by aligning wild type amino acids from the given list of variants to the 
corresponding UniProt curated protein sequences [150]. Any variants of minor protein 
isoforms were excluded (n=87).  
Using the sequence mapping, we identified nine incorrectly labeled variants (one 
functional and eight neutral mutations). The variants have interchanges between 
reference and alternate residues. For example, a functional variant ADRB2:c.79C>G 
(p.Gln27Glu) is listed as a risk factor for obesity, metabolic syndrome and asthma in the 
ClinVar database (classified by a single submitter) [149]. The amino acid variant has a 
sequence conflict with our data sources: Uniprot [150] and SwissVar [44] list Glu as the 
wild type amino acid at residue 27, but ClinVar (based on dbSNP [49] indicates the SNP 
induces a change from Gln to Glu. These errors are likely due to inaccuracies of 
sequencing or in the reference genomes; therefore, all unmatched variants were 





B) Genomic variants for testing the utility of the algorithm (test set) 
A collection of pharmacogenomic-associated variants was downloaded from the “Clinical 
Annotation” records at the PharmGKB website [146] (accessed February 16, 2014). 
PharmGKB annotates the variant-drug associations based on the number and/or strength 
of pharmacogenomic evidence (Table 5.1). The two conditions classify variants into four 
levels: 1A/1B, 2A/2B, 3, and 4. Level 1A/1B variants are the most significant variants for 
pharmacogenomics. They have either endorsed CPIC guidelines or clinical 
implementations (level 1A variants) or strongly suggestive evidence of variant-drug 
associations from multiple cohort studies with significant test statistics (level 1B 
variants). Level 2B variants are those with moderate indications of variant-drug 
associations, but may lack statistical significance of associations in some studies. For any 
2B variants that are located in VIPs, their association levels are re-assigned to 2A. 
Genomic variants in level 3 require more replication to confirm the significant test 
statistics from a single study, or the data from multiple studies is available but has not 
provided clear indication of an association. Other variants that were derived from case-
by-case reports, non-significant studies, or in vitro data are assigned to be in level 4. 
There are a total of 96 associations in level 1A/1B, 81 are found in 10/48 VIPs 
(CYP2C19, CYP2C9, CYP2D6, CYP3A5, DPYD, G6PD, MTHFR, SLCO1B1, TPMT, and 
VKORC1). Non-VIP genes that harbor strong pharmacogenomic associations are CFTR 
and HLA-B for a total of six associations in level 1A, and ANKK1, CYP4F2, EGFR, 
GRIK4, IFNL3, TMEM43, and XPC for a sum of nine associations in level 1B. The level 





Among the 48 VIPs, there are 776 pairs of pharmacogenomic associations (Table 
5.1).The associations are listed in the format of variant-gene-drug partners. Some gene-
drug pairs are well recognized, while other genes may not directly relate to the drug’s 
mechanism of action. To account for the accuracy of the annotations, especially for level 
3 variants, we checked if their genes are listed as pharmacogenomic biomarkers in the US 
FDA drug labeling (http://www.fda.gov/drugs) (accessed March 7, 2014), namely, drug 
exposure and clinical response variability, risk for adverse events, genotype-specific 
dosing, mechanisms of drug action, and polymorphic drug target and disposition genes. 
Additional annotations for drug labels (informative/actionable pharmacogenomic labels 
from FDA and European Medicines Agency (EMA)) were obtained from the 
PharmGKB’s website  [146] (accessed March 7, 2014). In addition to the apparent 
pharmacogenomic evidence, some genes may have direct/indirect effects on drug 
efficacy or toxicity. The gene may be a drug target, enzyme, transporter, or carrier. We 
obtained this information from the DrugBank database [152] (accessed March 7, 2014). 
The clarifications of gene-drug pairs returned 307/776 associations with at least one of 
the listing drugs having FDA- or EMA- approved labels, (maximum 7 drugs/variant; 
CYP2D6 gene) and 548/776 listings in DrugBank [152] indicating that the gene has a 
known pharmacological action.  
Of all 776 associations, 471 are related to missense variants (Table 5.1); their 
pharmacogenomic associations can also be in different levels due to multiple drug 
partners. The absolute number of unique missense mutations among the 471 associations, 
regardless of the association levels, is equal to 81. (For example, Arg150His of CYP2C19 





unique count of this mutation is one (one and the same variant). Since 9 of the 81 unique 
variants do not lie in regions of overlap with the protein structure dataset, we were able to 
use 386/471 structural data points to assess the abundance of enriched disrupted protein 
features with respect to the PharmGKB’s three levels of pharmacogenomics association 
confidence. The equivalent 386 data points were used to evaluate the classification 
performance of six standard conservation-based predictors.   
Protein structure dataset 
We retrieved experimentally derived structures from the RCSB Protein Data Bank [60] 
and generated/downloaded numerous homology models following our previously 
described protocols [110]. We used two parameters, QMEAN6 [63] and ModFOLD4 
[153], to validate all protein models. 
Most (36/48) of the proteins in our dataset are well studied, granting access to multiple 
experimental structures (range 1 to 53 structures per protein). Nonetheless, almost all 
structures only partially represent the entire protein length. Among these PDB 
coordinates, we selected the best structural representative for each protein chain by 
comparing their resolution and the percentage of sequence coverage. To ensure that our 
3D structural analysis covers most of the protein chain; we compared each of the selected 
PDB structures with the matching best homology models (from single-, or multi-template 
methodology, preferably full length structures). The best overall structure for each non-






Note that some of the selected x-ray crystal structures contain sequence conflicts (from 
mutagenesis during crystallization) with respect to the reference protein sequences. For 
such cases, the structures were mutated back to the wild type proteins. We used the 
Swapaa tool in Chimera [65] to model the new side chain using the most probable amino 
acid rotamer [154]. Unfavorable atomic contacts between each modeled side chain with 
the remaining protein residues were assessed using the Find Clashes/Contacts tool in 
Chimera [65] with the default distance settings.  
A complete list of protein 3D structures used in this study, along with the structure 
sources and quality parameters are provided in Supplementary Table B.2. The genomic 
and structure datasets were combined into 3D structure maps for each genetic variant. 
Table 5.2 summarizes the genomic variability data of the 48 VIPs and the structure 
coverage statistics of the 3D maps. The complete list for genomic variability coverage of 
each gene and the percentage coverage of variants with structural data is presented in 
Supplementary Table B.3.  




All genomic data* Genomic data with available 3D structures 
# of variants 
Avg # of variants 
per gene 
# of variants 
Avg # of 
variants per 
gene 





779 (in 35 genes) 16 (range 0-186) 371 (in 31 genes) 8 (range 0-58) 80% 
Neutral 
mutations 
2537 (in 48 genes) 54 (range 4-245) 1811 (in 45 genes) 38 (range 0-140) 84% 
*Sources for functional mutations: MSV3d [43], SwissVar [44], ClinVar [149] databases 
and Uniprot databases [150]. Sources for neutral mutations: EVS [151] and Uniprot 
databases [150]. 
†Represents the average of all 3D variant coverage percentages of the 31 genes and 45 





Identification of conserved protein domain families 
Protein domain families are evolutionary conserved structural modules which exist 
independently from the rest of the protein chain. Large proteins often consist of several 
structural domains. Protein domains were identified according to the annotations 
provided by InterPro—a centralize database for protein family (Hunter 2011). We 
downloaded the “All UniProtKB proteins” dataset (January 27, 2014 release, accessed 
February 16, 2014) and extracted domain definitions for the 48 proteins. Identification of 
protein domain family was performed by first indexing the mutated protein residues 
relative to the full length protein chain, and then identifying the protein domain family 
that surround each variant residue. 
The InterPro database is made up from 11 external data sources [155], each with different 
identification and annotation methodologies for protein domains. We excluded the 
Gene3D-derived entries from the preliminary InterPro hits since Gene3D domains reflect 
the geometric similarity of protein structures rather than the functional or evolutionary 
relationships employed by the remaining algorithms. The exclusion of Gene3D hits 
yielded 4,599 remaining records; many variants have duplicate domain annotations from 
several algorithms. We further removed all duplicates to generate a non-redundant set of 
113 protein domain families present in the 48 proteins (Supplementary Table B.4). 
To detect protein domain families that harbor significantly more proportions of functional 
variants, we compared the relative abundance of functional and neutral variants that are 
located in a particular protein domain family. The calculations were performed by first 





domain family to the total number of functional (neutral) variants located within any 
domains (excluding variants found in domain boundaries). Each normalized value was 
then transformed into a percentage with respect to the sum of the two normalized values. 
The final two percentages were compared, and three types of domain family were 
identified: domains with more abundance of functional variants (n=36), domains with 
more abundance of neutral variants (n=42), and domains with only neutral variants 
(n=35). 
Characteristics of amino acid mutations at different protein regions 
1) Changes in physicochemical properties of amino acids 
We performed Fisher’s exact tests to examine the ratios of dramatic amino acid changes 
when the variants affect important vs. general protein regions. First, we used Grantham 
scores [56], which measure chemical dissimilarity between amino acid pairs, to classify 
amino acid changes into two classes. An amino acid replacement is considered 
conservative (mutation with similar amino acid property) if the Grantham score is less 
than 100 and radical (mutation with distinct amino acid property) otherwise. We used 
Grantham score to compare the amino acid changes at non-structural sites vs. structural 
sites [150], protein domains vs. domain boundaries [155], and binding sites (or around 
binding site) vs. other sites [72]. Second, we used the categorical classes of the amino 
acid side chain properties [156] to represent the four physicochemical changes between 
amino acid pairs: hydropathy index (hydrophobic and hydrophilic properties), volume, 
charge, and hydrogen donor/acceptor. The changes are empirically considered important 





E, K) side chains, between very small (A G, S) and large (R, I, L, K, M) or very large (F, 
W, Y) side chains, between very large (F, W, Y) and small (N, D, C, P, T) or very small 
(A, G, S) side chains, between positive charged (R, H, K) and negative charged (D, E) 
side chains, or between hydrogen donor (R, K, W) and acceptor (D, E) side chains. We 
tested the abundance of each altered side chain property at various protein locations: 
buried sites, exposed sites, binding sites, around binding sites, and any sites. 
The Uniprot’s sequence feature records provide descriptions of 11 functional features 
within a protein sequence. The annotations were either experimentally derived or 
computationally predicted. The features are: molecular processing, amino acid 
modification, sequence motif, sequence bias, active site, bond, natural variant, 
mutagenesis (indicates the amino acid has experimental mutation data), transmembrane, 
protein domain, and other region of interest. We re-organized the annotations into two 
groups: structural site and non-structural site. Our intuition is that the first four features 
do not necessarily have direct implications for the structural integrity of the protein; any 
variant annotation falling within these terms should be regarded as “non-structural site”. 
Our genomic data were not annotated to have the fourth feature, sequence bias. The 
content of the first three most prominent features detected in our variant dataset are 
propeptide and signal peptide; motif, zinc finger, and repeat; and modified residue, 
respectively. 
The grouping of missense variants into protein domain vs. domain boundaries was 
performed according to the aforementioned steps for identifications of protein domain 
families.  Similarly, the partitioning of variants into either predicted binding sites or other 





searched for ligand environments of each protein using 3DLigandsite [72]. The binding 
pocket residues were predicted from clusters of bound ligands that are present in protein 
homologs (average predicted binding site = 21 residues per protein, range 17-25 residues, 
95% CI). There are 41 functional and 104 neutral variants predicted to lie within binding 
pockets; these variants were grouped into “predicted binding sites”. Any other variants 
were assigned to the “other sites” category. Using the Cα- Cα atomic distances, we 
extracted a list of variant residues that are within 5 Å or 10 Å to the nearest predicted 
binding site [72]. The selected variants were grouped into either the “near binding sites (5 
Å)” or the “near binding sites (10 Å)” categories, and their structural features were 
compared with all other variant residues. 
2.) Changes in secondary structure preference of amino acids 
Amino acids have different preferences towards a certain protein secondary structure 
(coil, strand, 3-turn helix, α-helix, bend, or turn). Malkov et. al (2008) compared the 
occurrence of an amino acid in all types of secondary structures and defined the amino 
acid as a preferred or a prohibited residue for that structure type [157]. We use this 
information in conjunction with the predicted secondary structure of a variant residue 
[120] to identify if the altered amino acid will induce a secondary structure break (i.e., the 
amino acid changes from preferred to inhibited for the predicted secondary structure). 
Systematic 3D screening for structure-function relationships of amino acid mutations 
We implemented a systematic 3D screening methodology to investigate structure-
function relationships of each amino acid mutation. We concentrated the analyses on 





interacting with other molecules). The screening explores eight aspects of protein 
function: inter-residue bonding, protein stability, protein flexibility, drug binding 
capability, protein-protein interactions, residue localization, amino acid dissimilarity, and 
amino acid secondary structure preference.  A similar set of computational tools was 
adopted in our previous study of epilepsy variants [110].  The compendium of scores was 
used to predict structurally-related attributes for each amino acid residue in the context of 
its 3D structure (Table 5.3). The following sections explain several assessments that have 
been added to this 3D screening process for the first time. The new methods include 






Table 5.3: List of computational tools used to analyze structurally-related attributes for each amino acid residue. 
Structural 
feature 






Categorical The mutation occurs at one of an amino acid pair that forms a disulfide bond. DiANNA  [119]  




The mutation occurs at one of an amino acid pair that forms a salt bridge or an 
electrostatic interaction. 






The mutation occurs at one of an amino acid pair that forms an SC (two residues locate at 
least ten amino acids apart on the primary sequence but form close atomic contacts). 




The mutation occurs at one of an amino acid pair that forms an SR (a subset of SC that is 
also evolutionary conserved and located in the core region of the protein, and/or have 
many interacting partners). 
SRide  [71] 
∆∆G 
Categorical (transformed 
from continuous value) 
Stability change from a single point mutation; categorized into four groups: no change if 
∆∆G is between ±0.5 kcal/mol, mildly stabilizing if ∆∆G is between -0.5 and -2 kcal/mol, 
mildly destabilizing if ∆∆G is between 0.5 and 4 kcal/mol, and strongly destabilizing if 
∆∆G is ≥4 kcal/mol. 







from continuous value) 
Relative vibrational motion; indicates the mobility of each C atom. The mutation occurs 
at a highly dynamic (or highly rigid) residue if B-factorNorm ≥ 97.5 (or ≤ 2.5) percentile. 
PredyFlexy  [75] 
RMSFNorm 
Categorical (transformed 
from continuous value) 
Root-mean-square fluctuation; indicates the movement amplitude of each Cα atom over a 
period of time. The mutation occurs at a highly dynamic (or highly rigid) residue if 
RMSFNorm ≥ 97.5 (or ≤ 2.5) percentile. 







Categorical The mutation occurs at a predicted conformationally rigid or flexible site. FlexPred [76, 77] 




Binding site  Categorical The mutation occurs at a predicted binding site. 3DLigandSite [72] 
RSA 
Categorical (transformed 
from continuous value) 
Relative solvent accessibility; indicates percentage of solvent accessible compared to the 
fully exposed peptide. The mutation occurs at a buried site if RSA ≤ 20%, and at the 
protein core if RSA ≤5%. 
PoPMusic 2.1 [120] 
Γ 
Categorical (transformed 
from continuous value) 
Degree of residue non-optimality (summation of all stabilizing ∆∆Gs). A mutation occurs 
at a highly non-optimal residue if Γ ≤ 5 percentiles (an indication of being a catalytic site). 







Table 5.3 (continued) 
Structural 
feature 




Protein patch Categorical 
The mutation occurs at a conserved cluster on a protein surface (an indication for site of 
intermolecular interactions). 





Categorical The mutation occurs at a conserved protein domain family. InterPro [155] 
Structural site Categorical 
The mutation occurs at a structural site (any residues excluding the one with the following 









from continuous value) 
Indicates the dissimilarity of an amino acid pair. The substitution is radical (or 
conservative) if Grantham score is ≥ 100 (or < 100). 
Grantham matrix [56] 
Physicochemi
cal properties 
of amino acid 
side chains 
Categorical 
Indicates the classification of hydropathy index (hydrophobic and hydrophilic properties), 
volume, charge, and hydrogen donor/acceptor for amino acid side chains. 
IMGT standardized 
criteria for amino 














Salt bridge is the most commonly observed noncovalent interaction that contributes to the 
stability of entropically unfavorable protein folds [160]. The cut-off distance to define 
salt bridges in a protein structure varies, but generally centers around the distance of 3.0 
Å that is used to define hydrogen bonds (H-bonds). A distinction between salt bridge and 
long-range electrostatic interaction between charged groups was made [161], such that 
salt bridges are strong H-bonds between donor and acceptor atoms within the distance 
cut-off of 2.8 Å, whereas long-range electrostatic interactions can have variable cut-offs 
since the association energy depends upon types of environmental media. We used the 
WHAT IF server [158] to characterize bonding patterns between opposite charged 
protein residues. We followed the default distance cut-off of 7.0 Å so that the predictions 
were suitable for both salt bridges and long-range electrostatic interactions. 
Hinge residues are typically located at inter-domain boundaries of a protein. Hinges 
allow the domains to move relative to one another upon binding to another molecule, or 
upon activation/deactivation of the protein. Hinge points do not involve large number of 
residues and each region can rotate at a very large degree. All of the proteins in our 
dataset occur as multi-domain proteins, therefore, the study of hinge regions is considered 
very informative since their cooperative motions are a critical element of protein-drug or 
protein-protein interactions. There are numerous computational approaches for predicting 
this type of large-scale protein movement; their computational resource requirements also 
vary over dynamic time scales. One prominent tool, FlexServe [159], detects hinge 
protein residues using a coarse-grained based method as an alternative to the resource-
intensive Molecular Dynamic (MD) simulations. We performed hinge point predictions 





(distance-dependent potential), inter-atomic force constant 40 kcal/mol*Å, and maximum 
distance cut-off for close atomic pairs of 3.0 Å. 
Statistical comparison of disrupted protein residues and the implementation of SDS 
Pharmacogene for predicting the structural significance of a variant 
Our systematic 3D screening aims to identify protein characteristics that are commonly 
disrupted by functional variants. The specific details for performing statistical 
comparisons of disrupted protein residues can be found in our previous work [110]. 
Briefly, after all residues in the 45 protein structures had been evaluated by each of the 
selected tools, we populated all measures/predictions and generated a distribution of the 
scores (if the tool outputs a continuous parameter; i.e., B-factor, RMSF, or Γ) (Table 
5.3). Lower- and upper-bound thresholds were defined as suggested in the literature or 
empirically. Empirically-defined thresholds were set at the top and bottom 2.5 percentiles 
of each distribution. Based on the selected cut-offs, we transformed all measures into a 2-
level category: extremely small and extremely large values. Variants whose measures or 
predictions go beyond the defined threshold are most likely to be aberrant residues (with 
disrupted protein structures). We repeated the three steps of score assessment, threshold 
determination, and category assignment to all of the five continuous measures used in our 
study. For tools that report the prediction in categorical variables; e.g. predictions of 
disulfide bonds, salt bridges and electrostatic interactions, and stabilization centers, etc., 






Fisher’s exact test was used to determine whether the proportions of functional and 
neutral variants for a particular structural feature are significantly different. We applied 
this statistical method to variants located in our protein 3D structures (371 functional and 
1,811 neutral mutations) and report the test statistics when p-values are significant (α = 
.05). Structural characteristics that harbor different proportions of functional vs. neutral 
variants were identified (n= 11 features).  
Further refinement of the selected structural features was then performed according to the 
proportion comparisons (presence/absence) of the disrupted characters among the three 
groups of variants. Five out of eleven indicators showed significant differentiation of 
PGx variants from neutral mutations; in each case they also suggest PGx variants to have 
similar structural properties to the one that altered the protein functionality (functional 
variants) (Table 5.4). A list of five strong suggestive characters was populated as a 
“Structural Disruption Index”. Given the predictions of the five suggestive characters, we 
calculated the consensus prediction for the structural significance of a variant: “positive” 






Table 5.4: Fisher’s exact test statistics for enriched structural features present in functional mutations and the selection for 
strongest predictive features for structural disturbance (Structural Disruption Index). The complete statistics, including the 
absolute number of functional and neutral variants in all categories of structural indicators can be found in Supplementary Table 5. 
Structural features Indicators Descriptions 
Preliminary selection of 
structural features 
Final selection of structural features as 
Structural Disruption Index (SDI) 
Fisher's exact test  
(one-tailed) 
n 






Is a stabilizing residue 
(SR) 
Wild type residue = a stabilizing 
residue (SR) 
0.0037** 2182 .0154* (2.77/0.79/1.39) 
Induced any changes 
of stability 
Mutant residue reduces or increases 
stability (∆∆G ≥ 0.5 or ≤ -0.5 
kcal/mol)  
0.0311* 2182 - - 
Protein flexibility Conformationally rigid 
Located at conformationally rigid site 
(FlexPred label = rigid) 
0.0218* 2182 - - 
Drug binding 
capability 
At binding site Located at binding site  0.0003*** 2182 - - 
At 10 Å of binding site 
Located within 10 Å of binding site 
(Cα-Cα distance) 
0.0005*** 2182 .0058** (33.24/25.49/33.33) 
Protein-protein 
interaction 




Located at the core region (RSA ≤ 
5%) 
0.0021** 2182 .0151* (35.73/29.14/38.89) 
Induced Gly/Pro 





Table 5.4 (continued) 
Structural features Indicators Descriptions 
Preliminary selection of 
structural features 
Final selection of structural features as 
Structural Disruption Index (SDI) 
Fisher's exact test  
(one-tailed) 
n 




x variants (n=2214) 
Amino acid 
dissimilarity 
Large AA dissimilarity 
at structural site 
Induced large amino acid change 
(Grantham score ≥ 100) when 
located at structural sites‡ 
< 0.0001*** 3165 < .0001* ** (35.84/22.98/36.11) 
Change of volume, 
any site 
Induced volume change (very large -
-> small/very small, very small --> 
large/very large) when located at 
any sites‡ 
0.0002*** 3316 - - 
Worse hydropathy at 
buried site 
Induced unfavorable hydropathy 
(hydrophobic to hydrophillic) when 
located at buried site 
0.01** 1096 < .0001* ** (4.43/1.74/16.67) 
Significant p-values (α =.0001, .01 and .05) are designated with ‘***’, '**', and ‘*’, respectively.  
During the preliminary selection of structural features, except for the two tests marked with '‡', the dataset include variants whose 3D 
structures are available (371 functional mutations and 1811 neutral mutations in 45 gene products). The tests marked with '‡' were 
performed on protein sequences; the dataset represents the maximum of 3316 data points (779 and 2537 functional and neutral 
mutations, respectively). During the final selection of structural features as Structural Disruption Index (SDI), all tests were performed 
on non-overlap set of functional, neutral and PGx variants (n= 361, 1781, and 72 variants, respectively). The percentages of variants 
with particular disturbance features are reported.  




In addition to the binary classification of structural importance, our implementation also 
provides a composite structural score of those five measures—“Structural Disruption 
Score” (SDS), the score ranges from 0 to 5 (each point is taken from an individual –
“Structural Disruption Index” (SDI)). Since a structural feature indicates only one 
function, among possible multiple roles a protein residue may have. Therefore, mutating 
amino acid residues with multiple hits for potential structural disturbance should be of 
high priority; this interpretation is represented by the higher SDS (closer to 5). 
Evaluation of conventional deleterious classifiers and protein characters for 
assessing amino acid variants in pharmacogenes 
The pharmacogenomics (PGx) variants represent an independent set of genomic data that 
were used to evaluate the performances of sequence conservation-based predictors, 
protein characters, and SDS for the deleterious evaluation of amino acid variants in the 
48 VIPs. Some PGx variants were found to overlap with the training set, therefore, 12 
functional mutations and 32 neutral mutations that are duplicates with PGx variants were 
excluded from all evaluation tests. An additional filter was used to remove all variant 
with no available structural data, leaving a unique and non-overlapping set of 361 
functional variants, 1781 neutral variants and 72 PGx variants. We used this dataset to 
performed several evaluations. 
The first test compared means (ANOVA tests) and distributions of five continuous 
structural parameters (P(Flexible), RSA, ∆∆G, Γ, B-factor, and RMSF) (Table 5.3) and 




PolyPhen2_HumDiv and PolyPhen2_HumVar [19], LRT [17], MutationTaster [20], and 
MutationAssessor [18]) across three types of amino acid mutations. 
The second evaluation, chi-square test with α = .05, was performed on the numbers of 
variants with binary consensus structural disturbance predictions (positive/negative), as 
well as the categorical levels of structural disturbance (score 0 to 5). The results were 
compared with similar tests on the consensus deleterious predictions (whether or not ≥ 
3/6 conservation-based tools assign the variant to be “deleterious”) and the categorical 
assignment “deleterious count” (the number of tools that predict a variant to be 
deleterious, maximum score = 6).  
Next, we focused on the classification of PGx variants to match the annotation of 
PharmGKB’s three levels of annotation confidence. We evaluated the predictive power of 
different methods for PGx variants whose 3D structures are available (n=386 associated 
variants, equivalent to 72 unique variants). To test whether standard conservation-based 
predictors can statistically distinguish variants of each level, we first clustered the 386 
variants into 3 groups: level 1A/1B, level 2A, and level 3. Next, we compared the 
average deleterious prediction scores from the six conservation-based predictors. The 
comparisons were performed using each paired Student’s t-test on rescaled prediction 
scores (range 0 to 1). The tests were carried out with both the original and the revised 
listing of pharmacogenomic associations. The original list comprises of 386 associations 





Results and discussion 
Location of missense variants in protein structures  
A total of 113 conserved protein domain families harbor missense variants in our 
genomic dataset. To further define the relative abundance of the 3,316 amino acid 
mutations in specific protein domain families, we compared the normalized variant 
percentages between the functional and neutral variant groups. Although many protein 
domain families have both types of variant, we found that some domains contain much 
higher percentages of variants of either group. Of all 113 protein domain families that are 
present in the 48 proteins, we identified 36 domains with greater abundance of functional 
variants, 42 domains with greater abundance of neutral variants, and 35 domains with 
only neutral variants  (Figure 5.1, Supplementary Table B.4). Two explanations 
contribute to these observations. First, there is a strong preference for some protein 
domains to harbor more or less functional variants, since the relative variant abundances 
within the first two domain types are significantly different (p < .0001, Student’s t-test, df 
76). Second, the analysis discovered some protein regions with insufficient sampling 





Figure 5.1: Relative abundance of functional and neutral variants across conserved 
protein domain families. Of all 113 protein domains that are present in the 48 proteins, 
36 domains harbor more functional variants (Figure 5.1A) and 42 domains contain more 
neutral mutations (Figure 5.1B). The remaining 35 protein domains only have genomic 
data for neutral variants. The complete list of domain names and relative abundances of 





Physicochemical change of amino acids at different protein regions 
We used the Grantham matrix [56] to measure physicochemical differences of each 
amino acid substitution. We compared the proportion of conservative vs. radical 
mutations of functional variants with respect to the variant localization along the protein 
chain (Supplementary Table B.5). All analyses suggest that only when functional 
variants occur in non-structural sites (i.e., as propeptide, signal peptide, sequence motif, 
zinc finger, repeat, or modified residue), do they not tend to associate with large 
dissimilarities. For other regions, functional variants always have a stronger preference 
towards substitutions with large amino acid dissimilarity. 
The first comparison examined Grantham scores of variants in structural sites relative to 
non-structural sites. As expected, when functional variants are located in structural sites 
of the protein, they tend to be more of radical type (Grantham scores ≥ 100) (p < .0001). 
On the other hand, functional variants do not seem to induce large amino acid changes 
when the altered protein residues locate elsewhere (p = .6145).  
Next, we were interested to see if the localization of variants in conserved protein 
domains would increase the likelihood of drastic amino acid change, or if functional 
variants have a tendency to induce radical substitutions throughout the protein chain. 
Comparing amino acid substitution scores (Grantham ≥ 100 vs. < 100) of variants in 
protein domains to ones located at domain boundaries did not suggest unequal 
proportions (p = .42, one-tailed Fisher’s exact test, n=3,316). Conversely, when 




tend to equally promote large amino acid change compared to neutral mutations (p < 
.0001 and p = .0045 for the two locations, respectively). 
Lastly, we tested whether predicted binding sites tend to harbor more functional variants 
with a Grantham score ≥ 100. The test statistics indicate functional variants do tend to 
associate with amino acid dissimilarity when they are predicted to alter binding sites (p = 
.0259, n=145), and this tendency is much stronger if they are located within 10 Å of the 
binding site (p < .0001, n=591).  
Additional tests for unfavorable amino acid changes (hydropathy, volume, charge, 
hydrogen donor/acceptor) indicated that functional variants do not directly have large 
physicochemical dissimilarity at/around the binding sites (α = .05), and that change in 
side chain volume is the only significant physical disturbance caused by functional 
variants (p = .0002 at any sites, n=3,316; p = .0046 at around 10 Å of binding sites, 
n=591) (Supplementary Table B.5). The three most insignificant indicators are ligand-
specific: 40/48 VIPs serve as drug targets for 530 drugs and 23 genes have known 
pharmacological actions for 270 drugs [152]. This large number of highly interactive 
genes and the diversity of their drug partners may explain why we did not observe any 
enrichment in structural disturbances of the three physical changes. Besides the potential 
disruption in binding cavity volume, other notable changes we detected from functional 
mutations is that they tend to alter the hydrophobicity of buried residues (p = .01, 
n=1,096).  
The analysis of secondary structure preference for amino acids pointed out that although 




amino acids that are either very conformationally flexible or rigid, respectively), the 
secondary structure of the protein is still well maintained. We did not observe any 
structure break in the six secondary structure types (coil, strand, 3-turn helix, α-helix, 
bend, and turn) (Supplementary Table B.5). 
Implementation of systematic 3D screening for structure-function relationships of 
amino acid mutations 
PharmGKB is a knowledge-based database that provides curated resources on genetic 
variation and drug responses [146]. As of February 2014, there are 249 peer-reviewed 
scientific articles that were written by PharmGKB affiliated researchers. Among these, 25 
articles address the pharmacogenomics of an individual gene, and 29 publications 
emphasize drug metabolism pathways. The remaining 195 articles mostly describe 
population studies or dosage studies, or are review articles. Most significantly, only one 
article [35] utilizes 3D structure data (stability change) to improve the prediction 
accuracy of a popular conservation-based deleterious predictor—PolyPhen2 [19]. Their 
study showed that with a single structural parameter added to the sequence data, the 
deleterious prediction performance improved from 82 to 85% accuracy, and the 
Matthew’s correlation coefficient (a quality estimator for binary classifications) increased 
from 0.63 to 0.70. Although the authors of PolyPhen2 had mentioned that their algorithm 
includes 11 predictive features (6 conservation-based, 4 structure-based, and 1 derived 
parameter), we reasoned that since the number of included structural data annotations 
was very limited (only ~10% of the training set have available structural data), it can be 




side chain volume, accessible surface area, accessible surface area for buried residues, 
and B-factors (indicate mobility of individual atoms) [19]. 
A recent review presenting a protein structural perspective on drug responses [162] 
summarized the different structural characteristics that are important for 
pharmacodynamic and pharmacokinetic mechanisms. The authors considered five major 
classes of computational tool for examining drug-protein relationships: structure 
visualization tools, structure prediction tools, binding site prediction and comparison 
tools, ligand docking and scoring tools, and MD (molecular dynamics) simulation tools. 
We added to this list some other potential protein analyses that incorporate other types of 
interactions that occur within or between proteins even when no drug molecules are 
bound (Table 5.3). 
The nearly complete coverage for functional and neutral mutations which can be mapped 
to structural data of the 45 VIPs (average variant coverage of 85% per gene, range 75 to 
95%, 95% CI, Supplementary Table B.3) enhances the ability to study the structure-
function relationships of missense variants. We employed a similar approach in our study 
of epilepsy-associated variants [110] where we showed that quantifying the structural 
disruption features caused by functional mutations can prioritize risk variants. 
Furthermore, we added a few explicit test categories in this current study, namely, inter-
residue bonding, residue localization, amino acid dissimilarity, and secondary structure 




Implementation of SDS Pharmacogenes for predicting structural significance of a 
variant 
The analysis of context-dependent mutation effects describes a list of physical protein 
features that are commonly found in functional mutations as oppose to in neutral variants. 
These enriched characters are important because they suggest specific protein attributes 
and/or residues that are less tolerant of disruption. We have integrated scores of five 
selected components in “Structural Disruption Index” (SDI) into a composite “Structural 
Disruption Score for Pharmacogenes” (SDS Pharmacogenes). The score provides a 
measure of the likelihood that a mutation is damaging. It can be used to evaluate all 
missense variants found in this gene set whose protein 3D structure is available (currently 
45/48 gene products) and thus to derive a list of mutations that may cause altered protein 
functions when interacting with drug molecules, contributing to inter-patient variability 
of drug responses. 
Among the 68 structural features we compared between functional and neutral variants, 
11 features were found to be more common in functional mutations (Table 5.4). Six 
indicators may have pharmacodynamic effects due to altered protein stability, binding 
sites, or protein conformations. One indicator, conformational rigidity, also plays an 
important role in pharmacokinetic mechanisms of many proteins, including the CYP450 
system [163]. Two indicators also have close relationships with sequence conservation, 
namely, stabilizing residues and protein patches. In addition, all interior protein residues 
(RSA ≤ 5%) appear to be highly conserved. The full list of structural characteristics that 
were tested during the algorithm development and the correspondent test statistics are 




Next, we aimed to narrow the list of enriched structural features to a small number of 
protein characters that best assign PGx variants to resemble functional mutations, rather 
than to the neutral ones. Table 5.4 indicates that eight of the eleven structural measures 
illustrate a shift in PGx variants in the same direction as functional mutations, and away 
from the neutral ones (the three exceptions are induced Gly/Pro change, at patch, and at 
binding site). Among the eight features, five have significant statistics that cluster 
functional and PGx variants to the exclusion of neutral ones; the features are: unfavorable 
hydropathy change at buried site, large amino acid dissimilarity (Grantham score ≥ 100) 
if located at structural sites, located at core region (RSA ≤ 20%), located within 10 Å of 
predicted binding sites, and is a stabilization residue (SR). Jointly they define a 
“Structural Disruption Index” (SDI) that can be used to infer structural (and maybe 
functional) significance of an amino acid variants based on the consensus prediction of 
structural disturbance (positive/negative) and the magnitude of structural impact (SDS). 
Structural characteristics of functional variants 
The five components of the “Structural Disruption Index” (SDI) are unfavorable 
hydropathy change at buried site (RSA ≤ 20%), large amino acid dissimilarity (Grantham 
score ≥ 100) if located at structural sites, located at core region (RSA ≤ 5%), located 
within 10 Å of predicted binding sites, and is a stabilization residue (SR). 
Hydropathy is an important property of amino acid side chains. Hydrophobic residues 
tend to be at buried sites (RSA ≤ 20%) while amino acids with hydrophilic side chains 
are more commonly found on protein surfaces. Side chains with similar hydropathy 




major force that holds a protein structure in place [161]. Any amino acid substitutions 
that reduce hydrophobic interactions may cause serious folding defects. 
Grantham scores serve as a general criterion to classify amino acid dissimilarity for a pair 
of amino acids. The score is derived from an index that best correlated physicochemical 
properties of protein residue to the substitution frequencies [56]. The properties include 
amino acid composition, polarity, and molecular volume. We did not detect any 
difference in the proportion of large amino acid replacements (Grantham score ≥ 100) 
among the three levels of PGx variants. However, large Grantham score is a good 
indicator for separating PGx from neutral variants (p < .0095, Fisher’s exact test). 
Protein residues that have significant roles can be either solvent-accessible (e.g. some 
ligand binding sites or protein-protein interaction sites), or can be solvent-inaccessible 
(e.g. several ligand binding sites, catalytic sites). In addition, conserved residues within 
the protein are likely to have important structural roles in maintaining the correct protein 
fold. This feature is described as “stabilizing residue” (SR) [71], which indicates the 
protein residue has: (1) high surrounding hydrophobicity (sum of hydrophobic indices of 
all its neighbor residues within 8 Å is greater than 20 kcal mol-1), (2) high long-range 
order (the percentage of long-range neighbors (≥ 12amino acids apart) with the Cα-Cα 
distance of ≤ 8 Å is greater than 2% of the total number of protein residues), and (3) high 
conservation score (score ≥ 6/9 based on ConSurf predictions [164]). 
Although we only detect 1% (215/21457) of all the protein residues in our 3D structure 




the three criteria), the proportion is higher (p = .0034, Fisher’s exact test) in functional 
variants (2.8%, 10/361 residues) compared to neutral variants (0.8%, 14/1781 residues).  
Among the72 PGx variants, only one mutation is detected as an SR (equivalent to 1.4% 
of the dataset). This PGx variant, Y240C in TPMT (rs1142345) is classified asTPMT*3 
allele and is associated to five drugs at the PharmGKB’s level 1 annotation (azathioprine, 
mercaptopurine, purine analogues, and thioguanine) and one drug (cisplatin) in PGx level 
3. Four conservation based predictors (except MutaionTaster and MutationAssessor) 
predict the variant to be deleterious. 
In addition to being predicted as an SR, this Tyr240Cys substitution is independently 
predicted by by PoPMuSiC software [120] to severely reduce protein stability (∆∆G 2.24 
kcal mol-1). The functional significance of this variant has been confirmed by 
experimental studies [146] which demonstrate the loss of several side chain contacts, 
accelerate in vitro degradation, and reduce the protein activity. In addition, an MD 
simulation study indicates this variant of TPMT causes the most structural deformation 
during simulations [165].  
An exceptional case 
In general, the 386 pharmacogenomic-associated variants harbor at least one type of the 
eleven structural disrupted features (maximum SDS = 3/5). Only one variant, R26H in 
CYP2D6, has 0 hits in our SDI (SDS = 0/5) and in fact 0 hits among the initial selection 
of 11 predictive features. Prediction results from 5/6 conservation based predictors 




MutationTaster [20] is the only program which predicts this amino acid change to be 
deleterious with a score of 0.999 (cutoff = 0.5).  
The R26H amino acid change of CYP2D6 is identified as the CYP2D6*46 allele 
(rs28371696) [166]. CYP2D6 metabolizes a wide range of drugs—up to 25% of 
commonly used prescriptions, such as, antidepressants, antiarrhythmic agents, 
neuroleptics, opioids, and antihistamines [167]. R26H in CYP2D6 has been linked to 31 
drugs in the PharmGKB’s pharmacogenomic association schema levels 1-3. Overall, 
Africans metabolize CYP2D6 substrates at a slower rate than Caucasians owing to the 
higher alternate allele frequency (1.68% vs. 0.02%) [151].  
Of all 68 structural features that were tested during the development of SDS 
pharmacogenes (Supplementary Table B.5), the R26H does not unusual for any of those 
features. Arg26 is locate at the exterior loop of the protein (RSA = 53%). The amino acid 
change does not induce a secondary structure break at this coil region. In addition, Arg 
and His have very comparable physicochemical properties (Grantham score = 29). The 
substitution does not induce any stability change (∆∆G = -0.09 kcal mol-1). The only 
structural feature that comes close to being positive for this variant is the fact that Arg26 
is predicted to be a non-optimal residue (several of its mutations will indeed increase the 
protein stability) The Γ parameter (designates the degree of sequence non-optimality) for 
Arg26 is -3.16 kcal mol-1 (positive cut-off is when  Γ ≤ 3.47 kcal mol-1; an indication for 
resemble a catalytic residue).  
CYP450 enzymes consist of an N-terminal transmembrane α-helix and a catalytic 




domain cannot be elucidated due to insufficient x-ray density. Four crystal structures of 
human CYP2D6 are currently available [60], but the first 33 residues (N-terminal) have 
been replaced with an 11 amino acids long peptide to improve crystallography. The full 
length model of CYP2D6 predicts reside 1-25 as the N-terminal transmembrane α-helix, 
and residues 26-33 to be the linker between the N-terminal and the catalytic domain. 
Molecular dynamic simulations of related enzymes using full length protein structures 
revealed the N-terminal region exhibits a large range of flexibility [168, 169] and the 
presence of N-terminal region alters the conformational dynamics of opening and closing 
ligand channels compared to the N-terminal truncated crystal structure of CYP2D6 [170]. 
Further assessments are required for the functional roles of Arg26 in this enzyme. 
Performance of conservation-based predictors and SDS for assessing amino acid 
variants in pharmacogenes 
1) Classification of functional, neutral, and PGx variants 
The six deleterious predictors we chose for comparison with the SDS Pharmacogenes 
score differ in the underlying methodologies. Three algorithms (SIFT [16], LRT [17], and 
MutationAssessor [18]) were built from evolutionary conservation, while the other three 
(MutataionTaster [20], and PolyPhen2_HDIV, PolyPhen2_HVAR [19]) incorporate 
various SNP data as predictive features. SIFT calculates the normalized probability of a 
substitution from sequence alignments of orthologous proteins [16]. LRT uses sequence 
alignments of related proteins from vertebrate species to check for negative selection of 
codons [17]. MutationAssessor partitions sequence alignments to identify evolutionary 




sources of information to generate a supervised-learning classifier [20]. 
PolyPhen2_HDIV and PolyPhen2_HVAR use protein sequence (orthologs and paralogs) 
and structure-based information (side chain volumes, accessible surface areas, accessible 
surface areas for buried residues, and B-factors) to generate a Bayesian model for variant 
deleteriousness [19].  
We found the classification of genetic variants (functional, neutral and PGx) in the 48 
pharmacogenes is challenging. The poor performance of most conservation-based scores 
is illustrated by the plots in Figure 5.2. Although the consensus prediction, deleterious 
count, for the six tools can rank functional and neutral variants in the correct order, the 
deleterious assignment for PGx mutations is not meaningful. Likewise, each pair of 
Student’s t-tests indicates all programs properly rank the functional variants to be more 
deleterious than the neutral ones (p < .0001 for all predictors). On the contrary, every 
program failed to place PGx variants closer to the functional mutations. More 
importantly, PGx variants were assigned less deleterious scores (less damaging) than 
neutral variations (p < .0001 for all predictors except p=.0112 for SIFT). Density plots 
suggest the conservation-based programs have a tendency to under-predict the damaging 





Figure 5.2:  Performance of conservation-based predictors across the three types of 
mutations in 48 VIPs. The first row represents the consensus prediction for 
deleteriousness (deleterious count, score 0-6). The remaining rows demonstrate the score 
distributions for different types of variants (n= 361, 1781, and 72 for function, neutral, 
and PGx variants, respectively). Some scores were rescaled to [0, 1] so that deleterious 
scores of the six predictors can be interpreting in the same manner—scores closer to zero 
indicate the prediction is “benign” while score closer to one indicate “deleterious”. The 
horizontal (vertical) dashed black lines in the scatter (density) plots indicate the 





We performed chi-square tests on the numbers of variants that receive consensus 
“positive” or “negative” predictions for inducing any structural disturbance. The test 
statistics demonstrated that the proportions of “positive” variants differed significantly 
among the three groups of mutations (p < .0001). Approximately 78% of PGx variants (n 
= 56/72) will interrupt at least one of the five elements of the SDI, and this bias is in the 
same direction as the 66% of functional mutations (n=239/361), whereas only 57% of 
neutral mutations (n=1013/1781) have a positive SDI (Figure 5.3). Structurally disrupted 
variants are more abundant in PGx than neutral variants (p = .0002, n = 1,853, Fisher’s 
exact test), and in slightly more excess in PGx than functional variants (p = .0647, n = 
433, Fisher’s exact test).  
 
Figure 5.3: Percentages of variants with respect to their scores for structural 
significance (Structural Disruption Score; SDS) and the consensus scores for 
conservation-based deleteriousness (Deleterious count). The graph shows the 
percentage of positive variants (variants that are predicted to disrupt at least one of the 
five components of Structural Disruption Index (SDI)) which have score of at least n for 
SDS and deleterious count. Note the SDS can distinguish between PGx and neutral 
variants, and PGx variants receive comparable or higher SDSs than functional variants in 
all SDS thresholds, whereas deleterious count (del count) assigns the score for PGx and 






























We also observed that SDS correlates highly with the deleterious count (p = < .0001, 
n=1,902), although the correlation is not strong (Pearson’s correlation coefficient = .248). 
SDS also correlates (p < .0001) with SIFT, PolyPhen2_HDIV, PolyPhen2_HVAR, and 
MutationAssessor but with small coefficient (range 0.18 to 0.29). 
2) Classification of three levels of PGx variants 
PharmGKB has annotated 776 variant-drug pharmacogenomic associations for the 48 
VIPs (Table 5.1).The association strength is classified into four levels: 1A/1B, 2A/2B, 3, 
and 4. The most number of associations are linked to CYP450 enzymes; their variants 
account for 83, 81 and 48% of all levels 1A/1B, 2A/2B, and 3 variants, respectively. In 
addition, we observed that missense mutations contribute approximately 61% (471/776) 
of the overall associations, consistent with a recent remark that states 60% of disease-
causing variations are missense variants [14]. Among the remaining associations, just 3% 
(22/776) are caused by nonsynonymous mutations, and 36% (282/776) are induced by 
non-coding variants (variants in intergenic, intron, or 3’UTR regions). Their associations 
with pharmacological traits are not strong and the variants are mostly classified as level 4 
in the PhamGKB’s schema. Among the 471 missense mutations, many have 
pharmacogenomic associations with more than one drug (ranges 1 to 10), but the levels 
of association vary upon the interacting compounds. The CYP2D6 gene has the 
maximum number of FDA-approved pharmacogenomic drug labels per variant (seven 
drugs: amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, and 




The 471 variant-drug pairs uniquely involve 81 missense mutations (levels 1-3) of 27 
proteins. After we applied the six conservation-based deleterious predictors to the 471 
missense variants of all annotation levels, we compared the average prediction scores 
across the three levels: 1A/1B, 2A, and 3. Student’s t-test statistics indicate only one 
program, SIFT [16], can differentiate variants of the three pharmacogenomics association 
levels based on the score averages ( Plevel 1-2 = .0042, Plevel 1-3 =.0015). The trend for SIFT 
score is as expected; SIFT predicts pharmacogenomic-associated variants in level 1A/1B 
and 3 as the most and the least deleterious groups, respectively. This observation is 
consistent with PhamGKB’s curated levels of associations.   
Results from different conservation-based tools also demonstrate the unforeseen 
difficulties in analyzing genomic variants in this gene set. The ability of SIFT  [16] and 
inability of PolyPhen2 [19] to cluster PGx variants is worth investigating, since both 
programs perform exceptionally well in general. The poor performance of 
PolyPhen2_HDIV is surprising, since the structural information used by 
PolyPhen2_HDIV is related to the enriched disrupted features we detected among 
functional variants (Table 5.4). More importantly, the training set PolyPhen2_HDIV 
used comprises of SNPs that cause Mendelian diseases by affecting protein stability and 
function [19], therefore, the substantial contribution of structural features is expected.   
SDS is a numerical parameter; the value ranges from 0 to the maximum possible SDS 
(currently 5). In the dataset of 386 pharmacogenomic associations, the average SDS is 
1.26 and the maximum SDS is 3. We did not detect any differences between average SDS 
among the three levels of PGx associations; the observation is in agreement with the 




variant to be deleterious, average score 1.80/6). A major reason is that the dataset of 386 
associated variants are very much redundant (uniquely mapped to 72 variants). The 
identical protein residue can interact with many small molecules and other proteins in 
through various modes of interactions. 
Limitations of pharmacogenomics studies 
The need for expanded application of sequencing technologies in pharmacogenetics, 
especially for the ability to uniformly and fully capture all genomic variations within 
genes, was raised by [23]. They assessed the polymorphism coverage of 253 
pharmacogenes from the 1000 Genomes Project [171], and discovered that no current 
genotyping technologies cover more than 85% of residues within each gene. More 
importantly, data for only 30% of missense mutations are being generated across all 
sequencing platforms. This notable remark was also observed in our genomic dataset, in 
which we detect some protein domains seriously lack the data for functional variants 
(Figure 5.1). 
In addition to more extensive databases of variation in pharmacogenetic loci, exhaustive 
mutagenesis data is another key to the generation of accurate predictive tools for 
damaging variants. At this stage of genome analysis, the data on human studies is used to 
deduce the functional impact of variants in a binary format (functional vs. neutral 
variants). Experimental data provides observable phenotypes with measurable effects. 
The information has the potential to greatly enhance the development of deleterious 





A future direction of this work is to explore mutagenesis data and/or genomic data of the 
pharmacogenes to aid the refinement of feature selection. We also plan to populate SDSs 
for all amino acid mutations in the currently available set of 3D structures (n=45). Our 
future implementation of a database and a web-application for SDS Pharmacogenes will 
allow an easy retrieval of the pre-computed scores, thus promoting the practical utility of 
this research. 
Conclusions 
Our implementation of “SDS Pharmacogenes” provides a foundation for investigating the 
roles of amino acid mutations in drug responses from the standpoint of structural 
analysis. The pipeline introduces several conceptual shifts in assessment of genomic 
variations. First, the evaluation is strictly structure-based, therefore, offers a unique 
opportunity to explore the effects of amino acid mutations within the structure 
environment. Second, the analysis is systematic, through the investigation of structure-
function relationships in the context of each protein topology. Third, the implementation 
is scalable, suitable for the large and growing accumulation of genome data. Fourth, the 
prediction is informative, because the SDS Pharmacogenes combines results from several 
analyses, and the consensus prediction for structural disturbance (positive/negative) is 
meaningful. Unlike existing deleterious scores that do not consistently classify 
Pharmacogenetic VIP mutations as functional, we have identified five protein structure 
features that are significantly enriched in VIP variants. Further refinement of SDS 
Pharmacogenes, including the database-driven web application, will permit anyone, with 
or without protein expertise, to quickly obtain the comprehensive predicted drug 
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CHAPTER 6: CONCLUSIONS 
Sequencing technology development and the outlook for genomic 
variant analysis pipelines 
The rapid technological advances in sequencing technology are promising ever more 
breakthroughs from genome studies. The cost of sequencing is now estimated at about 
$1000 per genome, a huge drop compared to the first completed genome data 10 years 
ago that cost nearly $3 billion [26]. HiSeq X Ten, the newest sequencing platform from 
Illumina, is advertised to be capable of sequencing 18,000 genomes per year, while 
keeping the cost close to $1000 per genome (http://www.illumina.com). This remarkable 
development means affordable large-scale human genome sequencing projects are a 
reality, which in turn elevates the potential for improved understanding of variant-
function relationships and the identification of causative variant/genes for genetic traits 
and diseases. 
Even if new technologies can facilitate the completion of genome data with minimal cost, 
the main difficulty in genome studies is indeed the multi-filtration and iterative process 
for the identification of candidate genes and causal variants (Figure 6.1) [7]. Each person 
harbors about three million genomic variations; the variants are present throughout the 
genome [1]. Proper analyses can help narrow down millions of whole genome variants to 





Figure 6.1: Variant analysis and filtration in whole genome sequencing. The 
identification of candidate genes and causal SNPs require multiple filtration steps (taken 
from [7]). 
Although whole genome data can be informative, the functional annotation of variants in 
various genomic regions (coding, splice site, regulatory region, etc.) is quite complex—
different types of functional variants have different weights. An example is illustrated by 
a complicated decision tree for analyzing candidate variants (Figure 6.2) [13]. This 
approach has been implemented in a bioinformatics tool, F-SNP [172], which uses 
conditional probabilities to assign the maximum likelihood that a SNP has significant 





Figure 6.2: Tools for analyzing SNPs form different genome regions.  Each box lists the common tools for analyzing certain type 




Given that disease-causing variants are mostly located in the protein coding regions, the 
focus on analyzing coding variants can promote the detection of true causative factors. 
Above all, missense variants enable straightforward functional annotations since they 
underlie the best understood biological concept: DNARNAprotein. 
Whole exome sequencing (WES) offers a cost effectiveness alternative approach to 
whole genome sequencing (WGS) for conducting the large-scale human genome 
research. While WGS reads an individual’s entire DNA, exome sequencing targets only 
the protein coding regions (1% of the whole genome). More importantly, a whole exome 
is (for now) 1/6 the cost of whole genome and 1/15 the amount of data [173]. It is 
suggested that more than 10,000 exomes are needed to achieve statistical power [174]. 
Undoubtedly, the lower cost of WES can ensure more samples, better sequencing 
coverage, and better quality control of sequencing data. The relatively small amount of 
data facilitates exhaustive variant analysis and the possibility to combine effects of 
multiple variants together. As a result, the study of amino acid mutations caused by 
coding variants will greatly benefit from the advantages of WES. 
Complexities and future directions for interpreting amino acid variants 
Detailed knowledge about an individual variant is essential for the elucidation of 
molecular mechanisms that underlie their functional impact. The emerging practice in 
variant interpretation is to combine functional predictions from several sources to 
improve the annotation confidence and/or accuracy. At the moment, the accurate 
functional annotation of amino acid variants is still under development, since several key 




limited in terms of availability, quality and variability of experimental data. For proteins 
that bind to multiple ligands, it is also possible that mutagenesis tests only examine one 
substrate in the same in vitro experiment; the results present substrate-dependent effects 
as opposed to generalized functional significances of the variant. (2) The accurate 
prediction of protein-ligand interactions is limited by large computational resource 
requirements. (3) For genes that a have high number of genetic variants (such as genes in 
the CYP450 system), structural variations e.g. indels, copy number variants, and gene 
fusions which are coupled with missense mutations, introduce additional challenges for 
variant analysis [175]. 
Protein structural analysis may have a major impact in the next phase of genome studies 
as missense variants contribute to at least 60% of Mendelian disease development [5]. 
Computational prediction of various structural changes can be used to guide subsequent 
biological assays which will include functional implication of the specific amino acid 
mutations. Current trends in structural analysis use static protein data, e.g. stability 
change of the protein, physicochemical changes of the amino acid side chain, or changes 
in ligand binding environment to classify functional roles of a protein residue. However, 
it is very important not to ignore dynamic data since proteins are flexible biomolecules 
that can have functional interactions with substrates, biological compounds, or other 
proteins. 
The strength of exhaustive molecular dynamic simulations for the ability to detect large-
scale structural changes will increasingly become a desired method for in silico 
functional assessment of amino acid mutations at the level of tertiary and quaternary 




conservation degree of amino acid substitutions, physicochemical/biological properties, 
and possibly structural-derived parameters are deemed essential for the preliminary 
process of variant prioritization. 
Summary of this dissertation 
Numerous genetic variations an individual carries joint with the potential impacts of 
some variants towards his/her health profiles create the demands for analyzing personal 
genome data. The ideal practice is that a variant assessment pipeline needs to be efficient 
and informative—using a systematic evaluation which is suitable for large genome data 
while providing a good combination of computational predictions (conservation-based 
and structural-based) and knowledge-based parameters in human genomics (disease and 
trait associations) [28]. In addition, a suitable user interface shall be implemented to 
promote the practical utility of the developing variant assessment protocol. 
Although sequence conservation can be used to assess variant effects, it is not the only 
indicator for residue functionality. This dissertation asked if it is possible to overcome the 
weaknesses of the conservation-based assumption for variant deleteriousness. 
Specifically, can we combine the conservation-based approach with clinical information 
and structural data to attain a better understanding of the variant effects? 
Using several data sources for the development of the three variant assessment pipelines 
(Chapters 2, 4 and 5), the dissertation highlights some of the difficulties yet to be 
overcome. The difficulties arise from several attributes: (1) limited number of curated 




characteristics of mutating proteins caused by disease causing mutations. (4) Errors in 
homology models. (5) Error in prediction programs.  
The details for each observation are described below. 
(1) Limited number of curated gene-disease data. The list of clinically curated gene-
disease associations is not exhaustive, and the annotations often have different 
levels of significance (e.g. variants that were concluded from a single significant 
study, variants with moderate statistical associations, and variants derived from 
case-by-case reports, non-significant studies, or in vitro data). Notably, SNP 
databases frequently list associated diseases without specifying the annotation 
confidences. 
(2) The limitation of gene knowledge. My research examined variant effects in three 
complicated situations. The analysis of personal genomes (Chapter 2) focused on 
homozygous missense variants (highly penetrant effects are most likely to be 
recessive) and identified 60-84 known homozygous nsSNPs per genome (across 
40-77 genes). In addition, some individuals also carry de novo homozygous 
variants (range 1-5 variants per genome). Genomic variants of healthy individuals 
are less likely to have observable effects, although some variants are predicted to 
be deleterious. Without additional information of clinical data, the deleterious 
prediction is not as informative as expected. The AACDS classification scheme 
(Chapter 2) provides a concise description (and eight-level category) of a variant 
from the perspectives of consensus sequence-based deleterious prediction, types 
of mutation (disease-associated vs. neutral), and information on disease- or trait-




The analysis of variants in epilepsy disorders suffered from very minimal 
information on the gene functions towards the disease development (Chapter 4). 
Literature searches indicated only 1 gene, among 68 genes of our dataset, may be 
linked to epilepsy. In addition, the number of candidate case variants is only one 
per a gene. The two limitations created difficulties in incorporating prior 
knowledge of gene biology to the functional assessments.  
(3) Diverse structural characteristics of mutating proteins caused by disease-causing 
mutations. While ~75% of amino acid changes leading to Mendelian diseases 
(single gene diseases) consistently induce protein destabilization [37], the 
structural evaluation of missense variants in complex diseases (multiple gene 
diseases) is not that simple. The high contributions of missense variants in 
Mendelian genes on protein structures provide a better interpretation of variants 
effects than a list of the same variants that are linked to complex disorders—
multiple variations in one gene and/or of several genes may work synergistically 
to create protein malfunction.  
Furthermore, in vivo activities and/or structural characteristics of mutating 
proteins may be dissimilar between different types of disease-causing mutations. 
A study on protein kinase [176] indicates germline disease causing mutations 
mostly affect the substrate binding sites or protein-protein interaction sites, while 
cancer causing somatic mutations tend to altered ATP binding sites or catalytic 
residues. Bearing that some disease genes may harbor both types of causal 
mutations, but given the small number of causal variants per a gene, the sorting of 




structural disturbances maybe diluted when multiple structural changes from 
various disease types were combined during the development of the prediction 
algorithm (Chapter 5). 
(4) Errors in homology models. The understanding of genotype-phenotype 
relationships can be improved upon the examination of a mutated residue in its 
3D protein context. Homology modeling is fulfilling the largely unavailable 
known protein structures. Homology models have with a wide range of 
accuracy—depending upon the sequence identity to the structural templates. 
Errors of modeled proteins exist (and are recognized), but they should not prevent 
the roles of computationally derived structures to assist functional annotations of 
amino acid variants. Errors from homology models include misplaced side chains, 
inaccurate loop modeling, distortions of protein core, or even wrong folds [177]. 
The model quality can be assured by performing structural minimizations (to 
resolve steric contacts) and assess the models using a series of quality scores (to 
evaluate the overall geometrical accuracy). 
(5) Error in prediction programs. Many bioinformatics tools for predicting variant 
deleteriousness have been established, each with their own strengths. Nonetheless, 
the output of one tool may not be entirely reliable. During the analysis of variants 
in pharmacogenes (Chapter 5), large disagreements among six conservation-
based indicators were discovered. More importantly, despite the fact that high 
impact variants in pharmacogenes contain extensive available clinical data, most 
prediction programs underestimated the damaging effects of pharamacogene 




Despite these difficulties, this dissertation shows that the integrative approach for 
investigating variant-function relationships can be applied to at least three aspects of 
genome studies—personal genomics, genomics of epilepsy disorders, and genomics of 
variable drug responses. More importantly, the variant evaluation pipeline were 
implemented in a systematic manner, therefore, it is now possible to evaluate the large 
number of variants at a genome level (Chapters 2), in a disease-wise perspective 
(Chapter 4), and in a set of highly significant pharmacogenes (Chapter 5). Each 
implementation serves as a filter to identify functional significant variants which are 
worth clinical attentions (Chapter 2), which can guide subsequent experimental 
validations (Chapter 4), and which may induce the variability in drug responses 
(Chapter 5). The development of a database-driven web application for the AACDS 
classification scheme (Chapter 3) and the future development of a database for variants 
in pharmacogenes enhance the practical utility of research outcomes since minimal 
experience/expertise in genome interpretation is required.  
The incorporation of knowledge of clinical associations and protein structure data serve 
as complementary tools to the existing conservation-based algorithms for variant 
deleteriousness. My efforts in generating a large number of high quality homology 
models and the employment of diverse structural analyses offer a way to detect common 
structural features which are induced/targeted by most functional variants (variants that 
lead to functional differences between wild type and mutant proteins). As a result, 
functional implications caused by any amino acid changes in a protein can be elucidated 
by a fast and systematic screening of structural disturbances. The approach provides an 




many mutations in a specific protein and for establishing the likely causative variants in 
large genome data. 
Overall, the dissertation explains essential developments in genome analysis. It is the first 
introduction of three variant assessment pipelines that utilize an efficient way to catalog 




APPENDIX A: SUPPLEMENTARY INFORMATION FOR 
CHAPTER 2 
 
Figure A.1: AACDS summary report. The report is provided to the user with the 
AACDS category of the variant and its relevant information, along with additional 





Figure A.2: Cumulative distribution plots for the six deleterious prediction scores. 
The X-axis represents the prediction scores, ordered by deleteriousness such that low and 
high scores for each prediction algorithm indicate neutral and damaging nsSNPs, 
respectively. For each prediction program, the score threshold for defining damaging 
SNPs is indicated by a vertical green line (threshold for LRT is at 0.999). The genes were 
classified into four groups depending upon population prevalence of their SNPs, using 
the difference in minor allele frequencies (MAFs) (cut-off of ± 5%) between European 
American (EA) and African American (AA) populations. The four gene groups are EA 
bias, AA bias, EA&AA bias, and no bias. For each plot, the dashed lines illustrate the 
cumulative distribution of deleterious prediction scores for disease-causing SNPs located 
in each gene group. The numbers of genes and SNPs are as follows: EA bias (222 genes, 
3409 SNPs), AA bias (368 genes; 4,825 SNPS), EA&AA bias (234 genes; 4,225 SNPs), 
and no bias (965 genes; 12,214 SNPs). All disease-causing nsSNPs were retrieved from 
MSV3d [43] and SwissVar [44]. Population-specific minor allele frequencies for the 
variants were derived from NHLBI GO Exome Sequencing Project (ESP6500) (June 





Figure A.3: Allele frequency distributions by AACDS score. The three columns 
indicate the minor allele frequency (MAF) in percent, listed in the order of European 
American (EA), African American (AA) and all populations (All). Only SNPs with 
available allele frequency data are represented here and the numbers in each group are 






Figure A.4: Proportions of the 9 types of annotated protein regions found in all 
residues in the analyzed proteins vs. in SNP residues. Data were compiled from a set 






Figure A.5: Location of SNPs within proteins according to sequence feature type. A 
relative location near zero indicates the SNP is located near the N-terminus of that 






Figure A.6: Comparison of gene functional enrichment in the 12 genomes. The 
analysis was performed with g:Cocoa [78]. Each cell in the left most column indicates the 
number of queried genes from each individual that are associated with each annotation 
term. The highlighted cells indicate significant enrichment. The enrichment p-values are 
determined by the default multiple testing correction procedure g:SCS. The column 
“Term genes” indicates the total number of genes associated to each functional term. 
Abbreviations: bi BioGRID protein-protein interaction network, co CORUM protein 
complexes, hp human disease genes from Human Phenotype Ontology, ke/re  






Figure A.7: BioGRID network for protein interactions in one person’s genome. The 
red nodes highlight a subset of the query that is connected by an edge in the network. The 
black nodes are the immediate neighbors of the red nodes. The one private homozygous 















Details of PDB 
structures 













NMR (PDB) APOE 317 19-317 94 2l7bA [n/a] - - - 
X-ray (PDB) AMY2A 511 17-511 97 3oleA [1.55 Å] - - - 
X-ray (PDB) CHIA 476 22-398 79 3fy1A [1.70 Å] - - - 
X-ray (PDB) MTMR2 643 74-586 80 1lw3A [2.30 Å] - - - 
X-ray (PDB)  
& model 
(PMP) 
THBS1 1170 549-1169 53 1ux6A [1.90 Å] 
1yo8A     
[77%] 
0.745          
(-0.20) 




MYH6 1939 3-777 38 - 
4db1B 
[85%] 




Abbreviations: PDB RCSB Protein Data Bank [60], PMP Protein Model Portal [61], 
Phyre Protein Homology/analogY Recognition Engine [101]. 
Structure coverage represents the range of protein residues present in the 3D structure 
and the percentage of structural coverage with respect to the full length of the proteins. 
Each PDB accession number is indicated by its four letter code followed by the chain ID 
(in capital letter).  
Details of homology models include the template’ PDBs, sequence identity percentage 
between the target and the template sequences (in case of single-template modeling), or 
percentage of residues modeled at >90% confident (in case of multi-template modeling). 
Quality of homology models is evaluated by QMEAN6 [63] and ModFOLD4 [64] scores. 
QMEAN6 is a reliability score derived from a linear combination of six terms. It 
estimates model reliability between 0 and 1 (1 represents the best model). QMEAN Z-
score for a given model is a comparable quality score to experimental structures of 
similar size. Models of low quality will have strongly negative QMEAN Z-scores. 
ModFOLD’s global model quality score ranges between 0 and 1. In general, scores 
greater than 0.4 generally indicate more complete and confident models, which are highly 
similar to the native structure. ModFOLD’s P-value represents the probability that each 


















model (PDB) OPSR 236 364 1-364 100 1kpxA [n/a] 
x-ray (PDB) 1A03 121 365 25-298 75 3rl2A [2.39 Å] 
x-ray (PDB) 1A11 91 365 25-299 75 1x7qA [1.45 Å] 
x-ray (PDB) ADA 8 363 5-363 99 3iarA [1.52 Å] 
x-ray (PDB) AL4A1 470 563 23-563 96 3v9hA [2.4 Å] 
x-ray (PDB) AMYP 145 511 17-511 97 3oliA [1.5 Å] 
x-ray (PDB) ARSB 376 533 42-533 92 1fsuA [2.5 Å] 
x-ray (PDB) C1S 119 688 16-174 23 1nziA [1.5 Å] 
x-ray (PDB) CCL8 49 99 25-99 76 1esrA [2.0 Å] 
x-ray (PDB) CP2A6 160 494 30-494 94 2fdvA [1.65 Å] 
x-ray (PDB) CSF1R 245 972 20-295 28 4dkdC [3.0 Å] 
x-ray (PDB) DRB5 149 266 30-219 71 1fv1B [1.9 Å] 
x-ray (PDB) FCG2A 63 317 37-207 54 1fcgA [2.0 Å] 
x-ray (PDB) HGFA 644 655 393-646 39 1yc0A [2.6 Å] 
x-ray (PDB) IDHC 178 414 4-410 98 3inmA [2.1 Å] 
x-ray (PDB) IF16 723 785 575-766 24 3rloA [1.8 Å] 
x-ray (PDB) KC1G2 173 415 44-338 71 2c47A [2.4 Å] 
x-ray (PDB) LYAM1 193 372 39-194 42 3cfwA [2.2 Å] 
x-ray (PDB) MGA 755 1857 93-954 46 3l4yA [1.8 Å] 
x-ray (PDB) MICA 174 383 24-297 72 1hyrC [2.7 Å] 
x-ray (PDB) PUR6 141 425 7-425 99 2h31A [2.8 Å] 
x-ray (PDB) PYGL 222 847 23-830 95 1l5rA [2.1 Å] 
x-ray (PDB) SNX7 59 387 25-150 33 3iq2A [1.7 Å] 
x-ray (PDB) SUN2 671 717 521-717 27 3unpA [2.39 Å] 
x-ray (PDB) THBG 303 415 40-414 90 2ceoA [2.8 Å] 
Abbreviations: PDB RCSB Protein Data Bank [60]. 
Structure coverage represents the range of protein residues present in the 3D structure 
and the percentage of structural coverage with respect to the full length of the proteins. 
Each PDB accession number is indicated by its four letter code followed by the chain ID 



















features of variant 
AACDS 
category 
1 2 (2) 
3:14106202 
G-->A (G177S) 






ST17A       N-terminal 6 
2 3 (3) 
17:43319304 
C-->T (P559L) 
FMNL       Interdomain linker 6 
17:72839464 
G-->C (P938A) 











C-terminal 2B, 3B 




Young gene, generated 
by gene duplications 
during primate 
evolution 
  AIDS progression 





NBPFE         3A, 5 
10:23384581 
C-->T (T15I) 
MSRB2       Transit peptide 6 
4 1 (1) 
1:111217425 
C-->T (E3K) 
KCNA3       N-terminal 6 
5 2 (2) 
11:4967679 
A-->T (S218T) 
O51A4       Transmembrane 4 
9:69424057 
C-->G (L785V) 
A20A4 Putative protein     Coiled-coil 6 
6 none 
  
        
 
7 4 (4) 
19:55998135 
G-->T (A145S) 

























features of variant 
AACDS 
category 
7 4 (4) 
2:43451823 
T-->C (T374A) 
TISD         6 
9:69423770 
C-->T (S689L) 
A20A4 Putative protein     Coiled-coil 6 
8 none        
9 2 (2) 
7:106300898 
G-->A (P149S) 







Chromosome Y also 
has this pseudogene. 
    
Ig-like C2-type 6 
domain 
4 
10 2 (2) 
4:9251554 
A-->T (D400V) 
U17LI         6 
9:69424057 
C-->G (L785V) 
A20A4 Putative protein     Coiled-coil 6 
11 5 (5) 
1:145333904 
A-->T (Q804L) 
NBPFA       NBPF 6 domain 6 
2:97911728 
G-->A (D1802N) 
AN36A Putative protein       6 
4:9251554 
A-->T (D400V) 




The gene contains at 
least 53 genetic 
variants in families 
with hemophilia A. 
Hemophilia A   







































features of variant 
AACDS 
category 
12 5 (5) 
19:46394260 
C-->T (R274Q) 



















SRPX         6 
The “Remarks” column describes the interesting features of gene annotations, obtained from UniProt database [51]. The SNPshot text-
mining tool for PubMed abstracts [80] was used to explore if any of the private homozygous nsSNP-containing genes have clinical or 




Table A.4: List of all Categories 2A/2B variants affecting the same gene in more than one individual. 
Gene # SNPs Associated-diseases Associated-traits Variant categories Amino acid mutations Note 
I12R1 3 Mendelian susceptibility to mycobacterial disease   2A R156H 
same 
variant 
FRMD7 3 Nystagmus congenital x-linked type 1   2A R468H 
same 
variant 
FRAS1 3 Fraser syndrome Hair morphology 2A, 3A | 2A, 3A | 2A, 3A T2203I | G2230R | A2251T   
MUC5B 3 Pulmonary fibrosis idiopathic   2A | 2A | 2A R2211P | P2830L | S3061P   
ZC12D 2 Sporadic lung cancer   2A | 2A E51K | P405S   
CO6A5 2 Atopic dermatitis   2A | 2A V1276I | T1280P   
CUBN 2 
Breast cancer; Colorectal cancer; Renal cell 
carcinoma case; Recessive hereditary 
megaloblastic anemia 1 
Folate pathway vitamin 
levels; MRI atrophy 
measures 
2A, 3A | 2A, 3A I2984V | E3002G   




Pancreatic ductal adenocarcinoma; Severe 
combined immunodeficiency autosomal recessive 
  2A | 2A D8N | K80R   
OPSR 2 
Partial colorblindness protan series; Blue cone 
monochromacy 
  2A | 2A A174V | M236V   
MYH6 2 
Atrial septal defect type 3; Familial hypertrophic 
cardiomyopathy type 14; Cardiomyopathy dilated 
type 1ee; Sick sinus syndrome type 3 
Resting heart rate; 
Electrocardiographic 
trait 
2B, 3B | 2A, 3A G56R | A1130T   
PGCA 2 
Spondyloepiphyseal dysplasia type kimberley; 
Spondyloepimetaphyseal dysplasia aggrecan 
type; Osteochondritis dissecans short stature and 
early-onset osteoarthritis 
Height 2A, 3A | 2A, 3A D1142E | E1294D   
LAMB3 2 
Colorectal cancer; Epidermolysis bullosa 
junctional herlitz type; Generalized atrophic 
benign epidermolysis bullosa 




Progression of monoclonal gammopathy of 
undetermined significanceto multiple myeloma; 





2A, 3A | 2A, 3A M174V | P294A   





Supplementary Table A.4 (continued) 
Gene # SNPs Associated-diseases Associated-traits Variant categories Amino acid mutations Note 
GCP6 2 Microcephaly with chorioretinopathy   2A | 2A R1763W | A884V   
SP110 2 
Breast cancer; Hepatic venoocclusive disease 
with immunodeficiency 
  2A | 2A E207K | A128V   
VPP4 2 
Distal renal tubular acidosis with preserved 
hearing 
F-cell distribution 1, 2A, 3A M580T 
same 
variant 
#SNPs represents the total number of homozygous nsSNP found in each gene from all 12 individuals. Multiple diseases or traits that 






Table A.5: List of all Category 2B variants. 
Gene Position 














GNAT2 1:110151395 G-->T (L107I) 3 3 5 Decrease   Achromatopsia type 4 
IDH1 2:209108317 C-->T (V178I) 4 3 29 Neutral   Glioma 
PRSS12 4:119203221 C-->T (R833Q) 3 3 43 Neutral DOMAIN Mental retardation autosomal recessive type 1 
LAMA2 6:129824406 A-->G (N2843S) 4 3 46 Decrease DOMAIN 
Merosin-deficient congenital muscular dystrophy type 
1A 
SYNE1 6:152443744 G-->T (L8741M) 3 3 15 Neutral 
TOPO_DOM; 
DOMAIN 
Spinocerebellar ataxia autosomal recessive type 8; 
Autosomal recessive cerebellar ataxia type 1; Emery-
Dreifuss muscular dystrophy type 4 
DNAH11 7:21778429 T-->C (Y2593H) 5 3 83 Neutral 
REGION  
(AAA 3 (By 
similarity)) 
Kartagener syndrome; Primary ciliary dyskinesia type 
7 
RP9 7:33134883 T-->C (K210R) 3 3 26 Neutral COMPBIAS Retinitis pigmentosa type 9 
ELN 7:73474825 G-->C (G610R) 3 3 125 Neutral COMPBIAS 
Cutis laxa, autosomal dominant, type 1; Supravalvular 
aortic stenosis 
SPTLC1 9:94830356 C-->A (R151L) 3 3 102 Neutral TOPO_DOM Hereditary sensory and autonomic neuropathy type 1A 
MYH6 14:23876267 C-->T (G56R) 4 3 125 Neutral DOMAIN 
Atrial septal defect type 3; Familial hypertrophic 
cardiomyopathy type 14; Cardiomyopathy dilated type 
1EE; Sick sinus syndrome type 3 
APOE 19:45412079 C-->T (R176C) 5 3 180 Decrease REPEAT 
Hyperlipoproteinemia type 3; Familial 
dysbetalipoproteinemia; Sea-blue histiocyte disease; 
Lipoprotein glomerulopathy 
NLRP12 19:54313707 G-->C (F402L) 3 1 22 Neutral DOMAIN Familial cold autoinflammatory syndrome type 2 
TRMU 22:46731689 G-->T (A10S) 5 3 99 Decrease NP_BIND Transient infantile liver failure 






Table A.6: List of all Category 3B variants. 
Gene Position 














NVL 1:224482084 C-->T (V404I) 4 3 29 Neutral   Major depressive disorder 
SRBD1 2:45640334 T-->C (K811R) 4 3 26 Neutral   Glaucoma 
ZNF385D 3:21706469 G-->T (P25H) 3 3 77 Neutral   Partial epilepsies 
DNAH1 3:52390789 C-->T (R1285W) 3 3 101 Decrease 




DNAH1 3:52429665 C-->T (R3809C) 3 3 180 Decrease 
REGION       
(AAA 6 (By 
similarity)) 
Bipolar disorder 




Chronic lymphocytic leukemia; Ulcerative colitis; 
Parkinson's disease 
LAMA2 6:129824406 A-->G (N2843S) 4 3 46 Decrease DOMAIN Body mass index 
SYNE1 6:152443744 G-->T (L8741M) 3 3 15 Neutral 
TOPO_DOM; 
DOMAIN 
Bipolar disorder and major depressive disorder 
(combined); Bipolar disorder; Tonometry 
LPA 6:160977059 A-->C (N4165K) 3 2 94 Decrease DOMAIN 
Protein quantitative trait loci; LDL cholesterol; HDL 
cholesterol;  Total cholesterol; Lp (a) level; Coronary 





Supplementary Table A.6 (continued) 
Gene Position 














DNAH11 7:21778429 T-->C (Y2593H) 5 3 83 Neutral 
REGION       
(AAA 3 (By 
similarity)) 
Multiple myeloma; LDL cholesterol; Total ventricular 
volume; MRI atrophy measures; Total cholesterol 
FRMD4A 10:13699338 T-->G (T751P) 5 3 38 Decrease COMPBIAS RR interval (heart rate); Alzheimer's disease 
MRC1 10:18138519 C-->G (P359A) 3 3 27 Decrease TOPO_DOM Cardiovascular disease risk factors 
ANKRD30A 10:37451768* T-->G (L665W) 3 1 61 Decrease   
Metabolite levels; Hemostatic factors and 
hematological phenotypes 




MYH6 14:23876267 C-->T (G56R) 4 3 125 Neutral DOMAIN Resting heart rate; Electrocardiographic traits 
HERC1 15:63988400 G-->C (L1682V) 4 3 32 Neutral   Iris characteristics 
APOE 19:45412079 C-->T (R176C) 5 3 180 Decrease REPEAT 
Cardiovascular disease risk factor; Alzheimer's disease; 
Quantitative traits; Response to statin therapy (LDL-
C); C-reactive protein 
GGTLC1 20:23965995 A-->T (V179E) 4 3 121 Decrease   Erectile dysfunction and prostate cancer treatment 
RTDR1 22:23482483 G-->A (T42M) 3 3 81 Neutral   Height 
SYTL5 X:37935825 T-->C (L187P) 3 3 98 Neutral   Erectile dysfunction and prostate cancer treatment 




Table A.7: List of all Category 4 Variants. 
Gene Position 













NBPF3 1:21809667 C-->G (P564A) 3 0 27 Neutral DOMAIN 
AMY2A 1:104161650 C-->T (P145S) 4 3 74 Decrease   
CHIA 1:111854859 C-->T (R35W) 3 2 101 Decrease   
ITGA10 1:145535814 C-->T (R668W) 4 3 101 Neutral TOPO_DOM 
QSOX1 1:180148012 G-->C (G200A) 3 3 60 Neutral   
SNTG2 2:1168781 C-->A (S168Y) 5 3 144 Increase   
CCDC142 2:74702756 C-->T (R534Q) 4 3 43 Neutral   
FOXD4L1 2:114257319 C-->G (N162K) 4 3 94 Neutral DNA_BIND 
UNC80 2:210798699 G-->C (V1984L) 3 3 32 Neutral   
SLC26A6 3:48669447 C-->T (V206M) 3 3 21 Neutral TRANSMEM 
DNASE1L3 3:58183636 G-->A (R206C) 5 3 180 Decrease   
KBTBD8 3:67053926 T-->C (F179L) 3 3 22 Neutral DOMAIN 
TKTL2 4:164393835 A-->G (F351S) 5 3 155 Decrease   
ENPP5 6:46135884 C-->G (R39P) 6 3 103 Neutral   
TCP10L2 6:167587284 G-->C (R63T) 3 1 71 Decrease   
RSPH10B 7:5983568 A-->C (I528S) 4 3 142 Decrease   
USP17L2 8:11995540 C-->T (E244K) 3 3 54 Decrease   
FER1L6 8:125115420 G-->A (R1720Q) 3 3 43 Neutral TOPO_DOM 
EPPK1 8:144944225 C-->T (R1066H) 3 3 29 Decrease REPEAT 
OR1N2 9:125316028 T-->C (F194L) 5 3 22 Neutral TOPO_DOM 
STAMBPL1 10:90673047 G-->A (E204K) 3 3 54 Neutral   
IFIT1B 10:91143374 G-->T (A102S) 4 3 99 Decrease REPEAT 
HABP2 10:115348046 G-->A (G534E) 5 3 98 Decrease DOMAIN 
NRAP 10:115410234 T-->C (Y249C) 4 3 194 Neutral REPEAT 
NPS 10:129350856 G-->C (V75L) 3 3 32 Neutral   
OR51A2 11:4976544 A-->T (Y134N) 4 3 143 Neutral TOPO_DOM 
OR52D1 11:5510598 A-->T (Y221F) 5 3 22 Neutral TOPO_DOM 
OR2D3 11:6942726 G-->C (W165S) 5 3 177 Neutral TRANSMEM 
ALDH3B2 11:67431914 G-->A (R276W) 3 0 101 Increase   
SCYL2 12:100708367 C-->T (P357L) 4 3 98 Neutral   
TEP1 14:20846927 C-->G (G1780R) 3 3 125 Neutral REPEAT 
THBS1 15:39882178 A-->G (N700S) 3 3 46 Neutral REPEAT 
SPESP1 15:69238272 G-->T (L133F) 3 3 22 Neutral   








Supplementary Table A.7 (continued) 
Gene Position 













PHLPP2 16:71683718 A-->G (L1016S) 4 3 145 Neutral DOMAIN 
PMFBP1 16:72184566 C-->T (E193K) 3 3 54 Neutral   
CTC1 17:8141897 C-->G (S83T) 4 3 58 Neutral   
KRT23 17:39092741 C-->A (G39W) 5 3 184 Neutral 
REGION 
(Head) 
KRT40 17:39135089 G-->A (T388M) 3 3 81 Increase 
REGION 
(Rod) 
KRTAP2-2 17:39211434 G-->C (F10L) 3 3 22 Decrease REPEAT 
KRTAP2-3 17:39216085 C-->T (C73Y) 4 3 194 Neutral REPEAT 
BTBD17 17:72353745 G-->T (A163E) 3 3 107 Neutral   
ENGASE 17:77078069 G-->A (R321H) 3 3 29 Neutral DOMAIN 
TBCD 17:80710097 G-->T (G10C) 3 3 159 Neutral   




CSNK1G2 19:1978927 G-->T (V173L) 3 3 32 Decrease DOMAIN 
OR10H5 19:15905468 T-->G (C204G) 3 3 159 Neutral TRANSMEM 
OR10H5 19:15905505 T-->C (L216P) 3 3 98 Neutral TRANSMEM 
NXNL1 19:17566634 T-->A (E154V) 3 3 121 Neutral DOMAIN 
ZNF737 19:20727903 T-->C (Y369C) 3 1 194 Increase ZN_FING 
PSG1 19:43373078 C-->G (W273S) 3 3 177 Decrease DOMAIN 
ZNF534 19:52942535 T-->G (C621G) 4 3 159 Neutral ZN_FING 
SDCBP2 20:1292989 C-->T (G242R) 5 3 125 Decrease DOMAIN 
LRRN4 20:6033004 G-->A (L148F) 6 3 22 Neutral 
TOPO_DOM; 
REPEAT 
OTOR 20:16729138 T-->C (L31P) 4 3 98 Decrease   
DDX27 20:47859217 G-->A (G766S) 3 3 56 Neutral   
UMODL1 21:43504286 G-->A (D138N) 4 3 23 Neutral 
TOPO_DOM; 
DOMAIN 










# SNPs in each category* 
2A 2B 3A 3B 4 5 6 
SDM (n=33) 
highly stabilizing/destabilizing  
(≤ -2 or ≥ 2 kcal mol-1) 
5 0 0 1 0 1 1 2 
stabilizing/destabilizing  
(between - 2 to -1 or 1 to 2 kcal mol-1) 
5 2 0 2 1 0 0 0 
Slightly stabilizing/destabilizing  
(between -1 to -0.5 or 0.5 to 1 kcal mol-1) 
8 2 0 0 0 1 2 3 
neutral (between ± 0.5 kcal mol-1) 15 4 1 9 0 0 0 1 
Crystalographic 
B-factor of Cα 
atom (n=31) 
small (B-factor <60) 27 6 1 10 1 2 2 5 
medium (B-factor ≥60 but <100) 4 0 0 2 0 0 1 1 
large (B-factor ≥100) 0 0 0 0 0 0 0 0 
PredyFlexy 
(n=32) 
rigid 19 5 0 5 0 0 3 6 
intermediate 9 1 1 5 0 2 0 0 
flexible 4 1 0 2 1 0 0 0 
FlexPred (n=33) 
conformationally flexible 3 0 0 1 1 0 0 1 
conformationally rigid 30 8 1 11 0 2 3 5 
PDBe (n =25) 
is a binding site 1 1 0 0 0 0 0 0 
is not a binding site 24 5 1 8 1 2 1 6 
3DLigandSite 
(n=7) 
is a binding site 0 0 0 0 0 0 0 0 
PatchFinder 
(n=33) 
Is part of conserved residue cluster 3 1 0 1 0 0 1 0 
Is not part of conserved residue cluster 30 7 1 11 1 2 2 6 
The “source” column lists the name of prediction program or sources of structural 
information.  
# of analyses refers to the number of 3D structures that were used to obtain the results. 




Table A.9: List of X-linked recessive mutations. 
Subject ID Gene Position 
Base change 
(AA change) 







3 ARSE X:2856155 C-->T (G424S) 
rs35143646 
(32.9/17.9/49.2) 
Chondrodysplasia punctata X-linked recessive type 1; Height 1 3 
9 
ZNF674 X:46360317 T-->C (K236R) 
rs201621696 
(0.8/0.1/0.6) 
Mental retardation X-linked type 92 0 3 
BMP15 X:50658966 G-->A (A180T) 
rs104894767 
(1.4/0.3/1.0) 
Ovarian dysgenesis type 2; X-linked hypergonadotropic ovarian dysgenesis 
or hypergonadotropic ovarian failure due to ovarian dysgenesis; Premature 
ovarian failure type 4 
0 1 
C1GALT1C1 X:119760594 G-->A (A143V) 
rs45557031 
(2.5/0.5/1/8) 
Tn syndrome 2 3 
FRMD7 X:131212642 C-->T (R468H) 
rs6637934 
(5.7/7.5/6.4) 
Nystagmus congenital X- linked type 1 1 3 
F9 X:138633280 A-->G (T194A) 
rs6048 
(29.8/12.3/23.5) 
Recessive X-linked hemophilia B;Christmas disease; Thrombophilia due to 
factor IX defect 
0 2 
10 
SYTL5 X:37985895 G-->A (R702H) 
rs143176819 
(0.03/0.0/0.02) 
Erectile dysfunction and prostate cancer treatment 1 3 
TIMP1 X:47444361 C-->T (P50S) 
rs145349279 
(0.07/0.1/0.09) 
Other erythrocyte phenotypes 0 1 
SERPINA7 X:105278361 C-->A (L303F) 
rs1804495 
(11.2/12.3/11.6) 
Thyroxine-binding globulin deficiency 2 2 
C1GALT1C1 X:119760629 A-->T (D131E) 
rs17261572 
(-/-/13.2) 
Tn syndrome 0 2 
FRMD7 X:131212642 C-->T (R468H) 
rs6637934 
(5.7/7.5/6.4) 
nystagmus congenital X- linked type 1 1 3 
F9 X:138633280 A-->G (T194A) 
rs6048 
(29.8/12.3/23.5) 
Recessive X-linked hemophilia B; Christmas disease; Thrombophilia due to 
factor IX defect 
0 2 
11 
TBX22 X:79281202 G-->A (E187K) 
rs34244923 
(6.8/0.8/4.6) 
X-linked cleft palate with ankyloglossia 5 3 
CHM X:85233820 T-->A (S89C) 
rs145707160 
(2.0/0.2/1.3) 
Choroideremia 1 3 
ZCCHC16 X:111698440 G-->T (D162Y) 
rs7474140 
(21.9/6.8/16.4) 
Biochemical measures 0 0 
OPN1LW X:153420176 A-->G (M236V) 
rs78093025 
(9.5/36.7/19.4) 





Supplementary Table A.9 (continued) 
Subject ID Gene Position 
Base change 
(AA change) 








SYTL5 X:37935825 T-->C (L187P) 
rs144659697 
(0.04/0.0/0.03) 
Erectile dysfunction and prostate cancer treatment 3 3 
OPHN1 X:67652748 C-->T (V39I) 
rs41303733 
(7.8/1.5/5.5) 
Mental retardation X- linked OPHN1-related 2 3 
OCRL X:128674722 C-->T (T14I) 
rs61752970 
(0.5/0.1/0.4) 
Lowe oculocerebrorenal syndrome; Dent disease type 2 1 3 
FRMD7 X:131212642 C-->T (R468H) 
rs6637934 
(5.7/7.5/6.4) 
Nystagmus congenital X- linked type 1 1 3 
OPN1LW X:153418524 C-->T (A174V) 
rs149897670 
 (7.6 /20.3/12.4) 




APPENDIX B: SUPPLEMENTARY INFORMATION FOR 
CHAPTER 5 
Table B.1: List of molecular functions and the numbers of drug partners for the 48 
VIPs. Functional terms were analyzed with the g:Profiler web server (accessed December 




































































































































ABCB1 Multidrug resistance protein 1 
       
77 68 40 
 
ACE Angiotensin-converting enzyme x 
      
6 
   
ADH1A Alcohol dehydrogenase 1A 




   
ADH1B Alcohol dehydrogenase 1B 




   
ADH1C Alcohol dehydrogenase 1C 
       
1 
   
ADRB1 Beta-1 adrenergic receptor x 




   
ADRB2 Beta-2 adrenergic receptor x 




   
AHR Aryl hydrocarbon receptor 
           
ALDH1A1 Retinal dehydrogenase 1 
     
x 
     







   
BRCA1 Breast cancer type 1 susceptibility protein 
      
1 
   
COMT Catechol O-methyltransferase 
       
2 
   
CYP1A2 Cytochrome P450 1A2  x x   x x  4 1 4 
CYP2A6 Cytochrome P450 2A6  x x   x x  11   
CYP2B6 Cytochrome P450 2B6  x x   x x  18 4 7 
CYP2C19 Cytochrome P450 2C19  x x x  x x  25 14 4 
CYP2C8 Cytochrome P450 2C8  x x   x x 9    
CYP2C9 Cytochrome P450 2C9 x x x   x x 16    
CYP2D6 Cytochrome P450 2D6 x x x   x x 38    









































































































































CYP2J2 Cytochrome P450 2J2  x x   x x 3    
CYP3A4 Cytochrome P450 3A4  x x x  x x 72    
CYP3A5 Cytochrome P450 3A5  x x x  x x 67 10   
DPYD Dihydropyrimidine dehydrogenase      x  3    
DRD2 D(2) dopamine receptor x       1    




     x  11    
GSTP1 Glutathione S-transferase P        6    
GSTT1 Glutathione S-transferase theta-1      x   8   
HMGCR 
3-hydroxy-3-methylglutaryl-
coenzyme A reductase 
     x  5    
KCNH2 
Potassium voltage-gated channel 
subfamily H member 2 
       43    
KCNJ11 
ATP-sensitive inward rectifier 
potassium channel 11 
       5    
MTHFR Methylenetetrahydrofolate reductase      x  6    
NQO1 NAD(P)H dehydrogenase      x  4    
NR1I2 
Nuclear receptor subfamily 1 group I 
member 2 
x       82    
P2RY1 P2Y purinoceptor 1            
P2RY12 P2Y purinoceptor 12        2    
PTGIS Prostacyclin synthase  x x   x x     
PTGS2 Prostaglandin G/H synthase 2  x    x  6    
SCN5A 
Sodium channel protein type 5 
subunit alpha 
       11    






Table B.2: A list of selected protein 3D structures, their data sources and the quality parameters. 
Protein 
 Protein  
full  length 





PDB ID [method] 
Template PDB  
[% confident] 
QMEAN6 score  
(Z-score) 
ModFOLD4 score  
(p-value) 
ACE 1306 30-639, 645-1223 44.3 3nxqA [x-ray, 1.99 Å], 1uzeA [x-ray, 1.82 Å] 
   
ADH1A 375 1-375 100 
 
multiple [100%] 0.856 (0.98) 0.725 (5.66E-05) 
ADH1B 375 2-375 99.7 1u3uA [x-ray, 1.6 Å] 
   
ADH1C 375 2-375 99.7 1u3wA [x-ray, 1.45 Å] 
   
ADRB1 477 1-477 100 
 
multiple [87%] 0.356 (-4.81) 0.351 (2.58E-03) 
ADRB2 413 1-413 100 
 
multiple [92%] 0.433 (-3.90) 0.417 (1.09E-03) 
AHR 848 113-426 37.0 
 
3gdiB [15.6%] 0.418 (-4.06) 0.237 (1.55E-02) 
ALDH1A1 501 1-501 100 
 
multiple [99%] 0.788 (0.25) 0.805 (3.14E-05) 
ALOX5 674 1-674 100 
 
multiple [100%] 0.686 (-0.85) 0.492 (4.69E-04) 
BRCA1 1863 1-103, 1649-1859 16.9 1jm7A [NMR], 1t29A [x-ray, 2.3 Å] 
   
COMT 271 1-271 100 
 
multiple [96%] 0.337 (-4.68) 0.370 (1.99E-03) 
CYP1A2 515 1-515 100 
 
multiple [93%] 0.702 (-0.78) 0.617 (1.39E-04) 
CYP2A6 494 1-494 100 
 
multiple [100%] 0.774 (0.07) 0.663 (9.31E-05) 
CYP2B6 491 1-491 100 
 
multiple [95%] 0.732 (-0.44) 0.562 (2.30E-04) 
CYP2C19 490 1-490 100 
 
multiple [95%] 0.694 (-0.88) 0.621 (1.34E-04) 
CYP2C8 490 1-490 100 
 
multiple [100%] 0.765 (-0.03) 0.645 (1.08E-04) 
CYP2C9 490 1-490 100 
 
multiple [95%] 0.742 (-0.31) 0.620 (1.35E-04) 
CYP2D6 497 1-497 100 
 
multiple [93%] 0.728 (-0.47) 0.615 (1.40E-04) 
CYP2E1 493 1-493 100 
 
multiple [94%] 0.736 (-0.38) 0.647 (1.07E-04) 
CYP2J2 502 1-502 100 
 
multiple [92%] 0.704 (-0.76) 0.651 (1.03E-04) 
CYP3A4 503 1-503 100 
 
multiple [94%] 0.664 (-1.23) 0.594 (1.71E-04) 
CYP3A5 502 1-502 100 
 
multiple [93%] 0.690 (-0.93) 0.592 (1.73E-04) 
DPYD 1025 1-1025 100 
 
multiple [99%] 0.777 (0.16) 0.223 (2.03E-02) 
DRD2 443 30-442 93.2 
 
2rh1A [20.8%] 0.250 (-6.02) 0.359 (2.29E-03) 
F5 2224 29-737, 1574-2224 61.2 1y61A [model] 




Supplementary Table B.2 (continued) 
Protein 
 Protein  
full  length 





PDB ID [method] 
Template PDB  
[% confident] 
QMEAN6 score  
(Z-score) 
ModFOLD4 score  
(p-value) 
G6PD 515 1-515 100 
 
multiple [94%] 0.627 (-1.69) 0.389 (1.55E-03) 
GSTP1 210 1-210 100 3dgqA [x-ray, 1.6 Å] 
   
GSTT1 240 1-240 100 
 
multiple [99%] 0.795 (0.26) 0.637 (1.16E-04) 
HMGCR 888 1-870 98.0 1dqaA [x-ray, 2.0 Å] multiple [64%] 0.424 (-3.74) 0.231 (3.74E-2) 
KCNH2 1159 26-135 9.5 4hqaA [x-ray, 1.96 Å] 
   
KCNH2 1159 667-869 17.5 
 
1q5oA [26.24%] 0.565  (-2.16) 0.491 (4.70E-04) 
KCNJ11 390 1-390 100 
 
multiple [84%] 0.430 (-3.95) 0.230 (1.76E-02) 
MTHFR 656 57-338 43.0 
 
1zrqC [33.6%] 0.757 (-0.15) 0.370 (1.99E-03) 
NQO1 274 1-274 100  multiple [100%] 0.738 (-0.33) 0.569 (2.15E-04) 
NR1I2 434 1-434 100  multiple [86%] 0.429 (-4.02) 0.307 (4.88E-03) 
P2RY1 373 1-373 100  multiple [96%] 0.352 (-4.78) 0.362 (2.20E-03) 
P2RY12 342 1-342 100  multiple [99%] 0.362 (-4.79) 0.459 (6.68E-04) 
PTGIS 500 1-500 100  multiple [96%] 0.692 (-0.91) 0.560 (2.34E-04) 
PTGS2 604 1-604 100  multiple [91%] 0.742 (-0.24) 0.485 (5.03E-04) 
SCN5A 2016 1776-1928 7.6 4dckA [x-ray, 2.2 Å]    
SLC19A1 591 1-591 100  multiple [73%] 0.418 (-3.82) 0.218 (3.10E-02) 
SULT1A1 295 1-295 100  multiple [99%] 0.861 (0.95) 0.674 (8.52E-05) 
TPMT 245 1-245 100  multiple [93%] 0.718 (-0.55) 0.460 (6.59E-04) 
TYMS 313 1-313 100  multiple [97%] 0.735 (-0.45) 0.651 (1.03E-04) 
UGT1A1 533 1-533 100  multiple [84%] 0.444 (-3.78) 0.314 (4.36E-03) 





Supplementary Table B.2 (continued) 
†Structure coverage represents the range of protein residues present in the 3D structure and the percentage of structural coverage with 
respect to the full length of the proteins. Each PDB accession number is indicated by its four letter code followed by the chain ID (in 
capital letter). 
*Details of homology models include the template’ PDBs, sequence identity percentage between the target and the template sequences 
(in case of single-template modeling), or percentage of residues modeled at >90% confident (in case of multi-template modeling). 
Quality of homology models is evaluated by QMEAN6 and ModFOLD4 scores. QMEAN6 is a reliability score derived from a linear 
combination of six terms. It estimates model reliability between 0 and 1 (1 represents the best model). QMEAN Z-score for a given 
model is a comparable quality score to experimental structures of similar size. Models of low quality will have strongly negative 
QMEAN Z-scores. ModFOLD’s global model quality score ranges between 0 and 1. In general, scores greater than 0.4 indicate more 
complete and confident models, which are highly similar to the native structure. ModFOLD’s p-value represents the probability that 




Table B.3: Complete list of genomic variability data of the 48 VIPs and the statistics 
of 3D structure maps. 
Gene name 
All genomic data 
Genomic data with 
















ABCB1 2 86 0 0 0% 0% 
ACE 2 148 0 140 0% 95% 
ADH1A 0 17 0 17  100% 
ADH1B 1 32 1 32 100% 100% 
ADH1C 2 17 2 17 100% 100% 
ADRB1 11 20 11 20 100% 100% 
ADRB2 4 35 4 35 100% 100% 
AHR 2 55 2 18 100% 33% 
ALDH1A1 0 31 0 31  100% 
ALOX5 16 48 16 48 100% 100% 
BRCA1 186 245 58 25 31% 10% 
COMT 3 22 3 22 100% 100% 
CYP1A2 0 71 0 71  100% 
CYP2A6 7 73 7 73 100% 100% 
CYP2B6 1 80 1 80 100% 100% 
CYP2C19 5 68 5 68 100% 100% 
CYP2C8 0 53 0 53  100% 
CYP2C9 7 52 7 52 100% 100% 
CYP2D6 1 95 1 95 100% 100% 
CYP2E1 0 41 0 41  100% 
CYP2J2 0 40 0 40  100% 
CYP3A4 0 54 0 54  100% 
CYP3A5 0 39 0 39  100% 
DPYD 4 85 4 85 100% 100% 
DRD2 1 28 1 25 100% 89% 
F5 8 165 7 91 88% 55% 
G6PD 52 38 52 38 100% 100% 
GSTP1 2 28 2 28 100% 100% 
GSTT1 2 16 2 16 100% 100% 
HMGCR 2 25 2 25 100% 100% 
KCNH2 117 65 35 9 30% 14% 
KCNJ11 51 29 51 29 100% 100% 
MTHFR 18 48 8 19 44% 40% 
NQO1 1 16 1 16 100% 100% 




Supplementary Table B.3 (continued) 
Gene name 
All genomic data 
Genomic data with 
















P2RY1 0 10 0 10  100% 
P2RY12 2 18 2 18 100% 100% 
PTGIS 0 61 0 61  100% 
PTGS2 2 21 2 21 100% 100% 
SCN5A 180 147 18 13 10% 9% 
SLC19A1 0 52 0 52  100% 
SLCO1B1 2 74 0 0 0% 0% 
SULT1A1 1 31 1 31 100% 100% 
TPMT 7 16 7 16 100% 100% 
TYMS 0 4 0 4  100% 
UGT1A1 42 38 42 38 100% 100% 
VDR 16 43 16 43 100% 100% 
VKORC1 19 5 0 0 0% 0% 
Total 779 2537 371 1811 - - 
Average 16 54 8 38 80% 84% 
Range 0-186 4-245 0-58 0-140 0-100% 0-100% 
# of proteins with 
variant data 
35 48 31 45 - - 
# of proteins 
whose structure 
covers  > 70% of 
total variants 





Table B.4: Complete list of domain names and relative abundances of functional 
and neutral variants. 
Domain Domain name Domain Domain name 
MF_00008 Thymidylate synthase PR01666 
Voltage gated sodium channel, 
alpha-5 subunit 
MF_00812 Thiopurine S-methyltransferase PR01683 
Cytochrome P450, E-class, group 
I, CYP1 
MF_00966 Glucose-6-phosphate dehydrogenase PR01684 
Cytochrome P450, E-class, group 
I, CYP2A-like 
PF00001 
G protein-coupled receptor, 
rhodopsin-like PR01685 
Cytochrome P450, E-class, group 
I, CYP2B-like 
PF00010 
Myc-type, basic helix-loop-helix 
(bHLH) domain PR01686 
Cytochrome P450, E-class, group 
I, CYP2D-like 
PF00027 Cyclic nucleotide-binding domain PR01687 
Cytochrome P450, E-class, group 
I, CYP2E-like 
PF00043 Glutathione S-transferase, C-terminal PR01688 
Cytochrome P450, E-class, group 
I, CYP2J-like 
PF00067 Cytochrome P450 PR01689 
Cytochrome P450, E-class, 
CYP3A 
PF00097 Zinc finger, C3HC4 RING-type PS00059 
Alcohol dehydrogenase, zinc-
type, conserved site 
PF00104 
Nuclear hormone receptor, ligand-




Zinc finger, nuclear hormone 
receptor-type PS00081 Lipoxygenase, conserved site 
PF00107 Alcohol dehydrogenase, C-terminal PS00086 Cytochrome P450, conserved site 
PF00171 Aldehyde dehydrogenase domain PS00198 
4Fe-4S ferredoxin, iron-sulphur 








NAD-binding PS00711 Lipoxygenase, iron binding site 
PF00520 Ion transport domain PS50089 Zinc finger, RING-type 
PF00685 Sulfotransferase domain PS50112 PAS domain 
PF00754 
Coagulation factor 5/8 C-terminal 
type domain PS50113 PAS-associated, C-terminal 
PF00989 PAS fold PS50156 Sterol-sensing domain 
PF01007 
Potassium channel, inwardly 
rectifying, Kir PS50262 GPCR, rhodopsin-like, 7TM 
PF01180 
Dihydroorotate dehydrogenase, class 
1/ 2 PS50405 
Glutathione S-transferase, C-
terminal-like 
PF01401 Peptidase M2, peptidyl-dipeptidase A PS51379 
4Fe-4S ferredoxin-type, iron-
sulphur binding domain 
PF01477 PLAT/LH2 domain PS51393 Lipoxygenase, C-terminal 
PF01596 O-methyltransferase, family 3 PS51557 Catechol O-methyltransferase 
PF01770 Reduced folate carrier PTHR10572 
Hydroxymethylglutaryl-CoA 
reductase, class I/II 
PF02219 Methylenetetrahydrofolate reductase PTHR11695 
Alcohol dehydrogenase 
superfamily, zinc-type 
PF02525 Flavodoxin-like fold PTHR11771 Lipoxygenase 
PF02781 
Glucose-6-phosphate dehydrogenase, 
C-terminal PTHR24231:SF2 P2Y1 purinoceptor 





Supplementary Table B.4 (continued) 
Domain Domain name Domain Domain name 
PF03098 Haem peroxidase, animal PTHR24248 Adrenoceptor family 
PF05724 TPMT family PTHR24248:SF13 Dopamine D2 receptor 
PF06512 Sodium ion transport-associated PTHR24248:SF21 Beta 2 adrenoceptor 
PF07732 Multicopper oxidase, type 3 PTHR24248:SF3 Beta 1 adrenoceptor 
PF08240 Alcohol dehydrogenase GroES-like SM00015 IQ motif, EF-hand binding site 
PF08447 PAS fold-3 SM00086 PAC motif 
PF11933 
Domain of unknown function 
DUF3451 SSF103473 
Major facilitator superfamily 
domain, general substrate 
transporter 
PF12820 BRCA1, serine-rich domain SSF46548 Alpha-helical ferredoxin 
PF14691 
Dihydroprymidine dehydrogenase 
domain II SSF48113 Haem peroxidase 
PIRSF000047 
Cytochrome P450, cholesterol 7-
alpha-monooxygenase-type SSF48508 
Nuclear hormone receptor, 
ligand-binding 
PIRSF000354 Coagulation factor 5/8 SSF49503 Cupredoxin 
PIRSF001734 
Breast cancer type 1 susceptibility 





eukaryotic SSF49785 Galactose-binding domain-like 
PIRSF500628 Prostacyclin synthase SSF50129 GroES (chaperonin 10)-like 
PIRSF500793 Folate transporter 1 SSF51206 Cyclic nucleotide-binding-like 
PR00170 
Voltage gated sodium channel, alpha 
subunit SSF52113 BRCT domain 
PR00242 Dopamine receptor family SSF52540 
P-loop containing nucleoside 
triphosphate hydrolase 
PR00350 Vitamin D receptor SSF52833 Thioredoxin-like fold 
PR00398 Steroid hormone receptor SSF53720 
Aldehyde/histidinol 
dehydrogenase 
PR00457 Haem peroxidase, animal, subgroup SSF55035 
Hydroxymethylglutaryl-CoA 
reductase, class I/II, 
NAD/NADP-binding 
PR00463 Cytochrome P450, E-class, group I SSF55831 
Thymidylate synthase/dCMP 
hydroxymethylase domain 
PR00464 Cytochrome P450, E-class, group II SSF56542 
Hydroxymethylglutaryl-CoA 
reductase, class I/II, substrate-
binding 
PR00465 Cytochrome P450, E-class, group IV SSF81296 Immunoglobulin E-set 









Potassium channel, inwardly 















Supplementary Table B.4 (continued) 
* The prefix of Domain ID indicates the data source. Abbreviations are MF: HAMAP; 
PF: Pfam; PIRSF: PIRSF; PR: PRINTS, PS: PROSITE; PTHR: PANTHER; SM: 




Table B.5: Complete statistics of Fisher’s exact test for enriched structural features 
present in functional and neutral mutations. 








At Cys Wild type residue = Cys 0.0003* 
Loss of disulfide 
bond 
Wild type residue forms disulfide bond 
(when wile type AA = Cys) and mutant 
residue eliminates the bond 
0.4039 
Salt bridge 
At charged AA Wild type residue = charged AA 0.6537 
At salt bridge 
Wild type residue forms salt bridges (when 
wild type AA = charged residues) 
0.9081 
Loss of salt bridge 
Mutant residues eliminate salt bridges 
















Any change of 
stability 
Mutant residue reduces or increases stability 
(∆∆G ≥ 0.5 or ≤ -0.5 kcal/mol)  
0.0311* 
Destabilizing 




Mutant residue highly reduces stability 
(∆∆G ≥ 4 kcal/mol)  
0.4059 
Stabilizing 
Mutant residue increases stability (∆∆G ≤ -
0.5 kcal/mol)  
0.1317 
Highly stabilizing 
Mutant residue highly increases stability 












Is a highly dynamic residue (B-factorNorm 
≥ 1.0909) 
0.7997 
Highly rigid or 
highly dynamic 
Highly rigid or highly dynamic residue (B-






Located at conformationally rigid site 
(FlexPred label = rigid) 
0.0218* 
Highly rigid 




Is a highly dynamic residue (RMSFNorm ≥ 
0.964) 
0.1088 
Highly rigid or 
highly dynamic 
Highly rigid or highly dynamic residue 
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At binding site Located at binding site  0.0003* 
At 5 Å of binding site 
Located within 5 Å of binding site (Cα-Cα 
distance) 
0.0123* 
At 10 Å of binding 
site 





Non-optimal residue Is a nonoptimal residue (Γ < 0 kcal/mol) 0.2014 
Highly-non optimal 
residue 
Is a highly nonoptimal residue (Γ < -3.47 








Induced hydropathy change (hydrophobic 
 hydrophilic) when located at binding 
sites 
0.2854 
Change of volume, at 
binding site 
Induced volume change (very large to 
small/very small, very small to large/very 
large) when located at binding sites 
0.2241 
Change of charge, at 
binding site 
Induced charge change (positive  
negative) when located at binding sites 
0.4870 
Change of H-bond, at 
binding site 
Induced H-bond change (H-bond donor 
 acceptor) when located at binding sites 
0.4870 
Change of any kind, 
at binding site 
Induced any of the four changes when 




5 Å of binding 
sites 
Change of 
hydropathy, around 5 
Å of binding sites 
Induced hydropathy change when located 
around 5 Å of binding sites 
0.4943 
Change of volume, 
around 5 Å of 
binding sites 
Induced volume change when located 
around 5 Å of binding sites 
0.0385* 
Change of charge, 
around 5 Å of 
binding sites 
Induced charge change when located around 
5 Å of binding sites 
0.6429 
Change of H-bond, 
around 5 Å of 
binding sites 
Induced H-bond change when located 
around 5 Å of binding sites 
0.6429 
Change of any kind, 
around 5 Å of 
binding sites 
Induced any of the four changes when 








10 Å of binding sites 
Induced hydropathy change when located 
around 10 Å of binding sites  
0.1117 
Change of volume, 
around 10 Å of 
binding sites 
Induced volume change when located 
around 10 Å of binding sites 
0.0046* 
Change of charge, 
around 10 Å of 
binding sites 
Induced charge change when located around 
10 Å of binding sites 
0.9107 
Change of H-bond, 
around 10 Å of 
binding sites 
Induced H-bond change when located 
around 10 Å of binding sites 
0.9585 
Any changes  around 
10 Å of binding sites 
Induced any of the four changes when 
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Interaction site At patch Located on protein patch < 0.0001* 
Residue 
localization 
Unusual AA At Gly/Pro Induced Gly/Pro change 0.0015* 
Residue 
localization 
At domain Located in protein domains 0.2355 
Residue 
localization 
At structural site Located at structural site 0.9978 
Residue 
localization 
At buried site Locate in buried site (RSA ≤ 20%) 0.0533 
Residue 
localization 







dissimilarity at any 
site 
Induced large amino acid change (Grantham 





Induced large amino acid change (Grantham 
score ≥ 100) when located at binding sites 
0.0259* 
Large AA 
dissimilarity at within 
5 Å of binding sites 
Induced large amino acid change (Grantham 




dissimilarity at within 
10 Å of binding sites 
Induced large amino acid change (Grantham 






Induced large amino acid change (Grantham 




dissimilarity at any 
domain boundary 
Induced large amino acid change (Grantham 






Induced large amino acid change (Grantham 





Induced large amino acid change (Grantham 
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Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at any secondary structure types 
0.1674 
Coil break 
Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at coil 
0.6199 
Strand break 
Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at strand 
0.2454 
3-turn helix break 
Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at 3-turn helix 
0.4586 
α-helix break 
Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at α-helix 
0.1256 
bend break 
Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at bend 
0.5348 
turn break 
Induced secondary structure break 
(preferred to least preferred amino acid 
propensity) at turn 
0.4898 
Significant p-values (α = .05) are designated with ‘*'. Non-significant p-values indicate 
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